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Background and aims 
Clostridium difficile infection (CDI) remains a healthcare burden and recurrent CDI (rCDI) still affects 
20-30% of patients. Probiotics are live microorganisms that confer a host health benefit, but evidence 
of their efficacy in CDI prevention/treatment is controversial. Non-toxigenic C. difficile (NTCD) have 
been used successfully used in animals/humans to reduce CDI. The present study aimed to assess 
efficacy of two probiotics, Lactobacillus casei Shirota (LcS, Yakult) and NTCD, in preventing 
simulated CDI in an in vitro human gut model.  
Methods 
C. difficile-negative pooled faeces from healthy volunteers (>65 yrs) was used to inoculate the gut 
model. Two probiotics, LcS (6.2 x 109 cfu) and NTCD (1 x 108 spores), were dosed into separate gut 
models prior to C. difficile (CD) ribotype 027 spores (RT027, 1 x 108). LcS was chosen given its 
commercial availability, in addition to studies that report the prevention of antibiotic-associated 
diarrhoea by LcS, and its role in preventing CDI. Similarly, NTCD was chosen given reports of its 
antagonism against toxigenic C. difficile. Probiotic dosing was for 28d; LcS once-daily and NTCD 
spores once-weekly. The rationale for dosing is consistent with literature and the ease of obtaining the 
probiotic. For example LcS is commercially available whereas NTCD had to be prepared using a 
rigorous process over a duration of 7 – 10 days.  Various antimicrobial groups such as lincosamides, 
aminopenicillins, fluoroquinolones, and third generation cephalosporins was used to disrupt the gut 
microflora in separate experiments. Gut model contents were assayed for microflora composition using 
viable counting techniques and CD cytotoxin production using a Vero cell cytotoxicity assay. Probiotic 
dosing ceased 14 days before the end of the experiment. 
Results 
LcS dosing resulted in marked increases in lactobacilli and bifidobacterial viable counts. However, 
during clindamycin (DA) dosing these viable counts declined by 4-log10cfu/mL. RT027 spore 
germination and cell proliferation was observed during/after antimicrobial instillation. Interestingly, 
another cycle of growth/cytotoxin was observed after LcS dosing ceased. NTCD did not colonise the 
gut model prior to DA instillation; spores were quiescent and washed out. NTCD spores germinated 
and vegetative cells multiplied, whereas, RT027 spores did not germinate and no cytotoxin was 
produced. NTCD remained vegetative until the end of the experiment and isolated cells retained their 
non-toxigenic phenotype. 
Conclusions 
Instillation of NTCD prevented primary CDI in a human gut model, whereas dosing with LcS did not. 
LcS, if beneficial in the antagonism of CD, is unlikely to be due to nutrient/adhesion competition or 
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production of antimicrobial substances. NTCD may be beneficial not only in treating rCDI but also in 
the prevention of primary infection. Further work is needed to better understand the protection that 
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1.0 Introduction 
 
1.1 The triple-stage gut model 
 
The triple-staged continuous culture system was validated by MacFarlane et al., (1998) to assess the 
effect of retention time on the ecology and metabolism of bacteria in the human colon. Unlike single 
stage fermenters that inaccurately depicts the entire colon as having the same pH and nutrient 
availability, the triple-stage system was designed to mirror the nutritional, physical, and chemical 
properties of the proximal, transverse, and distal colon. The gut model was made up of three glass 
fermentation vessels operating in a weir-cascade system, flowing into a waste unit. The uppermost 
vessel has a higher substrate availability, promoting increased bacterial growth, and is operated at an 
acidic pH mimicking the environment of the proximal colon. In contrast, the lowest vessel is consistent 
with the neutral pH, low substrate availability, and slow bacterial growth, which is obtainable in the 
distal regions of the colon.  Growth medium is supplied to the gut model with the aid of a peristaltic 
pump. This model is widely used to study antimicrobial induction of simulated CDI, in addition to 
studying the efficacy of CDI treatments (Baines et al., 2008; 2009; Freeman et al., 2005; 2007, Crowther 
et al., 2013; 2014; 2016; Chilton et al., 2014; 2015; Moura et al., 2019). This is in part because the 
system allows for the growth and retention of bacterial groups for a prolonged duration (Freeman et al., 
2007). Although pH is controlled in the system, it is still a useful model to study probiotics that act by 
altering the pH of the environment. This is because the pH control is slow and gradual, thereby affording 
the probiotic strains time to outcompete its pathogenic counterparts. Besides, the different vessels are 
set to different pHs. Nevertheless, a major limitation of the gut model is its inability to mimic 
immunological events. Additionally, the gut model design makes it very difficult to investigate bacterial 
populations in biofilms but allows the retrieval of bacterial populations in planktonic state with relative 
ease. Furthermore, the gut model is also limited in terms of bacteria-host interactions. Nevertheless, 
reports suggest that data from the gut model closely reflect in vivo observations (Freeman et al., 2003; 
Moura et al., 2019). 
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1.2 Historical background of Clostridium difficile 
 
C. difficile is a spore-forming, Gram-positive obligately anaerobic bacterium. The organism was first 
identified by Hall and O’Toole in 1935 as part of the microflora of healthy infants. The authors 
described this bacterium as an ‘’actively motile, heavy-bodied rod with an elongated sub terminal or 
nearly terminal spores’’ (Hall & O’Toole, 1935). The bacterium was named Bacillus difficilis at that 
time to mirror the difficulty experienced in isolating and culturing it. Although the bacterium was 
present as a commensal organism in infants, the early researchers observed that it could cause disease 
in animals, possibly due to the production of a toxin (Hall & O’Toole, 1935). Subsequent research 
showed that the main disease-causing (virulence) factors were the high molecular weight clostridial 
toxins: toxin A and toxin B (Cebeci & Gürakan, 2003). It was in the 1970s that the bacterium then 
called Clostridium difficile was shown to be involved in human disease (Tedesco et al., 1974).  This 
disease became widely known as C. difficile-associated diarrhoea/disease (CDAD) and then C. difficile 
infection (CDI). In more recent times Lawson and Rainey (2015) proposed that the genus Clostridium 
be restricted to Clostridium butyricum and related species. The proposal has implications for C. difficile 
because it has been reported to be phylogenetically distant from the rRNA clostridial cluster I (Collins 
et al., 1994). The ‘’rRNA cluster I’’ is referred to species of the genus C. butyricum which can be called 
Clostridium sensu stricto (Lawson & Rainey, 2015). Accordingly, ‘’Clostridioides difficile’’ was 
proposed as a reclassification of the bacterium. Since both names can be used, and have been validly 
reported in accordance with the requirements of the Prokaryotic Code (Oren & Garrity, 2016; Oren & 
Rupnik, 2018), the name ‘’Clostridium difficile’’ shall be used throughout this work.    
Yutin and Galperin (2013) had previously attempted to change the taxonomy of Clostridium based on 
phylogenetic relationships. They proposed the genus ‘’Peptoclostridium’’ to cover C. difficile and some 
other Clostridium species, but no validation request was sent to the International Journal of Systemic 
and Evolutionary Microbiology (IJSEM) List Editors (Oren & Rupnik, 2018). This is seen as positive 
event, as the acceptance of ’Peptoclostridium’’ might have meant abbreviations such as CDI, CDAD 
and C. difficile would not have been retained, and this would have brought even bigger confusion 
especially in clinical settings. This would have been in addition to the potential global economic waste 
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that would have accompanied an update of product packaging, trademarks, brand names, web pages, 
and educational materials for healthcare staff, patients, and customers.     
 
1.2.1 Epidemiology of C. difficile 
 
 In the early 2000s, increasing rates of CDI mortality and incidence in North America, and afterwards 
in a high number of European countries were documented. These were linked with PCR ribotype 027 
(Kuijper et al, 2006; He et al.,2013 ) and to a lesser extent, PCR ribotype 078 ( Freeman et al.,  2010). 
Similar increases have also been documented in Asia, Australia, and Central America (Van Gessel, 
2008; Collins et al., 2013; ). It is noteworthy that CDI and its associated epidemics are not restricted to 
these ribotypes. Accounts of outbreaks for strains of other ribotypes such as 017 (Kuijper et al.,2006), 
018 (Pépin et al ., 2005), 106 (Cebeci & Gürakan, 2003), 176 (Brazier et al., 2001), and 244 (Purdell et 
al.,2011) have been observed. In addition, ribotypes 001, 002, and 014/020 often give rise to CDI 
clusters in Europe and the US. (Tickler et al., 2014; Bauer et al., 2011). The European CDI study 
(ECDIS) undertaken by the European Centre for Disease Prevention and Control (ECDC) showed that 
PCR ribotypes 015 and 056 could also cause severe CDI (Kuijper et al., 2006). 
Following a survey of hospital-acquired infection by the ECDC in 2011/2012, C. difficile was identified 
as the most documented pathogen linked with gastrointestinal disease of healthcare origin in European 
hospitals; accounting for over 47% of all gastrointestinal diseases (ECDC, 2013a). It was estimated 
based on this data that about 153,000 new CDI cases occur in Europe every year with an incidence of 
3 cases in every 10,000 population. Furthermore, Cassini et al., (2016) reported that CDI was associated 
with up to 8382 deaths every year in Europe. Additionally, CDI is increasingly occurring in people in 
the community with no traditional risk factors such as recent hospitalisation and antimicrobial use 
(Wilcox et al., 2008). Epidemiological data on C. difficile in the Middle East and Africa are scanty 





1.2.2 The emergence of hypervirulent PCR ribotype 027 
 
The epidemic of CDI about 15 years ago owing to the emergence and predominance of a hypervirulent 
strain that caused several outbreaks and increased disease severity (Loo et al., 2005; Pepin et al., 2005). 
This strain was characterised as polymerase chain reaction ribotype 027, restriction endonuclease 
analysis group BI, and pulse-field gel electrophoresis type NAP1, designated BI/NAP1/027(McDonald 
et al., 2005; Kilgore et al., 2008). This strain has since been isolated from patients in several countries 
around the world including the UK, US, Canada, and Australia (Kato et al., 2007; Hensgens et al., 2009; 
Riley et al., 2009). Several studies have associated this strain with increased toxin production, high 
sporulation rates and fluoroquinolone resistance (Akerlund et al., 2008; McDonald et al., 2005; Warny 
et al., 2005; He et al., 2013). This is in addition to higher resistance to tetracycline, aminoglycosides, 
and erythromycin (Knetsch et al., 2018). 
Prior studies reported that the elevated toxin production by BI/NAP1/027 strains was due to a ∆117 
frameshift mutation and an 18bp deletion in the tcdC gene (Warny et al., 2005; MacCannell et al., 
2006). In contrast Merrigan et al., (2010) demonstrated that no significant difference exists in the 
amounts of toxin produced by hypervirulent and non-hypervirulent strains in the exponential phase, 
suggesting the tcdC did not play a repressive role. These findings were supported by Cartmen et al., 
(2012) who reported no association between tcdC status and toxin production in both hypervirulent 
strain R20291 and wild type C. difficile 630. 
Furthermore, the use of trehalose as a food additive possibly contributed to the dissemination of RT027 
strains. This ribotype is thought to have acquired unique mechanisms to utilise low trehalose 
concentrations. Ribotype 027 strains exhibit a single point mutation in the trehalose repressor which 
results in a more than 500-fold increase of sensitivity to trehalose and also increased the virulence of 
RT027 strains in mouse models of CDI (Collins et al., 2018). The authors suggested that the 
incorporation of trehalose as a food additive into the human diet, shortly prior to the emergence of the 
epidemic lineage, helped select for RT027 emergence and contributed to hypervirulence (Collins et al., 
2018). The role of trehalose metabolism on CDI severity may be due to the increased toxin production 
22 
 
that accompanies trehalose utilisation by RT027 strains (Collins et al., 2018). However, Eyre et al., 
(2019) did not find any correlation between trehalose metabolism variants and severe disease outcomes.  
  
1.2.3 Molecular typing of C. difficile 
 
Due to their capacity to type a strain precisely, discriminatory power, and high reproducibility, 
genotyping methods are employed for C. difficile typing. PCR ribotyping, pulsed-field gel 
electrophoresis (PFGE), and restriction enzyme analysis (REA) are commonly used molecular typing 
methods. In the past, PCR ribotyping which is based on rRNA-based phylogenetic analyses has been 
the preferred method in Europe, whereas PFGE and REA were mainly used in North America. Given 
the 16S rRNA gene is the most conserved among the rRNA genes, 16S rRNA gene sequencing has 
been employed as the gold standard for the taxonomic classification and identification of bacterial 
species (Mishra & Swain, 2020). PCR ribotyping employs primers directed at conserved regions of the 
16S rRNA and 23S rRNA ribosomal genes to amplify the intergenic spacer region between these 
sequences (Tanis et al., 2015). Given distinct C. difficile strains may possess varied complements and 
configurations of rRNA operon, amplification of the intergenic spacer region culminates in a 
reproducible and highly discriminatory banding pattern that could be used for C. difficile outbreak 
investigations and surveillance purposes (Tanis et al., 2015) 
The use of different approaches by different regions have led to a situation in which epidemic strains 
are usually known by multiple typing names (Tenover et al., 2011). For example, PCR ribotype 027 are 
also known as PFGE type NAP1 and REA group BI. In a similar manner, PCR ribotype 078 strains are 
classified as PFGE type Nap7/NAP8 and REA group BK. Owing to the need for global surveillance, 
efforts are geared to reconcile the different typing schemes (Smits et al., 2016). Sequence-based 
methods such as whole genome sequencing (e.g. single nucleotide polymorphism (SNP)), and 
multilocus sequence typing have drawn more attention, especially in phylogenic studies (Knetsch et al., 
2013). Multilocus variable number tandem repeat analysis (MLVA) is often employed to study the 
relationship between strains in an outbreak (Knetsch et al., 2013). Data from a European survey on C. 
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difficile showed that the most applied method for C. difficile characterisation for the purpose of 
surveillance was PCR ribotyping (used in 25 countries), followed by MLVA (13 countries), whereas 
whole genome sequencing was used only in five countries (Krutova et al., 2018).  In the UK, the C. 
difficile reference laboratory is situated within the Public Health England and C. difficile Ribotyping 
Network in Leeds, and new ribotypes are assigned from the reference laboratory. Currently there are 
over 950 distinct C. difficile PCR ribotypes (Dr Warren Fawley – personal communication). 
 
1.2.4 Life cycle 
 
C. difficile is transmitted through the faecal-oral route. Due to the fact that metabolically active cells 
are unlikely to survive the acidic conditions of the stomach or in the oxygenated conditions outside the 
host, it is thought that spores are the infectious form of the organism. Spores are resistant to 
environmental conditions (Debast et al., 2014; Paredes-Sabja et al., 2014), in addition to a high number 
of antimicrobials (Baines et al., 2009; Paredes-Sabja et al., 2012) and some disinfectants. Structurally, 
spores are made of several layers (Henriques & Moran, 2007). The core of the endospore contains 
ribosomes, RNA, DNA, and a large quantity of dipicolinic acid, chelated with calcium which bestows 
heat resistance (Paredes-Sabja et al., 2014; Gil et al., 2017). An inner membrane made of phospholipids 
surrounds the spore core, followed by a layer of germ-cell wall that subsequently becomes the cell wall 
of the vegetative cell during outgrowth (Shrestha & Sorg, 2019). A specialised thick layer of 
peptidoglycan cortex protects the spore core against osmolysis by surrounding the germ-cell wall. The 
cortex is surrounded by an outer membrane derived from the parent cell, spore coat proteins, and an 
exosporial layer (Paredes-Sabja et al., 2014; Zhu et al., 2018; Henriques & Moran, 2007). Upon 
favourable environmental conditions, spores germinate, and outgrow to the vegetative forms of the 
bacterium (Zhu et al., 2018; Burns et al., 2011).      
Germination of spores is thought to occur when the germinant receptor CspC senses primary bile acids 
in the gut such as taurocholate (produced by the liver). Conversely, C. difficile spore germination is 
inhibited by secondary bile acids in the large intestine (Paredes-Sabja et al., 2014; Theriot & Young, 
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2015; Bhattacharjee et al., 2016). Moreover, glycine is capable of acting as a germinant via an unknown 
mechanism (Sorg & Sonenshein, 2008). A proteolytic cascade results in the breakdown of the spore 
peptidoglycan, calcium dipicolinate release, and the rehydration of spore, eventually leading to an 
outgrowth of the vegetative cell (Paredes-Sabja et al., 2014). More recent research indicates that a minor 
mutation in the region of cspBA that codes for cspA culminated in spore germination in response to 
taurocholic acid alone, with no role for an amino acid, strongly suggesting that the amino acid germinant 
receptor is the CspA protein (Shrestha & Sorg, 2018). 
C. difficile spores have the ability to adhere to colon cells prior to germination into vegetative cells 
(Paredes-Sabja & Sarker, 2012). In addition, the shift between the motile phase of C. difficile and the 
sessile phase is closely regulated by cyclic di-GMP, a secondary messenger (Bordeleau & Burrus, 
2015). Furthermore, C. difficile is also able to, (at least in vitro) form biofilms and the spore form of C. 
difficile has been isolated from multi-species biofilms and also pure culture biofilms, which may 
facilitate survival of the organism in adverse environmental conditions (Crowther et al., 2014). Also 
the ability to form spores has been proposed to contribute to the difference in virulence between RT027 
and other C. difficile strains (Burns et al., 2010; Lanis et al., 2010). 
 
1.2.5 Risk factors  
    
Age (above 65 years), previous hospitalization, and chiefly, the use of antibiotics are known risk factors 
for development of CDI. All classes of antimicrobials have been implicated in CDI, but clindamycin, 
third generation cephalosporins, and fluoroquinolones are more often associated with CDI (Freeman et 
al., 2015). Microbial imbalance of the protective intestinal microbiota caused by antibiotics is usually 
the underlying cause of C. difficile outgrowth and toxin production (Venugopal & Johnson, 2011). The 
alteration of the intestinal microbiota can persist for more than 3 months after antibiotic treatment, 
therefore patients might remain susceptible to CDI development even after the conclusion of treatment 
(Leeds et al., 2013). McDonald et al., (2015) reported a close association between proton pump 
inhibitors and CDI. Biologically, there is a plausibility for the suppression of gastric acid as a CDI risk 
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factor because a loss of acidity might distort the normal microbial diversity of the gastrointestinal tract 
(Seto et al., 2014) and even prolong the survival of C. difficile spores (Jump et al., 2007). Nonetheless, 
the specific role proton pump inhibitors play in CDI remains elusive (Lewis et al., 2009).  About 20 – 
30% antibiotic-associated diarrhoea is caused by C. difficile. Non-beneficial bacteria such as 
Enterococci increase in number in older individuals at the expense of beneficial short chain fatty acid-
producing bifidobacteria  (Goldstein et al., 2011), this might in part explain why elderly individuals are 
more prone to CDI.  
An immunocompromised state and medical comorbidities are also known CDI risk factors in the elderly 
(McDonald et al., 2017). However, CDI risk factors in children are not well defined. In addition, current 
understanding of CDI in children is even made more difficult owing to the fact that about 70% of infants 
less than a month to over 1 year of age may be asymptomatically colonised with C. difficile, as a result 
do not experience clinical illness until 1-2 years of age (McFarland et al., 2000). This may in part 
because children are thought to lack the toxin receptors (Eglow et al., 1992; Nicholson et al., 2014). 
Accordingly, a closer assessment of available evidence is required to better grasp the implications and 
significance of potential CDI risk factors for children.    
 
1.2.6 Toxin A and B 
 
The cytotoxic effect of C. difficile was initially associated to one toxin molecule (Lyerly et al., 1982). 
However, the exact molecular weight of the resultant toxin showed dissimilarities between researchers. 
Taylor & Bartlett, (1979) estimated the toxin to be 240 kDa, which was inconsistent to the 530 kDa 
reported by Rolfe & Finegold, (1979). This inconsistency was resolved when amongst others, Banno et 
al., (1984) reported that C. difficile produced two antigenically different molecules named toxins A and 
B, with molecular weights of 308 kDa and 270 kDa respectively. 
Toxin A has been historically seen as a more potent enterotoxin, as introduction of purified TcdA to the 
intestines of rodents and rabbits triggered tissue necrosis (Lyerly et al., 1985). In contrast, high levels 
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of TcdB in similar experiments did not bring about these effects (Smits et al., 2016). It is pertinent to 
note that these results are a representation of only the response of the small intestine. 
The significance of TcdA in CDI became questionable due to the existence pathogenic C. difficile 
isolates that were shown to produce TcdB but not TcdA (Drudy et al., 2007). These isolates gave rise 
to the full clinical spectrum of CDI with some researchers even suggesting that these strains give rise 
to more serious CDI than strains that produced both Toxins A and B (Drudy et al., 2007). Unlike the 
studies which employed purified toxins, these variant strains showed that TcdA was not necessary for 
CDI onset and that strains producing only TcdB were as virulent as strains producing both toxins in 
patients. Consequently, these works revealed that TcdB carried out a more pivotal role in disease than 
reported from earlier studies. This argument gained more support as the use of purified TcdB was shown 
to elicit an acute inflammatory response and resulted in more severe damage than TcdA to the intestinal 
epithelium of mice (Smits et al., 2016). Furthermore, it is now well established that both toxins are 
crucial for inducing the death of colonocytes and colitis, as well as mounting evidence suggesting their 
role in CDI extra-intestinal effects (Bella et al., 2016) 
A high number of functional and structural studies have elucidated the mechanism of action of TcdA 
and TcdB. Upon secretion, these toxins enter and bind the colonic epithelium, and brings about the 
production of inflammatory chemokine and cytokine, neutrophil influx, fluid secretion, tight junction 
disruption, and ultimately epithelial cell death (Shen, 2012). 
 
1.2.7 Clindamycin  
 
Clindamycin is a broad-spectrum antimicrobial that mainly targets anaerobic bacteria, as well as Gram-
positive aerobic bacteria (Dhawan & Thadepalli, 1982). The antimicrobial is primarily excreted in bile 
and is able to reach very high concentrations in the intestinal lumen, culminating in considerable 
imbalances in the gut microbiota (Sullivan et al., 2001; Jernberg et al. 2010). Following a culture-based 
study of the faecal microbiota of healthy individuals, the administration of clindamycin prompted a 
significant decline in anaerobic bacterial populations (Bacteroides, bifidobacteria, clostridia, and 
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lactobacilli) and an increase in Enterococci and Enterobacteria (Citrobacter, Enterobacter, and 
Klebsiella), which are thought to be intrinsically resistant to clindamycin (Orrhage et al., 1994). Another 
culture-based study evaluating the impact of clindamycin prophylaxis in surgical patients reported a 
transient decline in Enterococci and Streptococci during antimicrobial administration (Kager et al., 
1981). A substantial decline in anaerobic bacterial populations also occurred following clindamycin 
treatment, however the bacterial populations returned to their initial concentrations within two weeks. 
 
1.2.8 Symptoms of CDI 
 
The symptoms of CDI vary from self-limiting, mild diarrhoea to fulminant pseudomembranous colitis, 
sepsis, toxic megacolon, multiple organ failure, and death. Mild cases are characterised by slight fever, 
abdominal pains, and loose stools (Welfare et al., 2011). C. difficile colitis might start with non-specific 
signs such as erythema and oedema on endoscopy. The left colon predominantly becomes inflamed. 
The condition can advance to severe colitis with characteristic adherent pseudo-membranes. Severe 
CDI is associated with fever, hypoalbuminemia (Joint, 2001),  and leucocytosis, which usually precedes 
signs of colitis (Ohashi & Ushida, 2009). Despite diarrhoea being the symptomatic hallmark of CDI, it 
might be absent initially, owing to a possible colonic dysmotility from the disease process or previous 
conditions (Jaber et al., 2008). This is particularly crucial in surgical patients that might have an 
accompanying ileus. Therefore, it is important to have a high suspicion index in surgical patients for 
CDI development (Sartelli et al., 2019).  
To evaluate the prognostic value of leucocytosis, renal failure, and fever, Bauer et al., (2012) examined 
the data from two randomised controlled trials (RCTs), that contained data on 1105 CDI patients. The 
authors reported that both renal failure and leucocytosis were important predictors of severe CDI. Miller 
et al., (2013) reported an analysis of the two same clinical trials to validate a system of categorisation 
to classify patients of CDI into mild, moderate, or severe. A blend of five commonly available and 
simple laboratory and clinical variables determined during CDI diagnosis were used accurately to 
predict treatment response upon CDI therapy. The criteria were: age, treatment with antibiotics, 
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leucocyte count, serum albumin, and serum creatinine levels (ATLAS). The ATLAS predictors of 
severe CDI included: WBC ˃ 15 x 109/L, Temperature ˃ 38.5 oC, Albumin ˂ 2.5 g/dL, and increase in 
serum creatinine level ≥ 133 µM/L. 
Recently, di Masi et al., (2018) showed that human serum albumin is able to bind toxins A and B, 
therefore impeding their internalisation to host cells; this may offer some explanation to the heightened 
CDI severity that hypoalbuminemic patients suffer.    
 
1.3 C. difficile pathogenicity locus 
 
There are several virulence factors that contribute to the retention of C. difficile within the 
gastrointestinal tract GIT (van Nood et al., 2013), however, the exotoxins TcdA and TcdB are the main 
virulence factors produced by C. difficile (Sokol et al., 2016). Clinical strains that do not produce at 
least one of these toxins are avirulent in animal models (Youngster et al., 2014). The genes that encode 
both toxins are situated within the pathogenicity locus or PaLoc, which is a 19.6 kb region of the 
chromosome (Forssten et al., 2015). In addition to the toxin genes, tcdA and tcdB, the pathogenicity 
locus also encodes TcdR, TcdC, and TcdE, proteins that are thought to function in the regulation of 
toxin production (Pirker et al., 2013). TcdR is a member of the extracytoplasmic function (ECF) family 
of alternative sigma factors and is crucial for up-regulating the expression of PaLoc  genes (McFarland, 
2006).  
Experimental data indicates that TcdC is an anti-sigma factor that regulates the expression of tcdA and 
tcdB by preventing the association of the core RNA polymerase with TcdR (Pirker et al., 2013). 
Epidemic ribotype 027 strains have a nonsense mutation within the tcdC gene, fuelling the hypothesis 
that de-repression of the toxin genes by inactivation of TcdC may be partly responsible for the reported 
elevated toxin expression in these strains and their elevated virulence (Wong et al., 2014). The role of 
TcdC remains controversial since conflicting data have been documented about the exact function of 
TcdC in toxin production and virulence (Smits, 2013). 
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TcdE is likely to be a holin family protein which might play a role in the export of TcdA and TcdB 
from the cell (Hundsberger et al., 1997; Tan et al., 2001). Nonetheless, the specific role of this protein 
is also enmeshed in controversy, as different studies reported conflicting data on the ability of TcdE to 
effect the export of TcdA and TcdB from C. difficile (Govind & Dupuy, 2012;   Olling et al., 2012).  
TcdA and TcdB share a high degree of similarity at the amino acid level, an indication that a gene 
replication event might have given rise to the separate toxins (von Eichel-Streiber et al., 1992). Multiple 
conserved domains shared by the toxins include a catalytic glucosyltransferase domain situated at the 
N-terminus, a cysteine protease domain that is essential for auto-processing and transport of the 
catalytic domain to the intoxicated cell. In addition, there is a hydrophobic translocation domain situated 
in the centre of the toxins, which is involved in pore formation and toxin insertion into the endosomal 
membrane before they are released into the cytosol. The fourth is a C-terminal receptor binding domain 
that consists of a repeating series of oligopeptides; that has been reported to bind to unknown receptors 
on target cells (Smits et al., 2016). 
Furthermore, a direct relationship between a quorum-sensing system and C. difficile toxin production 
and pathogenesis is thought to exist (Darkoh et al., 2015). The authors demonstrated that C. difficile 
toxins are regulated via an accessory gene regulator (Agr) quorum-sensing system. The purified quorum 
signal from the culture supernatant and faecal samples of CDI patients brought about toxin synthesis in 
non-hypervirulent and hypervirulent C. difficile strains. Strikingly, the sequenced genomes of all the C. 
difficile strains encode a cysteine-containing AgrDI autoinducer prepeptide. Hydroxylamine treatment 
which is known to disrupt thioester bonds (List et al., 2012) led to a loss of activity in the toxin-inducing 
(TI) signal. A suggestion that a thioester bond is present in the TI signal and necessary for its activity. 
Following a series of experiments, Darkoh et al., (2015) further suggested that the TI signal is a novel 
thiolactone. They postulated that following a disruption of the colonic microbiota by antimicrobial 
therapy which allows C. difficile to proliferate, the rapidly increasing bacterial population synthesises 
and releases the TI signal, which accumulates in the extracellular milieu. Consequently, the local 
concentration of the TI reaches a threshold level at high cell density and activates an Agr system leading 
to transcriptional activation of the toxin genes. The detection of the TI signal in faecal samples from 
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CDI patients is an indication that this process is active in human patients and contributes significantly 
to CDI.         
 
1.3.1 Binary toxin CDT. 
 
C. difficile transferase (CDT) or binary toxin is the third toxin produced by some strains of C. difficile; 
the epidemic PCR ribotypes 027 and 078 in particular (Smits et al., 2016). There has been increased 
interest in CDT due to its increasing prevalence in human and animal C. difficile isolates (Gerding et 
al., 2014). The cdtA and cdtB genes are situated in an operon on the binary toxin locus encodes CDT 
(Goncalves et al., 2004). The binary toxin locus (CdtLoc) has an approximately 2kb deletion in CDT-
negative stains (Stare et al., 2007). The role of CDT in the pathogenesis of CDI remain elusive, 
however, it is a member of the binary ADP-ribosylating toxin family and is made up of two components: 
one enzymatic component (CDTa) and a binding component (CDTb) that enhances the passage of the 
enzymatic component to the cell cytosol (Gerding et al., 2014). Because of its ADP ribosyltransferase 
activity, CDTa once in the cytosol initiates a total destruction of the actin cytoskeleton, and eventually 
cell death (Popoff et al., 1988).  
There are contradictory reports of the role of CDT in disease. Very rare cases of C. difficile-dependent 
enterocolitis have been traced back to CDT in the absence of toxins A and B in animal models. 
Following a study that investigated the virulence of isogenic toxin mutants in a hamster CDI model, 
researchers showed that CDT increased the virulence of C. difficile when toxins A and B were present 
(Kuehne et al., 2014). One possible mechanism of action proposed by the authors was that CDT might 
increase the adherence of C. difficile owing to the formation of a network of microtubule-based 
protrusions. However, CDI was observed following infection with a C. difficile strain that was toxin A- 





1.4 Biofilm formation 
 
Biofilms are multicellular communities of microorganisms that grow on abiotic and biotic surfaces, and 
are enmeshed in a matrix of extracellular polymeric substances (EPS) (Heydorn et al., 2000), conferring 
on the microbe an effective protection from antimicrobials and disinfectants (Peng et al., 2002), and an 
increased possibility of survival in nutrient-deficient conditions (Koch et al., 2001).    
Biofilm formation has been thought to promote the persistence and pathogenesis of C. difficile (Vuotto 
et al., 2018). The growth of biofilms is seen as a potent threat due to the associated increase in bacterial 
resistance which render antimicrobials often ineffective. In spite of the likely contribution of biofilms 
to the pathogenesis of CDI, the precise mechanism governing C. difficile biofilm formation, in addition 
to the role of biofilms in CDI have not been clearly elucidated. 
Recently, Soavelomandroso et al., (2017) reported that C. difficile formed biofilms in the caecum and 
colon of a mono-associated mouse model. Although the mono-associated mouse model may not present 
an accurate representation of the human colon given its lack of microbial diversity, it allows for the 
study of C. difficile behaviour in vivo. Additionally, C. difficile is capable of coexisting in multicellular 
communities, as well as in human periodontal-disease-associated biofilms (Semenyuk et al., 2015; 
Colombo et al., 2016). In a similar manner, C. difficile has been shown to form thick biofilms in vitro 
in the presence of Finegoldia magna (Donelli et al., 2012). Such in vitro biofilms confer protection of 
C. difficile against antimicrobials such as metronidazole and vancomycin (Dapa & Unnikrishnan, 2013). 
In contrast, antimicrobials such as fidaxomicin and surotomycin were shown to have a capacity to 
distort the biofilm structure (James et al., 2018). 
Structurally, the matrix of C. difficile biofilms is made up of extracellular DNA (eDNA), proteins, and 
polysaccharides (such as polysaccharide II) (Dawson et al., 2012; Dapa & Unnikrishnan, 2013). Toxins 
were reported to be found in the biofilm matrix and might contribute to CDI upon a rupture of such 
biofilms. C. difficile has been also shown to form spores in biofilms (Semenyuk et al., 2014). 
Additionally, Crowther et al., (2014) reported that C. difficile spores were preferentially found in 
biofilm structures in a triple stage human gut model of complex multi-species biofilms.  
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Researchers have sought to ascertain if the formation of biofilms was related to the PCR-ribotype and 
sequence type. Pantaleon, et al., (2018) demonstrated that biofilm formation is not uniform among C. 
difficile strains, for example ribotypes 020 and 005 formed high and medium biofilms; sequence type 
19 strains formed high, medium, and low biofilms, an indication that there is no relationship between 
the ability of a C. difficile strain to form biofilms and clinical symptoms during infection.     
 
1.5 Diagnosis  
 
There should be a suspicion of C. difficile infection in patients with more than three loose stools in a 24 
hour period without another clear possible explanation such as the use of laxatives, especially in a 
setting with known risk factors such as: advanced age, antibiotic use, and hospitalisation (Sartelli et al., 
2019). A precise and quick diagnosis is central to effective CDI management. Such early diagnosis 
enables early treatment and may likely improve outcomes. Similarly, a quick isolation of patients with 
CDI infection is crucial in mitigating C. difficile transmission (Barbut et al., 2014).  
Clinical signs and symptoms in addition to laboratory tests should form the basis for CDI diagnosis 
(Sartelli et al., 2019). The diagnostic tests for C. difficile can test for metabolic products of C. difficile 
such as glutamate dehydrogenate (GDH), aromatic fatty acids, TcdA and/or TcdB. The detection of 
toxin-producing C. difficile can be achieved by culture methods, whereas tests for the amplification of 
nucleic acid can be carried out for C. difficile genes to detect 16S rRNA, the GDH-encoding gene, or 
toxin genes (Van Tassell & Miller, 2011). The choice of test is important to differentiate between 
asymptomatic carriers and CDI patients. Tests that detect the bacterium might suggest colonisation and 
not necessarily the disease, in contrast those that detect toxins are distinct to CDI (Wong et al., 2015). 
Due to huge differences in sensitivity and specificity of the different diagnostic tests, a two-step 
algorithm, which includes a test for C. difficile presence and the other to detect free toxins in the faecal 
sample has been recommended by the European Society of Clinical Microbiology and Infectious 
Diseases (Debast et al., 2014). Another diagnostic algorithm employs a coupled enzyme immuno-assay 
which detects TcdA or TcdB and GDH simultaneously (Ota & McGowan, 2012). For the reason that 
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the sensitivity of the toxin element of the test is unreliable, GDH-positive samples but toxin-negative, 
are made to undergo further evaluation to find out if a toxigenic C. difficile is present using a nucleic 
acid amplification test (Smits et al., 2016)   
Dependence on molecular tests for diagnosing CDI without testing for toxins will leads to over-
diagnosis and inappropriate treatment (Polage et al., 2015). Due to the fact that toxins can be found 
even after successful treatment (Louie et al., 2012), it is not advised to monitor patients regularly using 
toxin tests. Patients might be colonized asymptomatically by C. difficile and diarrhoea caused by other 
factors or patients may in fact be suffering from CDI but toxin levels are under the limit of detection of 
the chosen assay. For such patients, a clinical examination is useful to ascertain if treatment for CDI is 
required. 
The use of stool specimen limits the ability of clinicians to diagnose suspected severe CDI in patients 
complicated by ileus. Therefore, following a study by Kundrapu et al., (2012), evidence was presented 
that suggested PCR testing of perirectal swabs was an acceptable substitute to stool sample analysis for 
patients with ileus who might not be able to pass stool specimens.   
The presence of a consistent clinical picture and context such as recent antimicrobial use and 
hospitalisation are important in   deciding patients that should be tested for CDI. Abdominal pain, fever, 
leucocytosis, together with other laboratory investigations (e.g. serum lactate and creatinine) are 
important in ascertaining the severity of infection. Additionally, any of the following may be predictors 
of severe CDI a white blood cell count of > 15 × 109/L, temperature of > 38.5 °C, serum creatinine level 
of ≥ 133 μM/L or ≥ 1.5 times premorbid level, or Albumin < 2.5 g/dL (Sartelli et al., 2019). 
There is still no consensus on a single stool test that can be referred to as the reference standard for CDI 
diagnosis. Historically, toxigenic culture (TC) was used by many microbiologists as the preferred 
method for CDI diagnosis. The TC procedure involves stool culture for C. difficile in a selective medium 
and an assay to determine the capacity of colonies to produce toxins. Despite TC previously considered 
as the gold standard technique, the prolonged turnaround time, and its incapacity to discover toxins 
presence in stool are marked issues with the method. This might also result in false positive results 
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because about 7% of asymptomatic hospitalised patients might be colonised with toxigenic strains of 
C. difficile (Kyne et al., 2003). 
The use of Nucleic Acid Amplification Tests (NAATs) for the identification of C. difficile in stool 
samples from diarrhoeal patients was reported about three decades ago (Lyerly et al., 1991). NAATs 
possess low complexity, fast turnaround time, excellent specificity and sensitivity, simplified reporting, 
and a decreased requirement for repeat testing (Chen et al., 2017; Gerding et al., 2014; Smits et al., 
2016). Despite the superior specificity and sensitivity of NAATs, this assay is not routinely performed 
in many laboratories (Polage et al., 2012). Besides some setbacks have been linked with NAATs 
(Schmidt & Gilligan, 2009). An obvious limitation of NAATs is its inability to accurately differentiate 
between C. difficile colonisation and disease, which might culminate in over-diagnosis and 
overtreatment. There is still an ongoing debate if a positive stool sample from a molecular assay requires 
a confirmatory free toxin assay (Planche et al., 2013), because it is able to detect toxigenic C. difficile 
in asymptomatic patients. This reinforces the importance of testing only symptomatic patients. 
In some clinical settings, supplementary methods of testing such as radiological diagnostic imaging 
might be employed for diagnosing CDI. Computerised tomography (CT) imaging may provide useful 
information for early diagnosis, and may assist in ascertaining disease severity in CDI patients 
(Napolitano & Edmiston, 2017). CT has been widely studied as an imaging method for diagnosing C. 
difficile colitis (CDC) (Ros et al., 1996; Merine et al., 1987; Fishman et al., 1991; Boland et al., 1994). 
The most common CT finding of CDI is a thickened colonic wall. Although this is not specific and may 








1.6 Treatment  
 




Metronidazole has been the primary CDI treatment choice for over 3 decades. Nevertheless, reduced 
efficacy of metronidazole in treating CDI was documented by Musher et al., (2005). Metronidazole 
exerts its antimicrobial action by damaging bacterial DNA directly after reduction of its nitro group as 
soon as enters a bacterium (Baines & Wilcox, 2015). Reduced initial response to metronidazole and 
elevated recurrence of CDI following metronidazole first-line therapy have also been reported by Pépin 
et al., (2005), in addition to studies that have reported reduced susceptibility to metronidazole (Freeman 
et al., 2008; Brazier et al., 2001). Furthermore, metronidazole-resistant/reduced susceptible C. difficile 
have been reported in several studies (Brazier et al., 2001; Lynch et al., 2013; Orden et al., 2017). 
Notwithstanding the reports of reduced susceptibility and resistance to metronidazole, failure in CDI 
treatment has not been associated with antimicrobial resistance in C. difficile (Purdell et al., 2011). 
In Helicobacter pylori and Bacteroides fragilis, metronidazole resistance is often facilitated by 
nitroimidazole (nim) genes (Gal & Brazier, 2004), yet these genes have not been discovered in C. 
difficile (Moura et al., 2014). Despite gaps in knowledge, data from studies on strains ribotype (RT) 
010 and RT 027 indicate that metronidazole resistance in C. difficile is multifactorial with roles for 
altered metabolic pathways, such as nitro-reductase activity, DNA repair, and iron uptake (Moura et 
al., 2014; Chong et al., 2014). Additionally, the formation of biofilms has been suggested to contribute 
to metronidazole resistance in C. difficile (Vuotto et al., 2016). Although the exact role of biofilm 
growth in C. difficile metronidazole resistance remains unclear, Spigaglia et al., (2018) hypothesized 
that the biofilm matrix may act as a protective barrier, causing a change in the physiological state of the 
bacteria in the biofilm that brings about an increased resistance to antibiotics. 
Patients with moderate CDI may be treated with oral metronidazole, while on the contrary, for 
complicated or severe infections, oral vancomycin is recommended (Debast et al., 2014). Repeat 
courses of metronidazole are discouraged owing to the risk of cumulative and very likely irreversible 
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neurotoxicity (Kuriyama et al., 2011). Indeed, recent guidelines from the Infectious Disease Society of 
America (IDSA) suggested that metronidazole be administered only to patients with an initial non-
severe CDI episode in settings with limited access to vancomycin or fidaxomicin (McDonald et al., 
2018).    
Findings from different randomized controlled trials showed vancomycin was superior to metronidazole 
based on clinical cure rates in CDI patients (clinical cure rates 81.1% versus 72.7%) (Johnson et al., 
2014). Nonetheless, CDI patients with toxic megacolon or paralysed bowel, such that oral antibiotics 
are unable to reach the site of disease, can be treated with rectally delivered vancomycin plus 
intravenously delivered metronidazole (Smits et al., 2016). Furthermore, after the successful resolution 
of an initial CDI episode, the possibility of a recurrence in a period of 8 weeks is up to 25%, even worse 
for a patient with one or two prior recurrences, the risk of further recurrences is as high as 65% (Kelly, 
2012).  
 
              1.6.3 Vancomycin 
 
In a similar manner to metronidazole, vancomycin has been a first-line treatment option for moderate 
to severe CDI for over 30 years (Jarrad et al., 2015); its concentrations usually go beyond 1000 mg/L 
in faeces following oral administration (Baines & Wilcox, 2015) due to its poor absorption in the 
gastrointestinal tract (Keith et al., 2000). Vancomycin continues to have the desired activity against C. 
difficile, even against epidemic strains, and strains with reduced metronidazole susceptibility (Baines 
& Wilcox, 2015). Vancomycin brings about its antibacterial action by binding to polypeptide 
intermediates terminating in -D-Ala-D-Ala effectively inhibiting the biosynthesis of peptidoglycan, an 
important component of bacterial cell wall.  
There are sporadic reports of reduced susceptibility to vancomycin over in recent years, this is in 
addition to the emergence of single and multiple isolates from 6 European countries, resistant to 
vancomycin (MIC ≥ 8 mg/L) (Baines & Wilcox, 2015). The vancomycin resistance/reduced 
susceptibility mechanism(s) in C. difficile remain unclear. Despite Tn1549-like elements been identified 
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in several C. difficile strains (Brouwer et al., 2011; 2012), these elements, unlike the original Tn1549 
element reported in E. faecalis, have no functional vanB operon. Strikingly, a vanG-like gene cluster 
similar to that reported in E. faecalis have been also identified in C. difficile but it appears incapable of 
promoting resistance to vancomycin (Ammam et al., 2012; 2013). Interestingly, vancomycin-resistant 
mutants, with an amino acid change Pro108Leu in MurG were obtained in vitro recently (Leeds et al., 
2014). Given that MurG plays a role in the membrane-bound phase of peptidoglycan assembly, this 
amino acid substitution might affect vancomycin activity. Additionally, biofilm formation has been 
previously reported to contribute to vancomycin resistance. Indeed C. difficile within biofilms showed 
more resistance to high vancomycin concentrations (20 mg/L), and inhibitory and sub-inhibitory 
concentrations of vancomycin appeared to enhance biofilm production (Dapa et al., 2013).  
A systematic review and meta-analysis in 2015 that compared the safety and efficacy of vancomycin 
monotherapy and metronidazole monotherapy in CDI patients showed that there was no statistically 
significant difference in the rate of clinical cure between vancomycin and metronidazole for mild CDI. 
However, the rate for clinical cure was higher for vancomycin than metronidazole for severe CDI (Li 
et al., 2015). More recently, in 2017, a Cochrane review was published that suggested vancomycin was 
superior to metronidazole in all CDI cases (Nelson et al., 2017). This might be due to the superior 
pharmacokinetics of vancomycin, resulting in substantially higher intra-luminal gut concentrations 
compared to metronidazole. 
 
               1.6.4 Fidaxomicin 
 
Fidaxomicin is a narrow spectrum, macrocyclic, bactericidal antimicrobial drug, which is absorbed 
poorly following oral administration, and inhibits bacterial RNA polymerase at a site different from the 
rifamycins (Venugopal & Johnson, 2011). Fidaxomicin is the foremost new drug licensed for CDI 
treatment in 3 decades; and is now recommended for treatment in recurrent bouts of CDI (Debast et al., 
2014). Fidaxomicin has a high potency against C. difficile, with MICs typically 0.02-0.025 mg/L 
(Freeman et al., 2015). Although there are very few reports of reduced susceptibility (MIC 2-4 mg/L) 
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(Leeds et al., 2013) and resistance (MIC 16 mg/L) (Goldstein et al., 2011), even these higher MICs are 
about two  orders of magnitude lower than fidaxomicin concentrations attainable in the gut lumen 
(Baines & Wilcox, 2015). 
The antibiotic agent (orally 200 mg twice a day for 10 days) shows cure rates superior to vancomycin 
and a considerably lower CDI recurrence rate (Louie et al., 2011). Similarly, two prospective trials 
showed that fidaxomicin was superior to vancomycin for initial CDI cure (Fekety et al., 1984; Barlett 
et al., 1980) Furthermore, its deleterious effect on the composition of the indigenous microbiota, 
especially on Bacteroides species is minimal (Tannock et al., 2012). Accordingly, fidaxomicin may be 
considered for treating patients at increased risk of recurrence. 
Mutations in CD22120 (or rpoB), which encodes for a MarR (multidrug resistance-associated 
transcriptional regulator) homologue have been identified in C. difficile mutants showing resistance to 
fidaxomicin obtained in vitro (Leeds et al., 2014). Given the mutations that cause fidaxomicin resistance 
appear in rpoB gene at a different loci compared to those that cause resistance to rifamycins (Spigaglia 
et al., 2018), fidaxomicin does not lose activity against rifamycin-resistant strains (Anti-Infective Drugs 
Advisory Committee Briefing Document, Optimer Pharmaceuticals, Inc. 2018). 
The use of other antimicrobials such as teicoplanin, fusidic acid, rifamixin (Cornely et al., 2012), 
nitazoxanide (Musher et al., 2007) and tigecycline (El-Herte et al., 2012; Herpers et al., 2009) for CDI 
treatment has been reported, however, they are not recommended currently for general use. 
  
1.7 Recurrent CDI   
 
A diagnosis of recurrent CDI (rCDI) is made if CDI recurs less than 8 weeks following the resolution 
of an initial episode, as long as the symptoms from the earlier episode resolved upon completing the 
first treatment and other causes are excluded (Sartelli et al., 2019). Symptomatic rCDI occurs in about 
one in five of CDI patients (Eyre et al., 2012). Accordingly, experienced clinicians should direct the 
treatment of rCDI patients. Oral vancomycin (125 mg four times daily for 14 days) may be used for the 
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treatment of first CDI recurrence (especially if the first episode was treated with metronidazole) or 
fidaxomicin (200 mg twice a day for 10 days).  
In rCDI, vancomycin is usually administered by a prolonged tapered regimen which is thought to be 
more efficient than the standard 10 to 14 days course, even though no RCTs have been published in 
second or later CDI recurrences (Cornely et al., 2012). Fidaxomicin is associated with a lower 
propensity of CDI recurrence after an initial recurrence (Louie et al., 2011; Cornely et al. 2012; O’Horo 
et al. 2014). However, there is still an absence of prospective RCTs investigating the potency of 
fidaxomicin in patients with multiple RCDI. Nonetheless, faecal microbiota transplant have been 
reported to resolve rCDI (Gough et al., 2011). 
 




Changes to the microbiota that result in reduced strength of the mucosal barrier can result in CDI. 
Accordingly, a plan to boost mucosal barrier function will confer health benefits in a healthy individual 
and may play a role in disease prevention. 
Prebiotics are non-digestible (by the host) oligosaccharides that selectively enhance the activity and/or 
growth of a limited number of beneficial bacterial species in the gut which benefits host health (Gibson 
& Roberfroid, 1995). Therefore, adding prebiotics to the diet might increase the activity and biomass 
of lactic acid-producing bacteria (lactobacilli and bifidobacteria), that boosts the host’s mechanism of 
defence. Some compounds that have been documented to show prebiotic activity are fructo-
oligosaccharides, lactulose, galacto-oligosaccharides (Gibson et al., 2004), and inulin (Joshi et al., 
2018). Some of these prebiotic compounds for example inulin are present naturally in foods such as 
bananas, onions, leeks, garlic, asparagus, and wheat (van Loo et al., 1995). Prebiotic compounds can 
also be extracted from tubers and vegetables, for example Jerusalem artichoke and chicory root. Pectins 
and xylans are examples of polysaccharides in plant cell walls with a growing potential to be prebiotics 
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(Scott et al., 2019). The growing popularity of such prebiotic candidates is largely due to their 
indigestibility within the upper GIT and their selective fermentation by microbiota in the colon.  
Current prebiotics are mainly carbohydrate-based, however, other compounds like polyunsaturated 
fatty acids and polyphenols might have prebiotic activity (Gibson et al., 2017). It is important to 
highlight that increased ingestion of prebiotic foods might not lead to an expression of a profound 
prebiotic effect given the dose of prebiotic required for such beneficial health effect. Although the 
optimum prebiotic dose is unclear, studies have reported different prebiotic doses ranging from 5-8g/d 
(Bosscher et al.,2006; Ramnani et al., 2010) 12 g/d (Lewis et al., 2005; Van Loo et al., 2005), 15 g/d 
(Den Hond et al., 2000; Jain et al., 2004), 25 g/d (Welters et al., 2002), to 32 g/d (Anderson et al., 2004) 
that recorded improved clinical outcomes such as anti-carcinogenic effect, improved nutritional status, 
as well as a reduced incidence of hypercholesterolemia.  Accordingly, frequently consumed foods may 
be fortified with prebiotics. 
More recent knowledge of the gut microbiota composition has revealed that lactobacilli and 
bifidobacteria which were the original targets of prebiotics constitute only a small component of the gut 
microbiota which is predominantly dominated by Firmicutes and Bacteroides, including 
Ruminococcaceae and Lachnospiraceae. Specifically increasing concentrations of butyrate, the 
metabolic outcome of some prebiotics can be improved (Riviere et al., 2016). Research has now shown 
that inulin-type fructans (ITFs) enhance the growth of bifidobacteria, as well as increase the populations 
of Faecalibacterium prausnitzii (Ramirez-Farias et al., 2008). Similarly, Neyrinck et al., (2011) 
reported that Roseburia species numbers are enhanced by arabinoxylans.  Roseburia spp. and F. 
prausnitzii constitute the most prevalent producers of butyrate in the human gut (Louis et al., 2010).       
There is evidence that various bacterial genera are capable of utilising prebiotics as growth substrates 
in vitro (Scott et al., 2014). Observed effects in vitro may not guarantee similar effects in vivo because 
other individual factors may affect the capacity of prebiotics to bring about beneficial effects. For 
example, different individuals have a tendency to be colonised by distinct particular bifidobacterial 
species, and in the Bifidobacterium genus there exists a marked difference in the capacity of different 
species to utilise differing chain lengths of inulin-type fructans (Selak et al., 2016). Therefore, if the 
41 
 
indigenous microbiota lacks the particular bacterium that is able to utilise the added prebiotic, the effects 
may not be seen. The structure of most prebiotics often consists of sugars with β(2→1), β(1→6), 
β(1→3), or β(1→4) linkages. This linkage bonds in FOS and GOS are readily degraded by β-
fructanosidase and β-galactosidase enzymes respectively, which are abundant in particular 
bifidobacterial species (Gibson et al., 2017). Additionally, Scott et al., (2014) demonstrated that the 
chain length of some prebiotics for example fructans is an important criterion in ascertaining which 
bacteria can ferment them.    
It is equally important to highlight that gut bacteria coexist in a mixed, competitive ecosystem. This 
implies that results from pure culture experiments do not necessarily mean a particular strain can utilise 
the same substrate in a competitive condition. Some bacteria depend on metabolites released by other 
bacteria for growth. This was shown in a co-culture experiment where Eubacterium hallii was unable 
to grow on FOS substrate, whereas Bifidobacterium adolescentis grew well on FOS, subsequently 
releasing acetate and lactate. Interestingly, in the mixed culture, q-PCR quantification confirmed the 
growth of both bacteria, and no lactate, only butyrate was detected in the growth medium (Belenguer 
et al., 2006; Moens et al., 2017).   
Batch-culture experiments using isolated bacteria in vitro showed that bifidobacteria (Gibson & Wang, 
1994), in addition to some lactobacilli, such as Lactobacillus plantarum (Cebeci & Gürakan, 2003) 
grew in culture medium with oligofructose or inulin as the single source of carbon, as well as a 
corresponding decrease in faecal pathogens, clostridia, coliforms, and Bacteroides spp. This is 
consistent with a report of the bifidogenic effects of oligofructose and inulin in human subjects that 
were fed oligofructose 15g/d with a supplementation of the diet with inulin 15g/d for 2 weeks (Bosscher 
et al., 2006). The numbers of fusobacteria, clostridia, and Bacteroides spp. decreased considerably (P 
< 0.01). Consequently, prebiotics have become an attractive intervention to potentially prevent CDI. 
Indeed, Piotrowski et al., (2019) reported a concentration-dependent anti-adhesive effect of mannose 
and fructooligosaccharides against C. difficile by significantly reducing the adhesion of C. difficile 






The gut microbiota is a very diverse and complex community of microbes which has co-evolved in a 
commensal manner with humans (Donaldson et al., 2016). This community of microorganisms in a 
healthy state confers protection to the host by preventing colonisation by pathogens; so-called 
colonisation resistance. However, the intestinal microbiota can be disturbed by exposure to 
antimicrobial agents, resulting in a decreased species diversity and microbial abundance. This in turn 
can compromise the gut barrier and can culminate in antibiotic-associated diarrhoea (Valdes-Varela et 
al., 2018). In some individuals (ca. 20% of antibiotic associated diarrhoea), the dysbiosis upon antibiotic 
treatment permits an overgrowth of C. difficile owing to the fact that the perturbed intestinal 
environment has a high abundance of carbohydrates and primary bile acids, a decreased concentration 
of short chain fatty acids, and an immunocompromised host with no microbial competitors in the gut 
(Lawley & Walker, 2013). 
The standard treatment for CDI is metronidazole, vancomycin, or fidaxomicin, but reduced 
susceptibility and resistance to these agents, as well as the recurrence rate of CDI and a perpetration of 
dysbiosis has prompted scientists to seek alternative therapies which have been reviewed by different 
researchers (Martin & Wilcox 2016; McFarland 2016; Padua & Pothoulakis, 2016). Consequently, 
probiotics have been suggested as a potential therapy for the prevention of microbiota dysbiosis caused 
by antibiotic administration, and restoration of the microbiota following antibiotics use (Reid et al., 
2011).      
Probiotics are live organisms that present beneficial effects to the health of host when administered in 
sufficient quantity (Joint, 2001). To an increasing extent, they are readily available as dairy-based 
products and capsules, and can be purchased in supermarkets. Inasmuch as there exist a high number 
of commercially available probiotics, their beneficial effects (if any) and the specific organisms that 
might be most potent in a specific patient group remains debatable (Hempel et al., 2012). Commonly 
employed microorganisms in probiotic preparations include Bifidobacterium spp., Bacillus spp., 
Lactobacillus spp., Saccharomyces spp., and Escherichia spp. (Ohashi & Ushida, 2009).  
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Many strain- and species-specific factors dictate what benefit a probiotic might confer. A probiotic must 
be able to colonise the GIT by adhesion to the gastrointestinal mucosa (Van Tassell & Miller, 2011) in 
order to bring about its beneficial effects. Even though it still remains unclear, present evidence 
indicates that the adhesive characteristics of probiotics might be as a result of distinctions in the 
expression of large surface proteins and their interactions with mucus-binding proteins (Van Tassell & 
Miller, 2011).  
Lactobacilli and bifidobacteria are thought to possess immune-modulating abilities. In mouse 
experiments (Pouwels et al., 1996), in addition to human studies (Kaila et al., 1992), the oral 
administration of lactobacilli has been demonstrated to lead to an increased production of gamma-
interferon and marked increased IgA secretory responses against Salmonella, and elevated stimulation 
of lymphocytes, macrophages, and natural killer cells.  Similarly, there is some evidence that 
Saccharomyces boulardii is capable of reducing the incidence of AAD (McFarland, 2010), 
notwithstanding, there is evidence of the probiotic properties of Lactobacillus rhamnosus GG 
(McFarland, 2006), L. acidophilus La-5 and Bifidobacterium Bb-12 (Wenus et al., 2008), and 
Streptococcus thermophilus (Hickson et al., 2007). A meta-analysis carried out by Hempel et al., (2012) 
included 82 randomised controlled trials, out of which 17 involved Lactobacillus interventions. The 
meta-analysis showed that probiotic administration was linked to reduced risk of AAD, although, there 
were differences in study designs, probiotic strain type, length of treatment, dosage, and study 
population, probably providing an explanation to previous discrepancies (McFarland, 2006).  
The use probiotics in preventing AAD and CDI in patients in spinal injuries centres was reported by 
Wong et al., (2015), this is in tandem with the findings of Lewis et al., (2009) that suggested probiotic 
fermented milk products containing probiotics reduced the risk of AAD and CDI by a number of 
mechanisms such as: competition for colonization sites and nutrients, SCFA production which reduces 
the pH of the gut, immune stimulation, and production of antimicrobials such as bacteriocins that 
directly antagonize pathogenic bacteria. Bifidobacterium have been reported to produce proteinaceous 
compounds that impact on the growth of a vast array of both Gram-positive and Gram-negative bacteria 
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(Gibson & Wang, 1994). Fukuda et al., (2011) demonstrated that the acetic acid produced by 
bifidobacteria has a key role in the protection against invading microbial pathogens 
The capacity of probiotics to inhibit C. difficile growth has been documented by employing various 
experimental techniques (Auclair et al., 2015; Forssten et al., 2015; Valdes-Varela et al., 2016b; 
Fredua-Agyeman et al., 2017). In spite of the large number of studies undertaken in vitro for the 
identification of probiotics with activity against C. difficile and the selection of probiotic strains for the 
treatment or prevention of CDI, strong evidence from human trials on a CDI-specific benefit of 
probiotic therapy is still limited. Various probiotic strains have been associated with an increased 
colonisation resistance against C. difficile (Hopkins & Macfarlane 2003; Auclair et al. 2015; Forssten 
et al. 2015). Some lactobacilli and bifidobacterial strains have been reported to decrease the adhesion 
to intestinal mucus or intestinal epithelial cells by C. difficile (Collado et al., 2005; Banerjee et al., 
2009) or shown an ability to prevent C. difficile growth (Lee Chung & Seo 2013; Valdes-Varela et al. 
2016b). Additionally, animal studies appear to reaffirm a likely benefit of probiotics in increasing 
colonisation resistance against C. difficile (Mansour et al., 2017). Nonetheless, a majority of the clinical 
studies have been centred on prevention, and there is an absence of data on the possible use of probiotics 
for CDI treatment. 
Despite the large number of probiotic strains studied in vitro, almost all the evidence from clinical trials 
were obtained from a handful of strains. Among the screened strains, the ability of the yeast 
Saccharomyces boulardii (Kotowska et al., 2005; Besirbellioglu et al., 2006) or Lactobacillus 
rhamnosus strain GG (Vanderhoof et al., 1999) in preventing AAD has been widely reported.  
Despite limitations due to inter-product and inter-strain variability, meta-analysis studies of probiotics 
for AAD prevention have continuously presented evidence for a beneficial role (Cremonini et al., 2002; 
Sazawal et al., 2006; Goldenberg et al., 2015). Moreover, some studies have paid specific attention to 
confirmed CDI and such studies have also reported positive results for primary CDI prevention (Gao et 
al., 2010; Allen et al., 2013; Dietrich et al., 2014; Maziade et al., 2015). For example, a Canadian 
hospital, the ‘’Pierre-Le Gardeur’’ administered a probiotic mix simultaneously with any antibiotic after 
a C. difficile outbreak. This culminated in a marked reduction in the number of CDI cases (Maziade et 
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al., 2015). In general, the data from systematic reviews and meta-analysis support a beneficial role of 
probiotics on the primary prevention of CDI. Although, the heterogeneity that exists between clinical 
studies makes it more challenging to define the most suitable probiotic to use, the dose, and its 
administration regime. 
Even though no cases of translocation of microorganisms have been reported in clinical trials with 
probiotics for antibiotic‐associated diarrhoea or CDI, probiotics should be used with caution. Several 
studies of invasive disease have been reported, resulting from the use of probiotics such 
as Saccharomyces boulardii in debilitated or immunocompromised patients (Enache-Angoulvant, & 
Hennequin, 2005; Munoz et al., 2005). Besides, probiotics were linked with increased mortality, partly 
due to non‐occlusive mesenteric ischaemia, in a randomized controlled trial in acute pancreatitis 
(Besselink et al., 2008). 
The available data on the use of probiotics in preventing CDI recurrence is more limited than that of 
primary CDI prevention. Some intervention studies have been carried out with varied outcomes 
(McFarland et al., 1994; Surawicz et al., 2000), with meta-analysis and reviews suggesting there exists 
only limited evidence on the benefits of probiotics in secondary CDI prevention (Allen et al. 2013; 
O’Horo et al., 2014; McFarland 2015). The absence of sufficient evidence on secondary CDI prevention 
reinforces the need for more intervention studies in this regard. 
Until recently, cost-effectiveness analyses of probiotics in CDI prevention have not been undertaken, 
with different results (Leal 2019; Starn et al., 2016), necessitating further research to be conducted in 
different healthcare systems.  
 
1.8.3 Faecal microbiota transplantation    
 
Evidence of the effectiveness of faecal microbial transplantation (FMT) continues to expand, yet it is 
still a non-regulated product. FMT entails implanting beneficial intestinal bacteria from a healthy donor 
to the gut of an individual with a dysfunctional microbiome. FMT is a very efficient rescue treatment 
and should be contemplated in patients who have had more than two recurrences, as antibiotics efficacy 
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in these patients is not more than 30% (Smits et al., 2016). The rationale behind FMT is that intestinal 
dysbiosis might be corrected by reintroducing normal flora through healthy donor faeces, and normal 
bowel functioning restored (Bakken et al., 2011)   
Van Nood et al ., (2013) reported that FMT was 81% effective in treating multiple recurrent CDI in a 
randomised controlled trial, although only 16 patients participated in the study. It is better to set aside 
FMT for patients with several recurrences of CDI who do not respond to other options of treatment 
(Bakken et al., 2011; Johnson et al., 2012; Cammarota et al., 2014; Goldenberg et al., 2017). 
Nonetheless, FMT lacks public acceptance and it is not a standard procedure, and the long-term effects 
of changing the gut microbiota of a patient are not known. These acceptability and safety concerns have 
meant FMT is yet to be adopted widely as a therapy.  Therefore, a number of national guidelines have 
been devised to standardize FMT. Such guidelines include donor screening and selection (Sokol et al., 
2016).  
Data from a preliminary study of patients with a degenerative CDI showed that FMT using encapsulated 
inoculum (frozen) from different donors culminated in an improved outcome (Youngster et al., 2014). 
Such encapsulated preparations are simpler to administer and are less invasive, which might improve 
cost-effectiveness (Hirsch et al., 2015). Despite the high success rates of FMT (Orenstein et al., 2016), 
the ‘’handling’’ of faeces and the enteral instillation techniques are not only unattractive for patients 
and physicians but it is also laborious.  There is an increasing likelihood that future research will result 
in the production of cocktails of important microorganisms, combined according to the roles of the 
microorganisms in the microbiota against CDI, in place of FMT. This might improve the social 
acceptance and feasibility of microbiota transplantation.  Petrof et al., (2014) reported that a mixture of 
33 bacteria was effective against CDI in two patients. Similarly, bacteriotherapy using a cocktail of 
twelve bacteria retrieved from healthy donors resolved CDI and prevented CDI recurrence inside 30 
days in 64% of patients (Tvede et al., 2015). In a murine study, Buffie et al., (2015) demonstrated that 
a mixture of four bacterial species protected mice from CDI, suggesting an activity via indirect effect 
on metabolism of bile acid. 
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Following a systemic review in 2011, Gough et al. reported that out of 317 CDI patients treated across 
27 case series and reports, FMT was effective, recording CDI resolution in 92% of cases. Furthermore, 
35% of patients in those studies administered FMT through enema, with a response of 95%, 19% of 
patients were administered through colonoscopy with a response rate of 89%, and 23% via naso-jejunal 
tube by gastroscope, with 76% response rate. FMT effectiveness differed by volume of FMT received, 
route of administration, treatment prior to instillation, and relationship to the donor (Gough et al., 2011). 
Another systemic review by Cammarota et al., (2014) that included 20 full-text case series, 15 case 
reports, and 1 RCT, in which the majority of participating patients that were treated with FMT had 
suffered recurrent CDI episodes with diarrhoea in spite of standard antibiotic therapy. Out of 536 
patients that received FMT, 87% (467) had their diarrhoea resolved. The rates of diarrhoeal resolution 
varied depending on infusion site: 93% in the ascending colon/caecum, 86% in the jejunum/duodenum, 
84% in the distal colon, and 81% in the stomach. Severe adverse events due to the procedure were not 
reported. 
More recently, Quraishi et al., (2017) published a review that evaluated the efficacy of FMT in the 
treatment of recurrent CDI; thirty case series and 7 RCTs were included. The authors concluded that 
FMT was more efficient than vancomycin in resolving recurrent CDI. Across all studies, clinical 
resolution of CDI was 92%. A marked difference was recorded between upper GI (88%) and lower GI 
delivery (95%) (p=0.02). No difference was observed between frozen and fresh FMT (p=0.84). 
Instilling consecutive FMT courses upon failure of initial FMT led to an incremental effect. There was 
a consistent donor screening, although there were differences in FMT volume and recipient preparation. 
Severe adverse events were not common.  
Nevertheless, serious side effects such as disease flares have been reported following FMT (Cui et al., 
2015; Costello et al., 2017). A case of aspiration pneumonia was reported in a patient that received 
FMT via the nasogastric route (Vermeire et al., 2016), in addition to mortality due to sepsis and toxic 
megacolon (Grewal et al., 2016).            
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Successful FMT practice requires long-time safety data, owing to the far-reaching consequences of the 
gut microbiota in health especially how a new gut microbiota may affect immune responses and brain 
function.  
 
1.8.4 Non-toxigenic C. difficile 
 
Non-toxigenic strains of C. difficile (NTCD) are avirulent due to the absence of the major virulence 
factors of Toxins A and B within the C, difficile genome. In theory, it might be attainable for NTCD to 
displace their toxigenic counterparts in infected or colonised individuals by competing for germinants 
and essential growth factors. A phase 2 double-blind, randomised, dose-ranging placebo-controlled trial 
assessed the ability of a NTCD strain in preventing recurrent CDI (RCDI) in patients with primary or 
recurrent infection who had completed treatment with vancomycin, metronidazole, or both 
antimicrobials (Gerding et al., 2015). The NTCD-M3 strain successfully colonised 69% of recipients. 
In the NTCD-colonised subjects, CDI recurrence rates were 2%, in comparison to 31% of recipients 
who were not colonised (p ˂ 0.001), which was similar to placebo. This is an indication of the 
relationship between NTCD-colonisation and clinical efficacy. Strikingly, subjects that were colonised 
with NTCD at week 6 were no longer colonised at week 26. However, it has been shown experimentally 
that NTCD strains can be converted by genetic recombination and horizontal gene transfer into toxin 
producers in vitro (Brouwer et al. 2013). It is worrisome that distinct types of the pathogenicity locus 
could be acquired and transferred seemingly by any strain as this makes all the NTCD strains candidates 
for becoming toxin producers. Whether this acquisition of a toxigenic PaLoc can occur in vivo however, 
remained to be determined. The potential acquisition of the pathogenicity locus by NTCD strains that 
already show high resistance to antimicrobials widely employed in CDI treatment is a very troubling 
concern and therefore needs to be fully evaluated in any NTCD being considered as probiotics. For 
example, RT 010 strains are highly resistant to metronidazole (Moura et al., 2013). These findings about 
the PaLoc by Brouwer et al. might have far-reaching consequences on the probiotic prospect of NTCD, 
besides these events may be relevant to other pathogenic and commensal bacteria as well. A possible 
commercial development of NTCD strains remains to be seen. Unfortunately, it is very challenging to 
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develop new treatment/management for CDI, which will require well-designed studies with clearly 
defined populations.  
 
1.8.5 Monoclonal antibodies 
 
Owing to the fact that an expression of toxins A and/or B is essential for CDI development, the invention 
of monoclonal antibodies that work towards the prevention of the cytotoxic effect of the toxins holds 
promising potentials for disease prevention. The Food and Drug Administration (FDA) in 2016 
approved bezlotoxumab, a human monoclonal antibody to decrease CDI recurrence in adults receiving 
antibiotic treatment for CDI and are at a heightened CDI recurrence risk. Bezlotoxumab (MK-6072) 
reduces RCDI by interfering with the binding of toxin B to cells of the host, hence mitigating epithelial 
damage and enhancing microbiota recovery (Barlett, 2017). Actoxumab is another human monoclonal 
antibody developed recently to neutralise C. difficile toxin. 
Data from two randomised, double blind, placebo-controlled phase 3 trials, MODIFY I and II, which 
involved 2655 patients receiving antibiotics for primary or RCDI showed that bezlotoxumab 
successfully brought about a significant benefit compared to placebo in treating RCDI (Wilcox et al., 
2017). Patients were administered bezlotoxumab 10 mg/kg of body weight, bezlotoxumab plus 
actoxumab 10 mg/kg of body weight each, or placebo. Actoxumab alone was administered in MODIFY 
I.  
In both studies, the RCDI rate was considerably higher with placebo than with bezlotoxumab alone. 
MODIFY I: 28% vs. 17% respectively, p ˂ 0.001; MODIFY II: 26% vs 16% respectively, p ˂ 0.001 
(Lubbert & Nitschmann, 2017). Actoxumab when given alone was not effective and showed no 






1.8.6 Bacteriophage therapy 
 
Phages are viruses that specifically infect bacteria. Their use for the treatment of diseases has been 
widely discussed, and phages have been reported to remove or reduce specific bacteria that accounts 
for a number of infections in animals and humans (Loc-Carrillo & Abedon 2011; Hargreaves & Clokie 
2014; Parasion et al., 2014). There have been recommendations that phage therapy be used as an 
alternative to antibiotics intervention in CDI (Zucca et al., 2013; Hargreaves & Clokie 2014; Sangster 
et al., 2014). Moreover C. difficile phages with capacity to access the lytic life cycle have been isolated 
(Goh et al., 2005; Meader et al., 2010), although it is useful to point out that the isolation of phages for 
C. difficile is extremely challenging. Prior reports have shown C. difficile-specific phages form clinical 
and environmental samples did not follow a strictly lytic lifestyle, in spite of their lytic activity, as their 
genomes encode integrases (Goh et al., 2005; Govind et al., 2006; Sekulovic et al., 2014).  
Bacteriophage therapy is another promising treatment approach for multidrug resistant bacteria 
although phage therapy also suffers from resistance development against phages, and possibly phage-
mediated transfer of bacterial virulence and antibiotic resistance genes. Nonetheless, it is an attractive 
option for CDI treatment given its non-disruption of the microbiota and targeted mechanism of action.  
Studies in this regard are limited in part due to concerns about employing temperate phages which may 
possibly incorporate viral nucleic acid into DNA of the host and a limited availability of recognised 
lytic phages that are specific for C. difficile. Following a study that evaluated the capacity of 7 distinct 
phages, alone and when combined, to decrease the bacterial load of eighty different C. difficile strains 
covering 21 different ribotypes, Nale and colleagues (2016) reported that the most effective phage 
combination was strain-specific. However, multiple four or three phage combinations completely lysed 
C. difficile cultures in vitro within 2 to 5 hours. Additionally, combination phage therapy-treated 
hamster showed reduced C. difficile colonisation at 36 hours post-infection, a 33-hour delay in the onset 
of symptoms compared to untreated animals, and a 4-log decrease in C. difficile spore and bacterial 
counts in the colon. This suggests a likely therapeutic value for phage combinations in CDI, however, 
it is unlikely that such phage combinations would be useful in CDI where there are such diverse an 
array of virulent C. difficile strains causing infections in the clinical setting. 
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More recently, Nale et al., (2018) demonstrated that an optimised 4-phage cocktail was able to clear 
clinical ribotype 014 / 020 cultures in fermentation vessels spiked with faecal slurry form healthy 
volunteers. C. difficile counts declined by about 6-log after 5 hours and a total eradication after 24 hours 
upon the prophylactic regimen. Similarly, the effectiveness of FMT in CDI is thought to be associated 
with the abundance of bacteriophage in the donor (Park et al., 2019).  Nevertheless, developing a phage 
with no integrase activity to minimise the risk of transmitting mobile genetic elements, as well as safety 
concerns continue to be huge challenges with phage therapy.     
 
1.9 Non-human C. difficile sources and reservoirs. 
 
C. difficile can be found in humans, animals, and the environment. The sizeable overlap between 
ribotypes from all three reservoirs is an indication of extensive transmission. 
 
1.9.1 C. difficile in animals   
 
The presence of C. difficile in animals (horses and rabbits) and in the environment (sand, river mud, 
and hay) in Europe has been described in the literature over four decades ago (Hafiz, 1974). 
Subsequently, other researchers in different European countries have also reported the identification of 
C. difficile and infection in pigs (UK) Lysons et al., (1980), hares (France) (Dabard et al., 1979), goats 
(UK) (Hunter et al., 1981), Chickens, ducks, and geese (UK) (Borriello et al., 1983). The first mention 
of C. difficile in cattle in Europe in which C. difficile toxins were observed in samples from calves was 
published by Pirs et al., (2008). 
The pathogenic potential of C. difficile in farm animals has been a subject of research over the past two 
decades (Pirs et al. 2008; Koene et al., 2012; Spigaglia et al., 2015). Although the interest in C. difficile 
as an infectious agent in livestock and the likely accompanying economic losses are driving forces, the 
principal aim of many of the studies globally has been focused on demonstrating the presence of an 
52 
 
animal reservoir and to find explanations on the association between CDI in humans and potential 
reservoirs. 
As interest about a potential zoonotic C. difficile transmission increases, factors such as age, species, 
seasonality, microbiota, and breeding effect have been correlated with colonisation in farm animals 
(Rodriguez et al., 2016). Age is the most studied factor concerning C. difficile colonisation in farm 
animals. Studies indicate high colonisation rates in newly born animals and are significantly reduced or 
eradicated in adult animals (Alvarez-Perez et al., 2009; Schneeberg et al., 2013a). This widely reported 
reduction in both colonisation and infection prevalence with age means foodborne transmission risk 
from contaminated animals and animal products during harvest is largely reduced. Another 
consequence is that CDI in adult animals is sparse, accordingly, C. difficile is not currently regarded as 
a common health issue in adult farm animals.   
  
1.9.2 C. difficile in the environment and food 
 
Food borne zoonotic pathogens are often transmitted by the consumption of contaminated food and 
water. Since the initial report of the possible foodborne transmission of C. difficile in Europe in 1983 
(Borriello, 1983), the significance of the bacteria as a zoonotic disease remained uncertain.  C. difficile 
colonises the GIT of animals, then the bacterial spores are excreted in the faeces. In this manner, animals 
can act as a source of environmental contamination. Healthy animals may carry C. difficile spores into 
the slaughter phase and establish a potential risk of meat contamination in the course of processing. 
Indeed, a number of studies have reported retail meat contamination with C. difficile (Songer et al., 
2009; Bouttier et al., 2010; Weese et al., 2010) 
Irrigation with contaminated water or manure spread would contaminate vegetables. Although even 
without fertilizing, root vegetables can carry C. difficile spores present in soil. Furthermore, the 
bacterium (RT 009 and 066) has been isolated from zooplankton samples from the Gulf of Naples Italy 
(Pasquale et al., 2011). The work of Pasquale et al. showed for the first time that C. difficile can be 
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adapted to aquatic marine populations, an indication that C. difficile can be transmitted by ingesting 
undercooked or raw seafood.  
A proportion of C. difficile strains is probably transmitted constantly between humans, environment, 
and animals as partial overlap of PCR ribotypes isolated in the same country over a period of 3 years 
from humans, environment, and animals showed that 11 out of 90 PCR ribotypes were shared between 
all three reservoirs (Janezic et al., 2012). Even strains within a particular ribotype still represent a very 
heterogeneous group and WGS level is required for identity confirmation. So far, this has been 
undertaken in only two studies, one on ribotype 078 strains in Netherlands (Knight et al., 2016) and the 
other on ribotype 014 strains in Australia (Knetsch et al., 2014). Although the proportion of the shared 
strains in both studies was low, identity between human and pig strains was demonstrated.    
 
Overall aim: To investigate a probiotic intervention than can modulate C. difficile spore germination, 
growth, and toxin production in an in vitro human gut model. 
 
Hypothesis: The introduction of probiotic strains to an antimicrobial-depleted microbiota in an in vitro 
human gut model may modulate spore germination, growth, and toxin production by C. difficile due to 










 2.0 General materials and methods 
This study was approved by the University of Hertfordshire ethics committee for studies involving 
human participants (LMS/SF/UH/00103). 
 
2.1 Isolation and culture of C. difficile 
Agar and liquid-based cultures were incubated and maintained in an anaerobic cabinet (MG500, Don 
Whitley Scientific UK) in conditions of 80%, 10%, and 10% nitrogen, carbon dioxide, and hydrogen 
respectively. Antibiotic preparations were filter-sterilized using a 0.22µm syringe filters (SLGP033RS 
Millipore, Carrigtwohill Ireland).   
 
 2.1.1 C. difficile strains 
The C. difficile strains used in the gut model experiments are PCR ribotypes 027 and 010. RT 027 used 
in this study was isolated in 2005 from Portland Medical Centre, USA, and provided by Prof. Mark 
Wilcox, University of Leeds and Leeds Teaching Hospital NHS Trust. This strain was used because C. 
difficile PCR ribotype 027 has been responsible for the epidemic spread of CDI and produces higher 
levels of toxins (Debast, 2014). Moreover, RT 027 was responsible for the epidemics of CDI in North 
America and Canada between 2004 and 2005 (Loo et al., 2005; Warny et al., 2005) and England in 
2005 (Smith, 2005). RT 010 strain was also provided by Prof. Mark Wilcox. RT 010 was the first 
metronidazole reduced susceptibility C. difficile strain reported in the UK (Brazier et al., 2001). The 
RT 010 strain has a metronidazole MIC of 16 mg/mL (by E-test), it is nim negative and non-toxigenic 





2.1.2 Culture of C. difficile on solid medium  
Brazier’s agar (LAB160, Lab M limited, Lancashire, UK) was supplemented with 2 vials/L cycloserine 
(250 mg/L) cefoxitin (8 mg/L) supplement (X093, Lab M limited, Lancashire, UK), 20mL/L lysed 
horse blood (SR0050C, Oxoid, Basingstoke UK) was used for the isolation of C. difficile. Agar plates 
were pre-reduced for 24 hours at 37oC  in the anaerobic cabinet before inoculation. C. difficile colonies 
were observed as grey opaque, about 4mm in diameter, and with a phenolic or horse manure odour 
(Delmee, 2001). 
 
2.1.3 Culture of C. difficile in liquid medium 
Brain Heart infusion (BHI) broth (LAB049, Lab M limited Lancashire UK)) was prepared according to 
the manufacturer’s instruction. Schaedler’s anaerobic broth (CM496, Oxoid UK) was prepared 
according to the manufacturer’s instructions. In a similar manner to the solid medium, all liquid medium 
was pre-reduced for 24 hours at 37oC in the anaerobic cabinet before inoculation.  
 
2.1.4 Preparation of C. difficile spores 
C. difficile was cultured onto supplemented-Brazier’s agar plates and anaerobically incubated for 48 
hours at 37oC. Colonies were sub-cultured onto 50 Columbia blood agar (CBA) (LAB001, Lab M 
limited, Lancashire, UK) (CBA) plates and incubated in anaerobic conditions for one week at 37oC.  All 
growth was harvested from the CBA using a sterile swab (300230 Deltalab, Rubi Spain) and transferred 







2.2 Triple-stage gut model  
The triple-staged continuous culture system was validated by MacFarlane et al., (1998) to assess the 
effect of retention time on the ecology and metabolism of bacteria in the human colon. The fermentation 
system was designed to mimic the spatial, temporal, nutritional, physical, and chemical properties of 
the proximal, transverse, and distal colon. The gut model equipment is shown in Figure 2.1. The gut 
model was made up of three glass fermentation vessels (Vessel 1 (V1), Vessel 2 (V2), and Vessel 3 
(V3)) (Soham Scientifiic, UK) operating in a weir-cascade system, flowing into a waste unit. The 
fermentation vessels were made of an outer jacket through which heated deionised water at 37oC flowed 
from a circulating water bath (TC120 Grant, Royston UK) to maintain the contents of the inner reaction 
vessel at 37oC. V1 had an operating volume of 280 mL, while V2 and V3 had a working volume of 300 
mL. V1 had a higher substrate availability, promoting increased bacterial growth, and was operated at 
a pH mimicking the environment of the proximal colon. Contrastingly, V3 was similar to the neutral 
pH, low substrate availability, and slow bacterial growth, which is obtainable in the distal regions of 
the colon. The pH in Vessels 1, 2, and 3 were detected using pH probes (238764 Hamilton Bonaduz, 
Switzerland) and maintained at pH 5.5, 6.2, and 6.8 respectively (to mirror the increasing alkalinity of 
the human colon from proximal to distal) employing pH controller units (Anglicon Solo 2, Brighton 
systems, Newhaven, UK). Fermentation vessels were magnetically stirred (SB-161-3, Stuart, 
Staffordshire UK) and sparged with oxygen-free nitrogen (Parker, Domnick Hunter, Gateshead UK) 
via a 0.3 µm air inlet through a filter (6723-5000 Whatman, Buckinghamshire UK) to maintain 
anaerobiosis.  The tubing for attachments to the gut model was MarpreneTM autoclavable tubing (PHY-
695-061E  1.6mm wall, 6.4mm inner diameter, Watson-Marlow limited, Cornwall UK ), whereas 
growth medium tubing was TygonTM autoclavable tubing (1.6mm wall, 3.2mm inner diameter Fisher 
Scientific, Leicestershire UK). The constituents of the growth medium are listed in Table 2.1. Growth 
medium was supplied to the gut model at 13.2mL/h (Retention time 66.7h, D=0.015 h-1) using a 
peristaltic pump (120S Watson-Marlow, Cornwall UK). Addition of 10% (v/v) polyethylene glycol 
(P3015, Sigma Aldrich Dorset UK) was added to vessels to prevent foaming ad libitum. Controller units 
automatically dispensed 1M NaoH (S/4880/60, Fisher UK) or 1M HCL (H/1200/PB17, Fisher UK) to 




Figure 2.1. The triple-stage gut model 
  
2.2.1 Preparation of gut model growth medium 
Gut model growth medium was prepared in 2L volumes in conical flasks (Pyrex, England). Sterilization 
was carried out by autoclaving at 121oC for 15 minutes. Thereafter, resazurin (R7017-5G, Sigma USA) 
and glucose (G-5250 Sigma Aldrich, UK) was filter-sterilised into the medium to obtain final 





Table 2.1 Gut model growth medium constituents (Macfarlane et al., 1998). Chemicals were obtained 
from Sigma-Aldrich, UK unless otherwise stated. 
Formulation Catalogue number g/L 
Peptone water CM0009 2.0 
Yeast extract  LP0021 2.0 
Sodium chloride  S/3105/63/63 0.1 
di-Potassium hydrogen phosphate (K2HPO4) P/5240/53 0.04 
Potassium di-hydrogen phosphate (KH2PO4) P/4800/53 0.04 
Magnesium sulphate (MgSO4) M-7506 0.01 
Calcium chloride (CaCl2) C-7902 0.01 
Sodium hydrogen carbonate (NaHCO3) S/4240/60  2.0 
Tween 80 P1754 2.0mL/L 
Haemin 51280-5G 0.005 
Cysteine HCL 111785000 Acros organics 
Loughborough, UK 
0.5 
Bile salts B8756 0.5 
Glucose  G-5250 0.4 
Arabinogalactan  10830 1.0 
Vitamin K1 V3501 10µl/L 





Starch from potato S2004 3.0 
    
 
2.2.2 Collection of human faecal samples  
Sample donors were sourced by Dr. Simon Baines. Human faecal samples used for the inoculation of 
the continuous culture (gut model) were collected from five healthy elderly (over 65 years) donors that 
have not undergone antibiotic treatment 3 months before the collection date. Samples were conveyed 
in sealed bags containing an anaerobic gas generation system (TSMX5335D Oxoid, Basingstoke UK) 
and kept in the anaerobic cabinet within 6 hours of collection. The anaerobic gas generation system 
contains, activated carbon and ascorbic acid and upon contact with air, oxygen is absorbed, and a rapid 
production of carbon dioxide ensues, creating an ideal transport condition for anaerobes.  
 
2.2.2.1 Screening for C. difficile in faecal samples  
Faecal samples were streaked on to pre-reduced supplemented Brazier’s agar and incubated at 37oC for 
48 hours in the anaerobic cabinet.  C. difficile-containing faecal samples were not used for the gut model 
studies. C. difficile was identified based on growth on selective agar, colony morphology, smell, 
antimicrobial susceptibility, and UV fluorescence with reference to the Wadsworth anaerobic 
bacteriology manual (Jousimies-Somer et al., 2002).       
 
2.2.2.2 Faecal sample preparation for inoculation of the continuous culture 
C. difficile-negative samples (N=5) were pooled to make a faecal slurry used to inoculate the gut model 
in each experiment. This entailed suspending 50g of pooled samples in 500mL pre-reduced sterile 
phosphate buffered saline (PBS) (BR53 Oxoid UK) to yield a ca. 10% (w/v) faecal slurry. The PBS-
faeces mixture was initially mixed in a stomacher (400 circulator, Seward, West Sussex UK) in 200mL 
sterile pre-reduced PBS to achieve a smooth suspension, then coarse-filtered using sterile muslin to get 
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rid of larger particles, following which further PBS was added to yield the required 500mL of faecal 
emulsion. 
 
2.2.3 Preparation of L. casei Shirota probiotic from Yakult to inoculate the model 
Yakult yoghurt drinks were purchased from Asda stores Hatfield. The batch number of 65mL bottles 
was K22B. In two 50mL sterile conical polypropylene centrifuge tubes (ThermoFisher Scientific, UK), 
32.5mL of live bacteria-containing Yakult yoghurt was dispensed into and centrifuged (Hettich EBA 
21, Germany) at 6000 rpm for 35 minutes. The clear supernatant was decanted into waste, then 4mL of 
sterile PBS was added to the pellet to re-suspend bacterial cells. These procedures were performed 
aseptically. The PBS-bacteria suspension was dosed into the gut model, which comprised the viable 
bacteria contained within one Yakult bottle per dose.   
 
 2.2.3.1 Enumeration of L. casei Shirota.   
Five hundred microliters of Yakult was added to 4.5ml of peptone water to make a 1:10 dilution. This 
was serially diluted up to 10-8. Twenty microliters of each diluent was plated and spread on pre-reduced 
LAMVAB agar (Hartemink et al., 1997) plates and incubated in an anaerobic chamber for 48 hours. 
Experiments were performed in triplicate. The above procedure was repeated for the PBS-bacteria 
suspension used to inoculate the models to ensure it contained similar amounts of LcS to the original 
yoghurt. Again, these procedures were performed aseptically. Total viable counts were determined by 
counting between 30-300 colony forming units and accounting for the dilution factor; and 
concentrations of bacteria were expressed as cfu/mL. 
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 2.2.4 Solid medium to distinguish L. casei Shirota from other Lactobacillus spp. 
In a one litre bottle, 52 grams of MRS broth (CM0361, Oxoid, UK) and 0.5 grams cysteine 
hydrochloride was added to 500 mL water (bottle A). In a different 500 mL bottle was added 20 g of 
agar technical number 2 (LP0011 Oxoid UK) to 500mL water (bottle B). Both bottles were autoclaved 
separately. Bottle B was added to bottle A, and mixed gently. Using filter sterilisation, 0.03g/L of 2, 3, 
5-triphenyl-2H-tetrazolium chloride (A10870 Alfa- Aesar, Heysham, England) was added. The pH was 
adjusted to 5.0 and 20mg/L vancomycin was added (Sakai et al., 2010). The modified-rhamnose-2, 3, 
5-triphenyl-2H-tetrazolium chloride-LBS-vancomycin (M-RTLV) agar was previously reported to 
distinguish between lactobacilli strains (Sakai et al., 2010). Whereas L. casei formed red colonies on 
the M-RTLV agar, other lactobacilli formed pink colonies or white colonies with a red spot.  
 
2.2.5 Inoculation of the gut model  
The smooth 10% faecal slurry was used to inoculate Vessel 2 and Vessel 3 to approximately 130mL. 
The remaining slurry was added to V1, then the peristaltic pump, magnetic stirrer units, nitrogen 
generator, pH control units, and water baths were turned on. Vessels V2 and V3 were allowed to be fed 
from V1. The gut model was allowed to equilibrate in terms of bacterial populations for 14 days (period 
A) with no intervention. Bacterial populations were enumerated every other day during period A. 
 
2.2.6 Enumeration and identification of faecal bacteria 
Selective and non-selective agar-based culture medium was used for the isolation of gut-bacterial 
population from the gut model. A selective medium contains particular ingredients that inhibit the 
growth of certain microbes but support the growth of the organism of interest. However, a differential 
medium supports the growth of a wider range of microbes but distinguishes them based on how they 
metabolize or change the medium. Blood agar is an example of a differential medium as it distinguishes 
microbes based on their ability to lyse red blood cells. The modified Lactobacillus anaerobic de Man, 
Rogosa and Sharpe with vancomycin and bromocresolgreen (LAMVAB) agar is an example of a 
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selective medium. The growth medium, supplements and instructions for their preparation are 
highlighted in Table 2.2.  From each vessel 0.5mL of sample was taken and was serially diluted 10-fold 
to 10-8 in 4.5mL pre-reduced peptone water (CM0009, Oxoid UK) in an anaerobic cabinet (Freeman et 
al., 2003). Twenty microliters of four suitable dilutions were used to inoculate quarter plates of the 
different culture medium in triplicate.  Agar plates were incubated in an anaerobic cabinet for 48 hours. 
However, Inoculation and incubation of agar for facultative anaerobes were carried out aerobically. 
Following incubation, colonies were counted and identified on the basis of colony morphology, growth 
on selective growth medium, Gram reaction, microscopic appearance, biochemical reaction, and 
antimicrobial susceptibility. Viable counts (cfu/mL) was calculated as:  
Mean cfu per 20µL x 50 x 10x  
(X = dilution factor)  
Viable count expressed as log10 (cfu/mL) 
Furthermore, all enumerated bacterial colonies were also identified with MALDI-TOF as previously 
described by Seng et al., (2009) and Carbonnelle et al., 2011). Briefly, a single bacterial colony was 
spotted onto the MALDI-TOF sample target plate with 1 µL of matrix solution containing 1.5 mg of α-
cyano-4-hydroxycinnamic acid in 50% acetonitrile with 2.5% trifluoroacetic acid and allowed to air dry 
at room temperature. Then, the plate was inserted into the mass spectrometer. The dried matrix-sample 
mixture was bombarded with a laser to create gas phase ions that are then pulsed into a flight tube. The 
species of interest were identified by their mass/charge ratio, the mass/charge value is obtained from 
the centroid of the peak. Peptidic spectra were compared with the Saramis database, version 4.12, and 
the identification score was recorded. Measurements were performed with an Axima Confidence mass 
spectrometer (Shimadzu, Japan) equipped with a 337‐nm nitrogen laser and a 50Hz variable repetition 
rate N2 laser. Data were acquired automatically employing Flex control 3.0 (Bruker Daltonics GmbH, 




 Table 2.2. Constituents of different aerobic and anaerobic agar used for viable counting and their target 
species. 
Growth Medium  Preparation Target bacterial group 
Brazier’s CCEY  Prepared according to 
manufacturer’s instruction + 2 
vials of cycloserine-cefoxitin 
supplement + 20mL/L lysed 
blood after autoclaving. For the 
027 plates, 2mg/L of 
moxifloxacin was added.  
C. difficile. 
Nutrient Agar  Prepared according to 
manufacturer’s instruction 
Total facultative anaerobes.  
Bacteroides Bile Aesculin 
Agar (BBE)  
Prepared according to 
manufacturer’s instruction + 
5mg/L haemin + 20 µL/L 
Vitamin K1 prior to 
autoclaving, and 75 mg/L 
kanamycin + 7.5 mg/L 
vancomycin + 1 mg/L 
penicillin G. after autoclaving. 
Bacteroides fragilis group. 




Fastidious Anaerobe Agar 
(FAA) 
Prepared according to 
manufacturer’s instruction + 




50mL/L whole blood after 
autoclaving 
Beeren’s Agar  42.5 g/L Columbia agar base + 
5 g/L agar technical + 5 g/L 
glucose + 0.5 g/L cysteine 
hydrochloride. Agar is steamed 
for 1 hour until completely 
molten.  5 ml/L propionic acid 




anaerobic de Man, Rogosa and 




Bromocresolgreen was not 
used 
In a 1L bottle, 52 MRS broth + 
0.5g cysteine hydrochloride 
was added to 500 mL water 
(bottle A) in a different 500 
mL bottle was added 20g agar 
technical to 500mL water 
(bottle B). Both bottles were 
autoclaved separately. Bottle B 
was added to bottle A, and 
mixed gently. The pH was 
adjusted 5.0. 20mg/L 
vancomycin was added. 
Lactobacillus spp. 
Kanamycin Aesculin Azide 
Agar (KAA) 
Prepared according to 
manufacturer’s instruction + 





kanamycin was added. 
 
 
2.3 Enumeration of C. difficile spores 
From each vessel 0.5mL of sample was taken and added to 0.5mL 99% ethanol (10048291 Fisher 
scientific UK) and allowed to stand for one hour at room temperature. Alcohol-shocked samples were 
serially diluted in pre-reduced peptone water up to 10-7. Twenty microliters of each dilution was used 
to plate onto Braziers agar supplemented with cycloserine cefoxitin supplement, and 20mL/L lysed 
horse blood. Plates were incubated in an anaerobic cabinet for 48 hours. Upon incubation, single 
colonies were counted. The above procedure was used to count C. difficile on Braziers agar versus 
moxifloxacin supplemented Braziers agar to confirm counts were not reduced on moxifloxacin 
supplemented agar.  Moxifloxacin incorporation was used when enumerating C. difficile ribotype 027 
due to its high-level resistance to the antimicrobial agent; it was not incorporated into NTCD Brazier’s 
agar plates.   
 
2.4 Passaging of Vero cells 
African green monkey kidney cells (Vero cells, ECACC 84113001) were grown in 75cm3 cell culture 
flasks containing supplemented 20mL of Dulbecco’s modified eagles medium (DMEM) (D6429, Sigma 
UK). Five hundred millilitres of DMEM was supplemented with 50mL newborn calf serum (N4637 
Sigma UK), 5mL antimycotic solution (100U/mL penicillin, 100mg/L streptomycin, 0.25mg/L 
amphotericin, Sigma), and 5mL L-glutamine (G7513, Sigma). Cultures were incubated at 37oC in 5% 
CO2 (MCO-18AIC (uv) Japan) until Vero cell monolayers became confluent following examination 




2.4.1 Cell culture cytotoxicity assay  
Supplemented DMEM in the flask containing a confluent Vero cell monolayer was discarded. Cells 
were treated with 0.5mL of Hanks balanced salt solution (HBSS) (H9394, Sigma) that contained 
0.25g/L trypsin-EDTA (T4174, Sigma). Upon a gentle swirling, excess HBSS-trypsin-EDTA solution 
was decanted out, and a further 3mL of HBSS-trypsin-EDTA solution was added. Vero cell monolayers 
were incubated in 5% CO2 for 10 minutes at 37oC until monolayers were mobile. Trypsinised Vero cells 
were diluted 1 in 10 using fresh supplemented DMEM and 180µL dispensed into the wells of a flat-
bottomed 96-well microtitre tray (3585 Corning NY USA) but for the wells due to receive 20µL C. 
sordellii antitoxin (Pro-lab diagnostics, UK) to which 160µL of trypsinised were added. Trays were 
incubated for 48 hours in 5% CO2.  
Five hundred microliters of each gut model/culture sample was centrifuged at 13300g for 15 minutes 
(4oC) and the supernatants removed. The supernatants from the gut models were serially diluted in 10-
fold with 0.01M sterile phosphate buffered saline (pH 7.4) to 10-6. Twenty microliters of the appropriate 
dilution was added to each test wells containing Vero cell monolayer, in addition to a control well 
containing  a further 20µL of C. sordellii antitoxin and undiluted culture (PL6508, Pro-lab diagnostics, 
UK) (diluted 1 in 10 in PBS).   
Following incubation in 5% CO2 for 24 and 48 hours, monolayers were examined under an inverted 
microscope. Cell rounding was an indication of a positive result with a side by side neutralisation effect 
by C. sordellii antitoxin. Cytotoxin titres were expressed as relative units (RU), and reported in the 
highest dilution with more than 70% cell rounding, that is 100 = 1 RU,  10-1 =2RU,  10-2 = 3RU,  10-3 = 






2.5 Determination of minimum inhibitory concentration 
2.5.1 Antibiotic agar incorporation plates preparation  
The susceptibility of C. difficile RT 027, RT 010, and L. casei Shirota to clindamycin was determined 
using agar incorporation as described by Freeman and Wilcox, (2001) and Chilton et al., (2014). The 
same method was used to determine the minimum inhibitory concentrations (MICs) of cefotaxime, 
ciprofloxacin, ampicillin and tetracycline against RT 027 and RT 010. Briefly, antibiotic solutions were 
prepared in sterile distilled water. Antimicrobials dilutions were made to arrive at a final concentration 
range of 0.03 – 128 mg/L when 4mL was added to 36mL of molten Wilkins Chalgren anaerobe agar 
(CM0619, Oxoid UK). Each antibiotic-incorporated molten agar was mixed gently but thoroughly and 
poured into two sterile Petri dishes. Upon solidification, antibiotic agars were placed for 30 minutes in 
a 37oC incubator to remove excess moisture. 
 
2.5.2 Preparation of bacterial inoculum       
Bacterial isolates were grown anaerobically in pre-reduced Schaedler’s anaerobe broth (CM0479, 
Oxoid, UK) overnight (ca. 107cfu/mL). Approximately 400µL of each inoculum was added to the wells 
of the multipoint inoculator block (Mast group, Bootle, UK). The inoculator dispensed about 1µL per 
spot (104 cfu) unto the pre-reduced antibiotic-incorporated agar plates. The multipoint inoculator pins 
were flamed in alcohol between each set of antibiotics. Agar plates with no antibiotic were inoculated 
at the beginning and end of the procedure and incubated aerobically and anaerobically at 37oC for 48 
hours. MICs were read as the lowest dilution with no growth or a significant alteration in growth had 
occurred. Reference strains (ATCC 700057) were also included for MIC determinations.  
Although the enumeration of faecal bacteria was undertaken in triplicates, each gut model experiment 
was carried out once, alongside the controls. This was due to the labour-intensive nature of the 





 CHAPTER THREE 
3.0 Assessment of the effects of L. casei Shirota (LcS) (probiotic) intervention on C. difficile growth, 
spore germination, and toxin production in a human gut model of clindamycin-induced CDI. 
  
3.1 Background  
In the last decade, C. difficile has been identified as the main cause of nosocomial diarrhoea in Europe 
(ECDC, 2013) and most frequent healthcare linked pathogen in the USA (Magill et al., 2014). Besides 
strains that have been locally identified as the major cause of serious disease, the emergence of 
hypervirulent strains, PCR-ribotype 027 and 078 have been linked with the observed increase in 
morbidity and mortality of CDI (Cartman et al., 2010). Data from a recent European study (Davies et 
al., 2014) indicated that 23% of CDI go undetected and undiagnosed in Europe every year due to 
substandard laboratory methods and/or an absence of clinical suspicion. This underscores the need for 
a prophylactic measure against CDI. 
Lactic acid bacteria (LAB) are often found in milk products and synthesise lactic acid as a principal end 
product of metabolism following carbohydrate fermentation. Antimicrobial substances are also 
produced by a considerable number of LAB strains which further antagonises pathogenic and spoilage 
microbes (Sonomoto & Yakota, 2011). Indeed by using co-culture experiments, Gibson and Wang 
(1994) demonstrated that bifidobacteria excrete an anti-microbial substance that was not an acid, with 
a wide range of activity against bacterial species belonging to the genera Shigella, Listeria, Salmonella, 
and Campylobacter. This demonstrates that bifidobacteria are capable of inhibiting other colonic 
bacteria by mechanisms other than the fermentative production of acids such as lactate and acetate. 
Similarly, there are suggestions that the high bifidobacterial amounts in breast-fed infants may be a 
contributing factor to the heightened competitive exclusion of pathogens observed in this group 
compared with formula-fed infants (Gibson et al., 1997) 
 Furthermore, studies have reported the role of prebiotics in stimulating endogenous lactic acid bacteria. 
Gibson et al., (1995) reported that the consumption of 15 g of oligofructose for 15 days led to an increase 
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in bifidobacterial counts in the stool samples of volunteers, whereas populations of clostridia and 
fusobacterial declined. This reflects the observations of Wang and Gibson (1993) who observed that 
the health-beneficial bifidobacterial populations were preferentially stimulated by inulin and 
oligofructose in vitro, while maintaining populations of potentially pathogenic Escherichia coli and 
Clostridium at low levels. They demonstrated through batch culture experiments that the growth of 
Bifidobacteria infantis inhibited Clostridium perfringens and E. coli.        
The human microbiota presents a defensive barrier against pathogens in a phenomenon referred to as 
colonisation resistance.  Disruption of the microbiota and the resultant decrease in the degree of 
colonisation resistance due to antibiotic use is thought to be the main cause of C. difficile infection 
(CDI). This disruption of the indigenous colonic microbiota often leads to the germination of exogenous 
or endogenous C. difficile spores in the host gut, and consequently the colonization of the colon. 
Thereafter, vegetative C. difficile cells that are able to escape the host innate immune response, multiply, 
and produce toxins A and B; the main virulence factors. Freeman et al., (2005) reported that 
clindamycin was able to induce CDI in both in vivo and in vitro models. These findings are consistent 
with the reports of Crowther et al., (2014) that CDI was induced by administering 33.9 mg/L (equivalent 
to human bile concentrations) clindamycin, four times a day, for 7 days in a triple-stage in vitro human 
gut model. Other studies have also reported the capacity of clindamycin to induce CDI in a human gut 
model (Baines et al., 2008; 2011).  
Clindamycin is mainly prescribed for infections due to anaerobic bacteria. It is effective against 
anaerobic Gram-negative rod-shaped bacteria such as Fusobacterium, some Bacteroides, and 
Prevotella, as well as Gram-positive aerobic cocci such as some members of Streptococcus and 
Staphylococcus genera. It is not active against Enterococci and resistance in B. fragilis is increasing 
(Brook et al., 2005), mainly due to MLS-B mechanism mediated by ermB, ermF, and ermG genes) 
(Smith et al., 1992). Clindamycin primarily exerts a bacteriostatic effect, but may be bactericidal at 
higher concentrations (Spížek & Řezanka, 2004). The drug acts through inhibiting protein synthesis by 
blocking ribosomal translocation by binding reversibly to the 50S rRNA of the large ribosome subunit 
of bacteria (Wilson, 2014). 
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Public Health England documented that the incidence of CDI in the UK in 2013 stood at 26.7 cases per 
100,000, and the recurrence rate can be up to 35% of cases (Barbut et al., 2000). The cost of treating 
one individual with a recurrent episode of CDI was estimated to be approximately £11,000, owing to 
requirement for extended hospital stay (Ghantoji et al., 2010). Lee et al., (2010) reported that 
rehospitalisation for diarrhoea within 12 weeks was lower in patients treated with either metronidazole 
or vancomycin together with a probiotic, L. casei Shirota. They also observed a significant decrease in 
the incidence of recurrent C. difficile infection (p= 0.007).   
Lactic acid bacteria have been utilised in the fermentation of food for over 4000 years (Rotar et al., 
2007).  In the course of the last fifteen years, human probiotics use has received increasing attention. 
This is due to an increased level of awareness with regards to gut health and the idea of preventive 
therapy. Lactic acid bacteria, particularly Lactobacillus spp., are the most frequently employed 
microorganisms as probiotics because they are ‘Generally Recognised As Safe’ (Shokryazdan et al., 
2014). Species of LAB that are generally thought to possess probiotic properties include Lactobacillus 
acidophilus, L. fermentum, L. rhamnosus, L. gasseri, L. (para)casei, L. plantarum, L. helveticus, L. 
reuteri, and L. johnsonii (Castro et al., 2015; Linares et al., 2016b). 
A recent in vitro study demonstrated the probiotic capabilities of nine selected Lactobacillus strains 
isolated from infant faeces, fermented dates, grapes, and human milk. All the nine isolates showed 
antimicrobial activity against 12 human pathogenic bacteria (Shokryazdan et al., 2014). In the same 
study, neutralised supernatants (pH 6.5) of all Lactobacillus strains, did not inhibit the activity against 
the indicator strain, suggesting the inhibitory effects of the Lactobacillus strains were because of their 
organic acid production and not bacteriocin or hydrogen peroxide production. The health gains of 
probiotic bacteria may be directly via interactions with the host or indirectly through metabolites 
synthesized in the course of fermentation (Gobbetti et al., 2010). Similarly, following a placebo-
controlled, double blind, randomised trial undertaken in Germany, seventy chronically constipated 
individuals were given about 6.5 x 109 LcS or placebo for 28 days. A marked improvement in some 
constipation symptoms were recorded from the second week for individuals in the probiotic group (P < 
0.001) (Koebnick et al., 2003).    
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Recent literature suggests probiotics are able to re-balance intestinal microbiota, improve intestinal 
function, and also prevent/treat gastrointestinal disorders such as irritable bowel syndrome (Barrett et 
al., 2008), inflammatory bowel disease (Mitsuyama 2008), and antibiotic-associated diarrhoea (AAD) 
(Pirker et al., 2012). Other reported health benefits of probiotics include immunomodulatory effect 
against a breast tumor in a mouse model, and serum cholesterol reduction (Jones et al., 2012; Linares 
et al., 2014). One probable mechanism of lowering cholesterol by bile salt hydrolase (BSH)-active 
probiotics reported by Jones et al. (2012) is that increased intra-luminal BSH activity might result in 
increased excretion of deconjugated bile acids and a subsequent excretion of serum cholesterol by the 
liver, replacing bile acids lost from the enterohepatic recirculation. Jones et al., further reported that the 
metabolism of cholesterol to bile acids in the liver and their subsequent secretion and stool excretion is 
the principal route for excess cholesterol elimination.        
There is an agreement between studies that in order to be effective, probiotic strains must show an 
ability to survive the gastric acidic conditions of the stomach during transit, in addition to coping with 
exposure to bile in the upper small intestine to bring about their beneficial effects in the colon. This is 
in spite of the fact that there exists compelling data on beneficial probiotic effects from dead cells 
(Mottet & Michetti, 2005; Ghadimi et al., 2008; Lopez et al., 2008). It stands to reason that the 
maximum probiotic effects of probiotics might be achieved if the probiotic strains colonise (at least 
temporarily) the surface mucus layer of the intestine given they can displace enteric pathogenic 
microbes, positively stimulate the host immune system, and possibly exert other effects via cell 
signalling (Ljungh & Wadstrom, 2009). 
Probiotic interventions are thought to reconstitute a depleted gut microbiota and support competitive 
antagonism of pathogenic bacteria such as C. difficile. Probiotics prevent C. difficile proliferation 
through a wide range of mechanisms (Sekirov et al., 2010). Different probiotics have been shown to 
decrease the incidence of AAD (Lactobacillus rhamnosus GG, Saccharomyces boulardii), (McFarland 
et al., 2006). There are reports of the probiotic yeast strain S. boulardii preventing CDI recurrence, the 
potency of this probiotic was shown in two randomized controlled trials to be a successful treatment, 
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although it requires an extended treatment period of 4 weeks following the initial episode of CDI 
(McFarland, 1994). Nonetheless, a conclusive evidence of probiotics treatment of CDI remains elusive. 
 
3.2 Aims  
 
These series of experiemts sought to ascertain the impact of LcS within the gut model before, 
during, and after clindamycin dosing. This is in addition to observing the population of C. 
difficile in the indigenous microbiota without antimicrobial disruption, and also to ascertain the 
propensity of clindamycin to induce simulated CDI in a human gut model. Furthermore, the 
ability of L. casei Shirota to prevent simulated CDI in a human gut model shall also be 
evaluated. 
Clindamycin was used in the present study to bring about germination, growth, and cytotoxin 
production of C. difficile because of the high level of reproducibility recorded in previous gut 













3.3 Materials and Methods 
Materials and methods were earlier described in 2.0.  Selective and non-selective agars used for 
enumeration of bacterial populations of the gut models included: Nutrient agar, MacConkey agar, KAA, 
FAA, BBE, Beerens agar, LAMVAB, and Brazier’s agar. (See Table 2.2).  
 
 3.3.1 Probiotic strain 
L. casei Shirota, belonging to Yakult was isolated in Japan by Dr. Minoru Shirota in 1930. Yakult 
yoghurt drinks were purchased from Asda stores Hatfield. The batch number of 65mL bottles was 
K22B. Viability of LcS strains was confirmed prior to inoculation into the gut model. Details of 
preparation of L. casei Shirota probiotic from Yakult to inoculate the model, as well as viable counting 
of LcS prior to gut model inoculation are described in section 2.2.3 
 
3.2.2 Solid media to distinguish L. casei Shirota from other Lactobacillus spp. 
The components and mode of preparation of selective agar were earlier described in 2.2.4 
 
3.4 Antimicrobial activity  
The minimum inhibitory concentration (MIC) of clindamycin against Lactobacillus spp. 
Bifidobacterium spp., Enterococci, and Enterobacteriacea were determined using agar incorporation. 
These bacterial groups were chosen so that the sharp increase or decrease of these bacterial groups 
during clindamycin dosing can be explained.    
Antimicrobial solutions were prepared in sterile distilled water. Antimicrobials dilutions were made to 
arrive at a final concentration range of 0.03 – 128 mg/L when 4mL was added to 36mL of molten 
Wilkins Chalgren anaerobe agar (CM0619, Oxoid UK). Each antibiotic-incorporated molten agar was 
mixed gently but thoroughly and poured into two sterile Petri dishes. Upon solidification, antibiotic 
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agars were placed for 30 minutes in a 37oC incubator to remove excess moisture. Bacterial isolates were 
grown anaerobically in pre-reduced Schaedler’s anaerobe broth (CM0479, Oxoid, UK) overnight (ca. 
107cfu/mL). Approximately 400µL of each inoculum was added to the wells of the multipoint inoculator 
block (Mast group, Bootle, UK). The inoculator dispensed about 1µL per spot (104 cfu) unto the pre-
reduced antibiotic-incorporated agar plates. The multipoint inoculator pins were flamed in alcohol 
between each set of bacterial group. Agar plates with no antibiotic were inoculated in the beginning and 
end of the procedure and incubated aerobically and anaerobically at 37oC for 48 hours. MICs were read 
as the lowest dilution with no growth or a significant alteration in growth had occurred. Reference 
strains (ATCC 700057) were also included for MIC determinations.    
 
3.4.1 Antimicrobial preparation for gut model 
Clindamycin hydrochloride (C5269, Sigma-Aldrich, UK) solution was prepared in sterile distilled water 
to obtain a final concentration of 33.9 mg/L upon instillation into the gut model (280 mL). This is the 
Clindamycin concentration attained in human bile upon one 600mg intravenous dosage (Brown et al., 
1976) The antimicrobial solution was filter-sterilized using a 0.22µm syringe filters (SLGP033RS 
Millipore, Carrigtwohill Ireland) and aliquoted into 1 mL volumes into sterile micro-centrifuge tubes 
(ThermoFisher scientific, UK). One millilitre volume of antimicrobial was dosed into the gut model. 
Antimicrobial-containing tubes were stored at -20 oC until needed.   
 
3.5 Experimental design 
Time periods for these experiments are highlighted in tables 3.1 and 3.2. Upon inoculation of the gut 
model with a 10% faecal slurry, the model was allowed to equilibrate in terms of bacterial populations 
for 14 days (period A). Bacterial counts were monitored during this period. At steady state (when 
bacterial counts are constant for a number of days), the model was dosed with 6.2 x 109 CFUs LcS 
(Pirker et al., 2013) (the content of one 65mL bottle) daily for 7 days (period B). This was followed by 
an administration of C. difficile ribotype 027 (strain 210) spores (1 x 108 spores) (Baines et al., 2005; 
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2008), after which another single dose of C. difficile spores and 33.9mg/L clindamycin was 
administered 4 times daily for a further 7 days to achieve the faecal/biliary levels observed upon a single 
600 mg dose (Brown et al., 1976) (period C). LcS-dosing continued daily during clindamycin 
administration. The model was continuously dosed with LcS for a further 14 days (period D), upon 
which the model was allowed without any further intervention for another 14 days (period E). Bacterial 
populations and C. difficile cytotoxin titres were monitored throughout the period of the experiment 
(period A to E). Sampling was carried out at about the same time on each day.  
Experimental time periods for the L. casei Shirota and clindamycin (DA) are shown in Table 3.1 
whereas the experimental design of the C. difficile, L. casei shirota and clindamycin experimental are 
described in Table 3.2   
 
Table 3.1. Time periods in the control gut model experiment with L. casei Shirota and clindamycin 
(DA) to determine the effect of LcS on the microbiota prior to, during, and after antimicrobial 
instillation in the absence of C. difficile.  
Day       0-14     15-22     23-29 30-45 45-54 
Time period A B C D E 




every 6 hours 
+ LcS 
LcS Rest 






Table 3.2. Time periods in gut model experiments with C. difficile ribotype 027, L. casei Shirota and 







Day 0-14 15-21 22-28 29-35 36-49 50-62 
 Time period A B C D E F 
027 Control Steady 
state 
No intervention C. difficile 
spore 
instillation (1 
x 108 spores) 
C. difficile spore 
+ 33.9 mg/L 
clindamycin 
every 6 hours 











C. difficile spore 
+ 33.9 mg/L 
clindamycin 









3.6.1 Gut bacterial populations for the LcS and clindamycin control experiment.  
Changes in bacterial populations were very similar in all three vessels of the gut model, hence, only 
those observed in vessel 3 are shown in Figures 3.1 and 3.2, except for the Bacteroides spp. where there 
are marked differences between the vessels. Populations of all bacterial groups remained steady but for 
minor fluctuations in all of the three vessels during period A. Viable counts of lactose fermenters, 
Enterococcus spp., lactobacilli and bifidobacteria are shown in Figure 3.1. Similarly, viable counts of 
facultative anaerobes, total anaerobes, and Bacteroides (in vessels 1, 2, and 3) are shown in Figure 3.2. 
Bacteroides counts were unstable in vessel 1 almost throughout the experiment. Bacteroides numbers 
in vessels 2 and 3 were however stable but for a minor decline towards the end of period C. Obligate 
anaerobes outnumbered facultative anaerobes during steady state (period A).    
  
Figure 3.1. Mean (+/-SE) viable counts (log10cfu/mL) of total culturable lactose fermenters, 
Enterococcus spp., Lactobacillus spp., and Bifidobacterium spp., in the LcS control gut model. Vertical 
lines indicate the final day of each experimental period.  
 



















SS                LcS       LcS      LcS              Rest 
                                 +DA 
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MICs were carried out so that the high numbers of Enterococci and lactose fermenters, as well as the 
low numbers of bifidobacteria and lactobacilli during clindamycin dosing can be explained. The MICs 
of clindamycin against bacterial groups isolated from the gut model are shown in table 3.3 
 
 
Table 3.3. Distribution of clindamycin MICs for bacterial groups isolated from the gut model 
Bacterial genera MIC (mg/L) 
LcS (isolated from Yakult) 1 
Lactobacillus spp. (isolated from the gut model) 2 
Bifidobacterium spp. 0.06 
Enterococcus spp. 64 
Lactose fermenters  128 
 
 3.6.2 Effect of LcS dosing on the gut microbiota 
Following LcS dosing in both control and experimental models, there was a decline in the lactose–
fermenting Enterobacteriaceae and Enterococci populations by approx. 2 log10 cfu/mL in all three 
vessels. This was accompanied by a 2 log10 cfu/mL increase in bifidobacterial viable counts. 
Lactobacillus spp. viable counts also increased by 3 log10 cfu/mL, however, lactobacilli counts declined 
upon the cessation of LcS dosing, this was also the case for bifidobacterial populations. In contrast, 
following the cessation of LcS dosing lactose-fermenting Enterobacteriaceae and Enterococci 
populations increased during period E (Figure 3.1). Bacteroides fragilis group populations showed 
fluctuations upon LcS dosage. LcS and endogenous lactobacilli from the steady state period failed to 
show a distinguishable difference in terms of colony morphology on the modified-2, 3, 5-triphenyl-2H-
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tetrazolium chloride-LBS-vancomycin (M-RTLV) agar which was previously reported to distinguish 
between lactobacilli strains (Sakai et al., 2010) 
 
3.6.3 Effect of clindamycin instillation on the gut microbiota  
Clindamycin instillation elicited marked declines in bifidobacterial populations (approx. 6 log10 
cfu/mL), Lactobacillus spp. viable counts (approx. 4 log10 cfu/mL), and a less prominent decline in 
Bacteroides fragilis group in both experimental and control models. The observed decline in 
bifidobacterial populations due to clindamycin was more pronounced in vessel 1 (data not shown). 
However, enterococcal and total anaerobe viable counts increased by approx. 1 log10 cfu/mL and 2 log10 
cfu/mL respectively. Additionally, lactose-fermenting Enterobacteriaceae viable counts increased by 
approx. 3 log10 cfu/mL.  Upon cessation of clindamycin administration, lactobacilli and bifidobacteria 
groups recovered to at least steady state levels. However increased Enterobacteriaceae and enterococcal 
viable counts declined following cessation of clindamycin dosing (Figure 3.1)  
      
 
Figure 3.2. Mean (+/-SE) viable counts (log10cfu/mL) of total culturable facultative anaerobes, total 
anaerobes, and Bacteroides fragilis group in the LcS control gut model. Vertical lines indicate the final 
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day of each experimental period. SS is steady state, DA is clindamycin, LcS is L. casei Shirota, V1, V2 
and V3 are Vessel 1, vessel 2, and vessel 3 respectively.  
 
3.6.4 Gut bacterial population changes observed in the CD027 control and the CD027 vs LcS 
experiment. 
The total bacterial viable counts remained stable but for minor fluctuations during period A (Figures 
3.3 and 3.4) in all vessels of the gut model. Lactobacilli viable counts determined in the two 
experiments, revealed a difference of 1.3 x 107 cfu/mL between the LcS-dosed model and the 027 
control model upon LcS dosage. The LcS-dosed model showed higher counts (Figure 3.3a). Lactobacilli 
viable counts declined in both models by 1.5 log10 cfu/mL following clindamycin instillation (period 
D). Total anaerobes and Bacteroides fragilis group viable counts declined by 2.5 log10 cfu/mL and 2 
log10 cfu/mL upon addition of clindamycin in the 027 control and LcS-dosed model respectively. 
Bifidobacterial populations increased by 1.6 log10 cfu/mL in both models during period C but showed a 
pronounced decrease of 3.8 log10 cfu/mL and 4.7 in the 027 control and LcS-dosed model respectively 
upon clindamycin instillation (Figures 3.3 and 3.5). In contrast, although periods C and D were marked 
with fluctuations of Enterobacteriaceae counts, the counts increased upon instillation of clindamycin. 
However, LcS dosing led to a general decline in the Enterobacteriaceae viable counts throughout the 
experiment. Enterobacteriaceae populations in the LcS-dosed model were fewer than the 027 control 
model in all experimental periods (Figures 3.3 and 3.5). Furthermore, the addition of C. difficile spores 
coincided with a remarkable increase in enterococcal counts. Similarly, clindamycin instillation resulted 
in a 3 log10 cfu/mL increase in total viable counts of Enterococcus spp. in both models. All bacterial 
groups recovered following the cessation of clindamycin instillation. The biofilm formation in both 





























Figure 3.3a. Mean (+/-SE) viable counts (log10cfu/mL) of total cultivable, lactobacilli in vessels 3 of 
LcS vs CD 027 model and 027 control model. Vertical lines indicate the final day of each experimental 
period. SS is steady state, DA is clindamycin, LcS is L. casei Shirota, and CD is C. difficile RT027. 
Lactobacilli 027 control is without LcS; it is CD 027 control in the LcS vs CD experiment. 
 



















                   SS              LcS     LcS    LcS        LcS        Rest 
                                               +CD   +CD 
                                                         +DA     
 
 
Figure 3.3b Mean (+/-SE) viable counts (log10cfu/mL) of total culturable bifidobacteria, lactobacilli, 
Enterococci, and lactose fermenting Enterobacteriaceae in vessel 3 of the LcS vs CD027 gut model. 
Vertical lines indicate the final day of each experimental period. SS is steady state, DA is clindamycin, 
LcS is L. casei Shirota, and CD is C. difficile. 
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Figure 3.4 Mean (+/-SE) viable counts (log10cfu/mL) of total culturable Bacteroides fragilis group, 
facultative anaerobes, and total anaerobes in vessel 3 of the LcS vs CD027 gut model. Vertical lines 
indicate the final day of each experimental period. SS is steady state, DA is clindamycin, LcS is L. casei 
Shirota, and CD is C. difficile. 
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Figure 3.5 Mean (+/-SE) viable counts (log10cfu/mL) of total culturable bifidobacteria, Lactobacilli, 
Enterococcus, and Enterobacteriaceae in vessel 3 the 027 control gut model. Vertical lines indicate the 
final day of each experimental period. SS is steady state, NI is no intervention, DA is clindamycin, and 






















                        SS            NI      CD    CD       REST 
                                                          +DA   
 
Figure 3.6 Mean (+/-SE) viable counts (log10cfu/mL) of total culturable Bacteroides, Facultative 
anaerobes, and Total anaerobes in vessel 3 of the 027 control gut model. Vertical lines indicate the final 
day of each experimental period. SS is steady state, NI is no intervention, DA is clindamycin, and CD 
is C. difficile.  
  
 




3.6.5 C. difficile growth, spore counts, and cytotoxin production 
C. difficile was not recovered from the LcS-dosed model and the 027 control model before the 
inoculation of the models with C. difficile spores and no cytotoxin production was detected using the 
Vero cell cytotoxicity assay. Upon instillation with C. difficile spores (approx. 108 spores) into vessel 1 
of both models, C. difficile was detected in vessels 1 and 2 (4-log10-units) of both models, total viable 
counts were equivalent to spore counts; thus suggesting spore forms predominantly dominated the 
populations. C. difficile was detected in vessels 3 of both models on the next day in similar numbers 
and mainly as spores. During experimental period C, C. difficile numbers in all 3 vessels of both models 
declined steadily (Figures 3.8 and 3.9). Upon further inoculation of vessels 1 of both models with C. 
difficile spores (approx.  108 spores), a similar pattern of declining populations was observed in period 
D (CD+DA) (Figures 3.8 and 3.9)  
A cytotoxin titre of 1 relative unit (RU) was detected in vessel 3 of the 027 control model five days 
after cessation of clindamycin instillation. Toxin titres increased to 2RU on the 7th day after clindamycin 
instillation ceased, before climaxing at 4RUs on the eleventh day after cessation of clindamycin 
instillation. However, it took one more day following cessation of clindamycin instillation before 
cytotoxin titres were detected in vessel 2 of the same 027 control model. Although toxin production 
profiles between vessels two and three were similar, 3RUs was the maximum titre units recorded from 
vessel 2.  Similarly, cytotoxin production was detected in vessels 2 and 3 of the LcS-dosed model on 
the fifth day following the cessation of clindamycin instillation. It took a further two days for toxin 
titres to reach 4 RUs in vessel 3 and four days to attain 3RUs in vessel 2. Cytotoxin was detected in 










Figure 3.8. C. difficile total viable counts, spore counts (log10cfu/mL) and cytotoxin titres in vessels 3 
of LcS-dosed gut model. Vertical lines indicate the final day of each experimental period. Unit on 
vertical axis is log10cfu/mL +/-SE and relative log10 units, RU 
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Figure 3.9. C. difficile total viable counts, spore counts (log10cfu/mL) and cytotoxin titres in vessels 3 
of 027 control gut model. Vertical lines indicate the final day of each experimental period. Unit on 










Vancomycin, metronidazole, and fidaxomicin are the preferred treatments for CDI (Debast et al., 2014) 
and have been previously studied in the triple stage in vitro human gut model (Baines et al., 2008; 2009; 
Freeman et al., 2005; 2007, Crowther et al., 2013; 2014; 2016; Chilton et al., 2014; 2015; Moura et al., 
2020). In order not to perpetrate a cycle of further dysbiosis, and given antibiotics are chiefly 
responsible for CDI, there is an increasing interest to look away from antibiotics for treatment of CDI.  
Probiotics are thought to address one of the primary instigating factors in the development of CDI, gut 
dysbiosis, consequently there is a substantial research in this area of study, especially to evaluate if the 
risk of CDI can be reduced by consuming a probiotic before, during, or after antibiotics intake. A high 
number of studies have evaluated the potency of L. casei Shirota (in a probiotic milk drink) in this 
regard. Prior studies have mostly relied on human volunteers (Wong et al., 2013; Lee et al., 2013; Pirker 
et al., 2013) and this brings to fore a string of ethical issues and inaccessibility of the colon. Besides 
there may be concerns of inadequate compliance by some volunteers in studies that may require 
participants to take a specific dosage of a novel drug. The use of experimental models have some 
advantages over studies involving human participants. In animal models, such advantages include the 
ability to carry out invasive tests, the availability of study animals, and the possibility to test new 
treatment strategies. However, the use of animals in research still result in a number of ethical concerns. 
This is in addition to the fact that animals are not truly reflective of the human colon, as well as difficulty 
in handling animals. In contrast, the triple stage in vitro human gut model presents a human gut-
reflective, accessible, and easily controllable system, although its incapacity to mirror immunological 
events of the human colon is limitation of the current system design (Macfarlane et al., 1998).   
The present study is unique in that it is the first time that the behaviour of a commercial probiotic is 
studied in the presence of an antimicrobial with a high propensity to cause antibiotic associated 
diarrhoea in a model that closely mimics the human colon.  The findings of this study contribute to the 
previous knowledge acquired during probiotic studies.  Spanhaak et al., (1998) reported the effect of 
LcS on the intestinal microbiota and immune parameters in humans following batch culture 
experiments. However, following an experiment to ascertain factors that govern protease production in 
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the colon by Clostridium perfringens in both batch and continuous cultures, Allison & Macfarlane 
(1989) suggested that batch culture or single stage continuous culture were not able to effectively mirror 
the gut conditions.  
Subsequently, Macfarlane et al., (1998) developed and validated the triple-stage in vitro human gut 
model, engineered to permit the study of intestinal bacterial populations in the carbohydrate-rich, more 
acidic environment typical of the proximal colon, and the more neutral, carbohydrate-low conditions 
characteristic of the distal colon. Physicochemical measurements were validated against gut contents of 
sudden death victims (Macfarlane et al., 1998). Baines and other researchers used the triple stage in 
vitro human gut model in a study to compare oritavancin and vancomycin as treatments for 
clindamycin-induced CDI (Baines et al., 2008). Interestingly, observations from previous gut model 
experiments mainly mirrored clinical observations; C. difficile exposure to antibiotics with CDI-
inducing tendency in vivo (e.g. ceftriaxone, clindamycin, and cefotaxime) caused germination, growth, 
and toxin production in the gut model (Freeman et al., 2003; 2005). However, the gut model is unable 
to mirror immunological responses and its design makes it very challenging to obtain bacterial 
populations in biofilms for investigation but allows the retrieval of bacterial populations in planktonic 
state with more ease. This is in addition its limitation in terms of not being able to mirror bacteria-host 
interactions.   
The populations of major bacterial groups within the vessels in the LcS control experiment are 
consistent with the literature in that obligate anaerobes such as Bacteroides spp. and Bifidobacterium 
spp. were predominant over facultative anaerobes such as E. coli (Hopkins et al., 2001), in both models 
at steady state. Upon the addition of LcS to the model in the LcS control experiment, populations of 
Enterococci and lactose-fermenting Enterobacteriaceae in the affected model declined. Similar 
observations have been reported previously by Shokryazdan et al., (2014) in which L. casei strains 
showed antagonistic activity (inhibition zones of more than 20 mm) against lactose-fermenting 
Enterobacteriaceae and Staphylococcus epidermidis.  LcS is thought to exert its antimicrobial effect by 
the production of antimicrobial substances such as ethanol, hydrogen peroxide, carbon dioxide, acetoin, 
diacetyl, reuterin, bacteriocins, and organic acids (Suskovic et al., 2010). This is in addition to the 
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mechanism of competition, where probiotic strains outcompete pathogens for attachment surfaces and 
available nutrients, effectively preventing pathogens from colonising the intestine (Saulnier et al., 
2009). In the present study, the antimicrobial activity of LcS strains against Enterococci and 
Enterobacteriaceae may be due to their organic acid production profile. This reflects the observations 
of Jin, (1996), who reported that the antagonistic effects of 12 Lactobacillus strains on E. coli and 
Salmonella were because of their organic acids production. Although the study did not identify the 
specific organic acid, the inhibitory zones remained unchanged when the culture supernatants were 
treated with catalase and pronase, an indication that the inhibition was not due to the action of hydrogen 
peroxide and bacteriocin respectively. However, when Lactobacillus culture supernatants were adjusted 
to pH 6.5, no inhibitory zones were observed, suggesting the antimicrobial action of the Lactobacillus 
isolate was via the production of organic acids (Jin, 1996). This is also consistent with data that the 
antimicrobial effects of L. helveticus, L. acidophilus, L. gallinarum, and L. crispatus against 
Campylobacter jejuni strains were because of their lactic acid production, but not bacteriocin production 
(Neal-McKinney et al., 2012). Furthermore, Zalan et al., (2010) documented that the antifungal effect 
of lactobacilli against Fusarium spp. increased with increasing concentrations of organic acids (acetic 
and lactic acid) produced by the probiotic strains. They however noted that organic acid production 
differed between species and strains. Nonetheless, the production of lactic, succinic, and acetic acid in 
L. casei Shirota has been demonstrated (Zalan et al., 2010; Shokryazdan et al., 2014). In the present 
study, no considerable difference between the decline in the potentially pathogenic enterococcal viable 
counts between period E (two weeks of LcS-dosage) and period B (one week of LcS-dosage) was 
observed (Figures 3.3 and 3.5), suggesting patients may not benefit from an elongated consumption of 
LcS. Moreover, the decline in enterococcal populations in the non-LcS-dosed 027-control experiment 
were similar to the LcS-dosed model, indicating the microbiota might be recovering from the effects of 
clindamycin independent of LcS. Prior C. difficile studies on the human faecal microbiota using the 
triple-stage in vitro human gut model that employed clindamycin as the CDI-inducing antimicrobial 
have reported similar observations upon the cessation of clindamycin instillation (Freeman et al., 2005; 
Baines et al., 2008).  However, following the cessation of LcS dosing, enterococcal viable counts 
increased (Figure 3.3), suggesting populations of Enterococcus spp. might have been kept in check by 
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LcS-administration. Furthermore, human volunteer studies of the effect of L. casei Shirota consumption 
on the gut microflora have reported a general increase in populations of Lactobacillus spp. and 
Bifidobacterium spp., as well as a decrease in Enterobacteriaceae populations in the faecal samples of 
volunteers (Sur et al., 2010; Nagata et al., 2011). Sur et al., (2010) reported a reduced occurrence of 
acute diarrhoea in children following a daily consumption of L. casei Shirota drink for 12 weeks.       
The observations in this study mirror with the reports of Macfarlane et al., in that the triple stage in 
vitro human gut model was capable of maintaining a vast array of bacteria genera over a remarkable 
time duration (Macfarlane et al., 1998). In the LcS control experiment, populations of obligate 
anaerobes were slightly more than the facultative anaerobes (Figures 3.1 and 3.2). This is in slight 
contrast to common reports that obligate anaerobes are highly dominant to facultative anaerobes in 
numerical terms in the human gut (Pirker et al., 2013; Backhed et al., 2005). This discrepancy may just 
be due to the differences in individual gut bacterial populations. Bacteroides spp. counts in the present 
study were lower in vessel 1 in relation to vessels 2 and 3 (Figure 3.2). This was observed in a previous 
study in which viable counts of B. fragilis group in vessel 1 were slightly lower than vessel 2 and 3 of 
the gut model (Macfarlane et al., 1998). This may in part be due to the more acidic and unfavorable pH 
of vessel 1. An analysis of amplified 16S rRNA sequences showed a pH-dependence in populations of 
human fecal bacterial community in a continuous flow fermenter. Bacteroides spp. constituted 27% of 
16S rRNA sequences detected at pH 5.5, in contrast, at pH 6.7 they accounted for 86% of sequences 
(Duncan et al., 2009). Similar observations have been made in prior gut model studies (Freeman et al. 
2007).  
Clindamycin administration in vessel 1 was at 33.9mg/L, which is the concentration attained in human 
bile upon one 600mg intravenous dosage (Brown et al., 1976). Changes in the gut model bacterial 
populations due to clindamycin instillation mainly reflected data from previous studies (Baines et al., 
2008; Jernberg et al., 2010). Marked declines were observed in populations of lactobacilli (MIC 2mg/L) 
and even more remarkable declines in bifidobacterial populations in all three vessels during the 
antimicrobial instillation. These declines were expected owing to the known activity of clindamycin 
against these genera (Hopkins & Macfarlane, 2002; Hoque et al., 2010). However, Enterobacteriaceae, 
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Enterococci, and to a lesser extent Bacteroides spp. were either not severely affected, or even increased 
in viable counts, following clindamycin administration in the present study. The observations on 
Bacteroides spp. were consistent with the findings of a previous researcher that a clear correlation does 
not exist between reduced viable counts of B. fragilis and clindamycin concentrations above the MIC 
(Baines et al., 2006). Clindamycin was used in the present study to bring about germination, growth, 
and cytotoxin production of C. difficile because of the high level of reproducibility recorded in previous 
gut model experiments. Prior studies reported similar changes in the indigenous microbiota upon 
clindamycin instillation as seen in the present studies, such as decreased obligate anaerobes, stable or 
increased facultative anaerobes. C. difficile spores remained quiet before, during, and after clindamycin 
instillation (Baines et al., 2008). Although the antimicrobial concentrations in the gut model vessels 
were not determined in the present study, germination, growth and toxin production of C. difficile only 
occurred when concentrations of clindamycin had likely declined below the MIC (2mg/L) for C. 
difficile PCR ribotype 027. This is in tandem with the observations of Baines et al., (2008).  
While bacterial spores are metabolically dormant, they retain the capacity to sense environmental 
conditions and germinate when conditions become favourable (Setlow, 2003). The onset of C. difficile 
germination and cytotoxin detection in the present study occurred on the same day, 5 days after the 
cessation of clindamycin administration in both the LcS-dosed model and the 027 control, an indication 
that LcS administration does not delay or prevent the germination of C. difficile ribotype 027 spores 
and its subsequent toxin production. Indeed, toxin production climaxed at 4RU (maximum titre in this 
study) 3 days earlier in the LcS-dosed model than the 027 control (3 versus 6 days after initial toxin 
detection). Baines et al., (2008) suggested that PCR ribotype 027 releases toxins (A and B) earlier than 
other C. difficile strains in the growth cycle. Warny et al., (2005) reported that C. difficile PCR ribotype 
027 produced more substantial amounts of toxin A and B than comparator clinical strains. Baines et al., 
(2008) argued that Warny and his colleagues had failed to recognise the ‘’statistically significant greater 
cell density’’ in the C. difficile PCR ribotype 027 cultures in comparison to C. difficile toxinotype 0, 
and that might have accounted for the increase observed by Warny and his colleagues. Owing to the 
fact that a very high adherence to the intestine is required to bring about some probiotic effects, the 
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failure of LcS to prevent germination, proliferation, and toxin production might be due to the absence 
of colon epithelial cells (that may be required for attachment) in the gut model, although reports of 
beneficial probiotic effects from dead cells (Ghadimi et al., 2008; Lopez et al., 2008) contradicts this 
reasoning. The present study favours the model where live probiotic strains are required to exert 
probiotic effects. 
 In a study using Caco-2 cell line, a human intestinal cell line frequently employed to evaluate bacterial 
attachment due to its close similarities with human enterocytes, the different adherence capabilities of 
nine Lactobacillus strains were assessed. Shokryazdan et al., (2014) showed that the adherence capacity 
differed among the strains, suggesting adherence is strain-specific. Similar observations have been 
documented by Jacobsen et al., (1999). Furthermore LcS might not have exerted its probiotic effects 
observed by Pirker et al., (2013); Hickson et al., (2007); and Lee et al., (2013) in the present study due 
to the possibility of a dilution or washout of a nutritional molecule (required for organic acid production) 
from the gut model by the gut model growth medium. Alternatively, it may initially seem like the gut 
model growth media does not have a sufficient energy source for the production of organic acids such 
as acetate and butyrate by lactobacilli that may potentially antagonise C. difficile (Rolfe, 1984; 
Wheeldon et al., 2008). Indeed several studies have reported that the growth of lactobacilli, and their 
production of antimicrobial substances rely on the constituents of the growth media in which they are 
cultivated (Tomás et al., 2002; Avonts et al., 2004; Zalán et al., 2005). The primary reason for such 
differences is the presence or absence of nutritional substances in the different growth media. Although 
the impact of growth conditions such as temperature, time, and pH cannot be neglected (Gourama & 
Bullerman, 1997). Using the gut model growth media, Macfarlane and co-workers reported 
substantially higher amounts of organic acids such as butyrate and acetate in vessel 1 of the gut model 
and suggested it was due to the fermentation of larger amounts of carbohydrates present in vessel 1 
compared to vessels 2 and 3 (Macfarlane et al., 1998). Although organic acid concentrations in the gut 
models were not determined in the present study, it may be possible that the high quantities of organic 
acids produced in vessel 1 of the gut model were diluted into vessels 2 and 3 such that the levels of 
organic acids in vessels 2 and 3 (where C. difficile growth occurred) were below a concentration that 
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may exert an antimicrobial effect on C. difficile. A concentration-dependent inhibitory effect of acetic 
and lactic acids produced by lactobacilli have been demonstrated against Fusarium (Zalan et al., 2010) 
and Bacillus subtilis (Corsetti et al., 1996). 
Egervarn et al., (2006) suggested that an increase in the inoculum size of bacteria gave rise to increased 
MICs (reduced antimicrobial activity). Consequently, the high initial numbers of Bacteroides spp. (7-
log10-units) in Vessel 2 and Vessel 3 of the LcS control experiment (Figure 3.2) might be a plausible 
explanation for the comparatively reduced activity of clindamycin against this bacterial group in the gut 
models. Clindamycin resistance in Bacteroides spp. is increasingly being reported (Brook et al. 2005; 
Roh et al., 2009; Eitel et al., 2013), although no evidence of this was observed in the Bacteroides spp. 
isolates from the gut model in the present study. Interestingly, both lactobacilli and bifidobacterial 
populations had higher initial numbers of over 1010 cfu/mL (Figure 3.1) and were still more susceptible 
to clindamycin than Bacteroides spp. in the present study. The difference in clindamycin susceptibility 
of bacterial groups in this study is more likely to be species or strain-specific and not due to the initial 
inoculum size as suggested by Egervarn et al., (2006). 
Instillation of clindamycin in a previous similar study led to a drop in bifidobacterial populations 
(approx. 6 log10 cfu/mL), below the limits of detection (2 log10 cfu/mL) (Baines et al., 2008). This was 
not the case in the LcS control experiment in the present study. Although populations of bifidobacteria 
dropped by 6 log10 cfu/mL, viable counts were still above the limit of detection. Antimicrobial 
susceptibility testing in the present studies using agar incorporation showed clindamycin to have an 
MIC of 0.06 mg/L to bifidobacteria (Table 3.3). A variance in the bifidobacterial strains present in 
different faecal samples used for the two studies might in part provide some explanation for this 
discrepancy, as well as the initial number of bifidobacterial populations in the gut model which was 
higher in the present study. Nonetheless, lactose fermenters and to a lesser degree enterococcal 
populations were not severely affected following clindamycin instillation. These observations reflect 
the findings of previous studies (Baines et al., 2008; Chilton et al. 2014). These findings were again not 
surprising as clindamycin showed a minimum inhibitory concentration of 128mg/L and 64mg/L (up to 
2 folds higher than the clindamycin dosage of 33.9mg/L) to Enterobacteriaceae and Enterococcus 
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respectively, isolated from the gut model in the present studies (Table 3.3). Indeed, Enterobacteriaceae 
and enterococcal populations increased when antimicrobial concentrations may have dropped below 
their MICs (Figures 3.3 and 3.5). Clindamycin concentrations determined by prior gut model studies 
indicate that the peak antimicrobial concentration achieved was 62.3 mg/L in vessel 3 (Chilton et al., 
2014; Baines et al., 2015), which is still below the MICs for Enterobacteriaceae and Enterococcus 
isolates from the gut model in the present study. This is coupled with an absence of optimum 
competition from depleted bacterial groups. In addition, the resistance of these genera to clindamycin 
is well documented (Singh et al., 2002; Engberg et al., 2007).  
The steep decline in B. fragilis group populations observed in period D due to clindamycin instillation 
in the 027 control model was less severe in the LcS-dosed model Figures (3.4 and 3.6), suggesting LcS 
might be exerting its effects by playing a protective role in minimising the reduction in viable counts 
of this group, which are thought to have a possible role in colonisation resistance to CDI in the gut 
(Freeman et al., 2003).  Although clindamycin resistant B. fragilis has been reported by different 
researchers (Brook 2007; Mandell et al., 2004), the isolates from the gut model after clindamycin dosing 
did not show clindamycin resistance.  The possibility of a protective role for LcS is further given 
credence as B. fragilis group populations were seen to decline following cessation of LcS 
administration. Nevertheless, B. fragilis group viable counts in the 027 control recovered during the 
rest period and did not decline until the end of the experiment without LcS. The relationship between 
Bacteroides and LcS remains to be elucidated. 
Bifidobacterial populations between the LcS-dosed model and the 027 control did not show a marked 
difference following LcS administration for 1 week. These observations do not reflect the author’s 
observations in the LcS control experiment, and it is also inconsistent with the findings of Nagata et al., 
(2011) who reported an increasing abundance of bifidobacteria upon LcS administration. They argued 
that since the abundance of bifidobacteria represents a crucial short chain fatty acid-producing 
population, and these SCFAs enhance the colonic blood flow, in addition to electrolyte and fluid uptake, 
the reduced SCFA production could lead to mechanisms responsible for diarrhoea. Indeed, populations 
of bifidobacterial in the LcS-dosed model suffered a bigger decline following clindamycin 
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administration, contradicting the findings of Pirker et al., (2013) that LcS prevents the decline in 
bifidobacteria populations caused by antibiotic agents. This might in part be due to suggestions that the 
beneficial characteristics of probiotics are not distributed in all probiotic strains (Ohashi & Ushida, 
2009), and such effects might differ from one individual to another (Wong et al., 2014). Nonetheless, 
the validity of these reports relies on the reproducibility of their observations. 
The LcS dose used in the present study was 6.2 x 109 CFUs, which is the total viable count determined 
from a commercially available 65 mL bottle in the present study, as against 6.5 x 109 documented by 
the manufacturers. The discrepancy in LcS total viable counts from the 65 mL bottle may be due to 
methodological differences. This dose was used given the effective dose of probiotics that bring about 
beneficial effects on human health is thought to be about 106 – 109 live microbial cells/day, even though 
it is strain-dependent (Karimi et al. 2012; Watson & Preedy, 2015). Lactobacilli viable counts increased 
by 1.3 x 107 cfu/mL in the LcS-dosed model compared to the 027 control following LcS dosage. The 
rather limited increase on the total lactobacilli count might be due to the pre-existing high indigenous 
lactobacilli numbers (8 log10 cfu/mL). This is an indication that the consumption of LcS in high amounts 
increases the total lactobacilli counts but does not substitute the indigenous lactobacilli in the 
microbiota. An effort to select for LcS in the present study using selective agar plates was unsuccessful. 
Spanhaak et al., (1998) demonstrated that the administration of LcS resulted in an observed decrease in 
β-glucosidase and β-glucuronidase activities. These effects are seen as beneficial as there are reports 
that link these enzymes to chemical carcinogenesis (Goldin & Gorbach, 1984). Furthermore, there are 
suggestions that LcS administration could lead to a reduced intestinal transit time (Spanhaak et al., 
1998), and a shortened intestinal transit time has been thought to impede constipation and reduce the 
risk of colon cancer by facilitating the excretion of toxic compounds (Cummings et al., 1992). 
In an effort to mirror the likely manner of acquiring C. difficile by patients in a hospital setting, spores 
of C. difficile was inoculated into vessels 1 of the gut models. This presented an internal test period to 
evaluate the ability of the unperturbed microbiota to inhibit C. difficile and prevent spore germination, 
outgrowth, and cytotoxin production. The dynamics of C. difficile in an undisturbed microbiota have 
been previously studied (Freeman et al., 2007; Baines et al., 2008). C. difficile was unable to colonise 
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the vessels of the gut model without antimicrobial disturbance and was consequently washed out from 
the vessels of the gut model. Freeman et al. (2003) suggested these observations were similar to events 
in vivo. Observations from the present study mirror the reports of Freeman et al., (2007) and Baines et 
al., (2008), as C. difficile remained mainly as spores and was washed out (Figures 3.8 and 3.9) at the 
rate of the flow rate of the vessels. Similar studies in animal models showed that C. difficile- spore-
treated-hamsters without antimicrobial administration showed no symptom of disease (Larson & 
Borriello, 1990). Moreover, Borriello & Barclay, (1986) suggested that colonisation resistance to 
disease (CDI) necessitated the presence of viable microbes instead of metabolites production. This was 
not the case in the present study as C. difficile proliferation continued even after populations of 
indigenous members of the microbiota recovered from the effects of clindamycin, suggesting a role for 
a key metabolite(s). Reports of animal and in vitro studies aimed at ascertaining the role of organic acid 
in CDI have presented varied results (Forssten et al., 2015).     
Following cessation of clindamycin administration, decreased populations of lactobacilli and 
bifidobacteria recovered to at least steady state levels during period D. This is suggestive of a fall in the 
antimicrobial concentrations in the vessels of the gut model beneath the MICs of the affected bacterial 
groups (Freeman et al., 2003; 2005; 2007). Surprisingly, lactobacilli populations were observed to 
increase within 1 day of clindamycin dosing cessation. Inasmuch as antimicrobial concentrations might 
be rapidly declining, it is very unlikely that clindamycin levels will drop to less than 2 mg/L within one 
day. Perhaps some biofilm detached and was counted with planktonic phase bacteria. Alternatively it 
can be speculated that the lactobacilli recovered from the models one day following cessation of 
clindamycin instillation is LcS (from Yakult) introduced daily to vessel 1 of the model and not the 
indigenous pre-Yakult lactobacilli. Selective agar prepared in the present study in an effort to 
distinguish LcS (from Yakult) and lactobacilli recovered from faecal samples was not successful, in 
part because they have very close MIC profiles. The genetic sequences of the species can be used to 
differentiate them. However, the practicality and cost of such molecular techniques limited their 
application in the present study. 
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Similarly bifidobacterial populations increased immediately upon cessation of clindamycin instillation, 
against previous gut model experiments where bifidobacteria was not detected for 7 days following 
cessation of clindamycin instillation (Baines et al., 2008). It is noteworthy that probiotics (LcS) were 
not administered in the gut model experiment by Baines and others. Matsumoto et al., (2010) reported 
that drinking a fermented beverage drink that contained 4 x 109 LcS CFUs for 4 weeks led to an increase 
in the intrinsic bifidobacterial populations of healthy volunteers. This is consistent with the observations 
of Spanhaak et al., (1998). In addition, the swift bifidobacterial recovery observed just 1 day following 
cessation of clindamycin instillation might in fact be a possible disruption of a biofilm within the vessel, 
releasing bifidobacterial colonies into the planktonic population. This is reflective of the observations 
of Crowther et al., (2014). They showed that whilst the planktonic Bifidobacterium spp. declined below 
the limit of detection upon administration of 33.9 mg/L clindamycin, four times daily, for 7 days in a 
triple stage in vitro human gut model, the sessile Bifidobacterium spp. populations from biofilms in the 
same vessel were detected at approximately 3.9 log10 cfu/g. The decreased susceptibility of biofilm-
associated microorganisms to antimicrobials is well-documented (Stewart & Costerton, 2001).        
During the last 30 years, many studies have reported that consumption of the probiotic lactobacilli might 
reduce the length of diarrhoea due to infection, or antibiotic intervention (Sheen et al., 1995; Kaila et 
al., 1992). In addition, lactobacilli have been reported to influence certain aspects of the immune system 
(Pouwels et al., 1996). However, the effect of lactobacilli consumption on the gut of healthy individuals 
and during antibiotic therapy has not be sufficiently elucidated. In the present study, LcS dosage and 
subsequent increase in lactobacilli counts led to a decline in Enterococci and Enterobacteriaceae 
populations as shown in Figure 3.1. This is in tandem with the observations of Shokryazdan et al., 
(2014) who demonstrated the antagonistic activity of lactobacilli against 12 pathogenic bacteria. The 
antimicrobial activity of lactobacilli and other probiotic strains has been frequently linked to the 
production of organic acids (such as butyric, acetic, and propionic acid), bacteriocins, and the probiotic 
strains’ ability to outcompete pathogens for attachment sites and nutrients, effectively preventing 
pathogens from colonising the gut (Saulnier et al., 2009). The decline observed in the Enterococci and 
Enterobacteriaceae populations in the present study might be due to an increased production of organic 
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acids due to an increased lactobacilli population because a further increase in the lactobacilli 
populations was accompanied by a commensurate decrease in Enterococci and Enterobacteriaceae 
populations. 
Zalan et al., (2010) showed that the antagonistic effect of organic acids against Fusarium increased 
with increasing organic acid concentration. Unfortunately, due to a machine breakdown, gut model 
samples collected to assay for organic acids by high performance liquid chromatography (HPLC) was 
stored for over three months at 4oC. Following HPLC, no useful data was derived (data not shown); a 
pointer to the difficulty associated with storing organic acids. Although the present study is unable to 
provide conclusive evidence on the mechanism of action of LcS against Enterococci and 
Enterobacteriaceae populations, the probiotic’s antagonism of Enterococci and Enterobacteriaceae is 
evident. One explanation might be that the organic acids produced by LcS rapidly diffused and resulted 
in a local decreased pH which is unfavourable to Enterococci and Enterobacteriaceae populations 
(Ouwehand & Vesterlund, 2004). The capacity of lactobacilli to survive at low pH conditions is well 
known (García-Ruiz et al., 2014). Inhibition of bacterial growth by lactic acid is thought to be by an 
enhanced leakage of hydrogen ions across the bacterial cell membrane culminating in an acidification 
of the cytoplasm and a dissipation of pH gradient (Blom & Mortvedt, 1991). Indeed Neal-McKinney et 
al., (2003) demonstrated that lactobacilli produce organic acids. The acidity due to LAB is well known 
to be effective in disrupting colonisation of surfaces with potentially infectious bacteria. The vagina is 
a good example of this. Vaginal epithelial cells colonisation with Lactobacillus prevents a subsequent 
colonisation of the cell surface with pathogenic bacteria, hence, decreasing the incidence of chronic 
vaginal yeast infections (Boris et al., 1989). Taken together, one cannot rule out a role for organic acids 
in the antagonism of the bacterial groups by LcS in the present study.    
Nonetheless, it is noteworthy that lactobacilli populations declined following cessation of LcS-dosing, 
with an accompanying and proportional loss of the apparent effects of LcS. Such effects included, 
observed increase in lactobacilli and bifidobacterial populations and marked declines in Enterococci 
and Enterobacteriaceae populations.    This is an indication of poor colonization by LcS within the gut 
model vessels. Similar observations have been made in prior research. Spanhaak et al., (1998) reported 
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that L. casei Shirota was unable to colonize the gut permanently following a study that involved twenty 
male volunteers. This mirrors the findings of several other studies that L. rhamnosus was unable to 
colonize the gut (Saxelin et al., 1995; Goldin et al., 1992). The continued interaction of LAB such as 
LcS with the mucosal epithelial cells of the GIT and lymphoid cells of the gut promote an immune 
response against pathogenic bacteria (Bourlioux et al., 2003; Mazahreh & Ershidat, 2009). Since the 
triple stage in vitro human gut model used in the present study is limited in terms of immunological 
responses, it is very likely that the probiotic effects observed herein were not due to immunomodulation, 
but a likely prevention of colonisation by the affected bacterial groups, prevention of bacterial invasion, 
inhibition of adhesion to epithelial cells, and outcompeting the affected bacterial groups for nutrients 
(Matsumoto et al., 2010). Lactobacilli have been previously reported to outcompete Salmonella 
cholerasuis for epithelial binding sites in a study that used Human Caco-2 epithelial cells (Lin et al., 
2008). It is also very unlikely that immunomodulation may confer a more prolonged probiotic effect 
given studies involving human subjects (Saxelin et al., 1993; Alander, et al., 1999) have also reported 
the short term colonisation and temporary probiotic benefits of Lactobacillus species. More studies with 
an extended follow up period are needed to shed more light on this area.  
Interestingly cytotoxin was detected on day 58 in the 027 control model when total counts of C. difficile 
was below the limit of detection suggesting an accumulation of earlier produced toxins in the vessels. 
This might be the case in vivo as CDI patients may still suffer the consequences of C. difficile toxins 
even when vegetative cells of the bacteria have been killed by an antimicrobial intervention. 
Alternatively, it might be that such toxins were released from biofilms following biofilm detachment. 
Toxin in biofilms has been demonstrated in a prior gut model study after it has declined below the 
detection limit in the main vessel liquid contents (Crowther et al., 2014)    Data from the present study 
provides evidence that toxin production by C. difficile PCR ribotype 027 mirrors its growth cycle 
(Figures 3.8 and 3.9). Toxin production in both LcS-dosed and 027 control models occurred for 20 days 
until the end of the experiment, and the sigmoidal growth patterns of C. difficile seen in Figure 3.8 is 
suggestive of a biphasic growth cycle of the experimental strain, and consequently bestow on C. difficile 
PCR ribotype 027 an advantage of perpetrating prolonged illness (Freeman et al., 2007). Nevertheless, 
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the increased toxin production and higher vegetative growth observed in the LcS-dosed model is 
difficult to explain. Although it appears LcS encouraged the germination of CD spores in the present 
study, there is insufficient efficient to make this claim. Besides, to the best of the author’s knowledge, 
no study have reported the role of LcS in C. difficile spore germination. It may be that LcS interfered 
with the delicate balance of the gut microbiota required for promoting colonisation resistance to C. 
difficile. Furthermore, the gut model does not mirror in vivo secretory or immunological responses. 
Indeed, a considerable number of studies have attributed the probiotic ability of LcS to its 
immunomodulatory effects (Nagao et al., 2000; Reale et al., 2011; Dong et al., 2013) which cannot be 
replicated in the in vitro human gut model. It is therefore plausible to suggest that immunomodulatory 
events might determine LcS’ overall response to CDI.  
In summary, the results of the present study confirm the capacity of the triple stage in vitro human gut 
model to maintain different genera of bacteria over a prolonged period of time. This makes it a valuable 
resource in investigating the relationship between pathogens, antimicrobial agents, and the colonic 
microbiota. Clindamycin administration led to a dysbiosis of the indigenous gut microbiota and 
simulated CDI in the gut models although bacterial populations recovered following cessation of 
clindamycin dosage. L. casei Shirota dosage impacted positively on the gut microbial community 
confirming earlier studies, however, long term colonization of the gut by LcS was absent. C. difficile 
spores did not germinate, outgrow, or produce cytotoxins in an undisturbed colonic microbiota, on the 
contrary, upon dysbiosis precipitated by antimicrobial agents, C. difficile germinated, grew, and 
produced its cytotoxins. Daily LcS administration of a high probiotic dose failed to prevent C. difficile 
spore germination, outgrowth, and cytotoxin production although a decline in Enterobacteriaceae and 
Enterococci populations were observed. 
It is important to interpret in vitro research data alongside actual observations and treatment of disease 
in patients.  Sadly, research on the roles of individual microbial genera to human physiological 
wellbeing is constrained to the study of a few number of culturable and previously isolated organisms. 
Nevertheless, an improved understanding of microbial metabolism derived from culture-independent 
research and improvement to presently used culture techniques are crucial to future success in this field.  
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Metagenomics provides a well detailed view of all the genes present within a community, providing 
detailed insight to function and composition alike in one experiment (Sekirov et al., 2010). These results 
could be meaningful. Further large sample size and double-blind design studies are required to 
demonstrate the wider significance of these observations in terms of the capacity of LcS to prevent CDI 






















4.0 Evaluation of the capacity of nontoxigenic C. difficile to prevent antimicrobial-induced C. difficile 
infection in a triple-stage in vitro gut model.   
 
4.1 Background  
Antibiotic therapy is the principal predisposing factor for C. difficile infection (CDI). Consequently, the 
indigenous gut microbiota is disturbed quantitatively and/or qualitatively, to bring about a colonisation 
of the gut by C. difficile (Borriello & Barclay 1986; Borriello 1998). Hence, the disruption of 
colonisation resistance is often the initial step in the pathogenesis of CDI.  Upon ingestion of C. difficile 
spores, germination into vegetative cells is required for colonisation in the gut, with a successive toxin 
production culminating in clinical manifestations (Vedantam et al., 2012). Gut anaerobic bacteria are 
understood to play an important role in colonisation resistance although the exact components involved 
are yet to be well defined. Early studies employed in situ hybridization with 16S rRNA probes and 
bacterial culture to compare the components of faecal microbiota in children, young adults, healthy 
elderly individuals, and elderly patients diagnosed with CDI (Hopkins et al., 2001; 2002; Hopkins & 
Macfarlane, 2002). The faecal microbiota of CDI patients showed low bacterial quantity and reduced 
species diversity. CDI patients had a sharp decline in bifidobacteria, Prevotella, and Bacteroides and 
an increase in Enterobacteria, lactobacilli, and clostridia compared to other subject groups. Although 
the authors acknowledged that some of the changes might have been due to metronidazole 
administration to CDI patients before stool collection. Similarly, Chang et al., (2008) employed 16S 
rRNA gene clone libraries to compare the faecal bacterial communities of patients with an initial 
episode of CDI, patients with recurrent CDI, and healthy controls. In the patient group with an initial 
CDI episode and in the control subjects, a greater number of sequences matched with organisms in the 
Bacteroidetes and Firmicutes divisions, which are the two principal bacterial phyla in the gut of healthy 
individuals. On the contrary, the members of the faecal microbiota in patients with recurrent CDI were 
variable, and showed a considerable decline in bacterial diversity and quantity. In two of the patients 
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with recurrent CDI, the microbiota communities are dominated by Verrucomicrobia or Proteobacteria, 
which are usually minor components in a healthy gut microbiota.   
Any factor that impacts on colonisation resistance may potentially affect the risk of CDI associated with 
individual antibiotics (Freeman & Wilcox, 1999). Strikingly, C. difficile is part of the normal gut 
microbiota in up to 80% of infants but often does not promote CDI in spite of reports that a considerable 
amount of the C. difficile strains isolated from infants are toxigenic (Adlerberth et al., 2014).Treatment 
with broad-spectrum antimicrobials such as lincosamides, aminopenicillins, fluoroquinolones, and third 
generation cephalosporins are the chief risk factors for CDI (Oldfield et al., 2014), with C. difficile 
colonisation rates up to 73% in elderly inpatients (Deneve et al., 2009). Antibiotic treatment with 
vancomycin and metronidazole is the standard therapy for CDI. However, the efficacy of these 
antimicrobials are limited, with 20-40% of patients suffering a recurrent episode of CDI (Zucca et al., 
2013). In fact, the crucial role of an unperturbed microbiota which enables colonisation resistance is 
mirrored in the high rates of success of faecal microbiota transplantation which are up to about 92% in 
severe recurrent CDI cases (Gough et al., 2011).  
Given the complex network of co-dependence that exists among components of the indigenous gut 
microbiota, the microorganisms that suffer the deleterious effect of antimicrobials are not necessarily 
confined to those directly targeted by such antimicrobial (Willing et al., 2011). Furthermore, the spread 
of antimicrobial resistance genes form commensal bacteria to their pathogenic counterparts in the gut 
by horizontal gene transfer remains a concern (Jernberg et al., 2010). The degree of antimicrobial-
mediated intestinal microbiota disturbance depends on several factors: the antimicrobial used 
(mechanism of action, range of activity, extent of absorption, pharmacokinetic and pharmacodynamics 
properties, and in vivo drug activation), the dose and duration of therapy, the route of antibiotic 
administration and elimination, in addition to the extent of resistance of the microbial population 
(Jernberg et al., 2010; Britton & Young 2014). A number of molecular- and culture-based studies have 
investigated the long- and short-term impacts of antimicrobials on the intestinal microbiota of healthy 






Jernberg et al., (2007) employed terminal restriction fragment length polymorphism of the 16S rRNA 
gene to assess the long-term effects of a one-week clindamycin course on the faecal microbiota structure 
in four healthy volunteers. A substantial shift in the components of the total bacterial community was 
seen immediately after clindamycin administration, although the community restored its original state 
within 12 weeks after treatment ceased. In a sharp contrast, Bacteroides populations never returned to 
their pre-clindamycin levels and this imbalance remained up to two years after clindamycin treatment 
ceased. This is important as Bacteroides are thought to play a major role in C. difficile colonisation 
resistance (Freeman et al., 2003; 2007). Dramatic and prolonged increases in antibiotic resistance genes 
(erm) levels were also recorded in the faecal DNA samples following clindamycin exposure. The erm 
determinants were due to Bacteroides species. A number of CDI studies using the gut model have used 
clindamycin to induce simulated-CDI large due to its reproducibility (Baines et al., 2008; 2009; 2014; 
Chilton et al. 2014). 
 
4.1.2 Cephalosporins  
Given the range of activity of cephalosporins is wider than antimicrobial groups such as penicillins, a 
bigger disruption of the intestinal microbiota is expected following dosing in patients, especially with 
antimicrobials such as ceftriaxone that are eliminated through the biliary duct (Sullivan et al., 2001). 
Following culture-based studies, cephalosporin exposure was reported to reduce the abundance of 
Enterobacteria and elevate the concentrations of aerobic Gram-positive cocci, e.g.  Intrinsically resistant 
Enterococci. Cephalosporins are also linked with the emergence of resistance in Enterobacteria 
(Sullivan et al., 2001; Rafii et al., 2008). Perez-Cobas et al., (2013) used a multi-omics approach to 
examine the intestinal microbiome of a patient receiving cefazolin intervention for 2 weeks. The 
patient’s faecal samples were collected before and during cefazolin treatment, as well as 40 days after 
cessation of the treatment. Before the antimicrobial treatment and during the early days of treatment, 
populations of the Firmicutes were predominant in the faecal microbiota. On the eleventh day, a 
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substantial reduction in microbial diversity was observed. There was a displacement of firmicutes and 
a marked increase in Bacteroidetes (Bacteroides and Parabacteroides genera) and betaproteobacteria. 
Metabolomic and proteomic analyses indicated the intestinal microbiota responded swiftly (on day 6) 
to antimicrobial administration by activating mechanisms such as multidrug efflux pumps or expression 
of β-lactamases to detoxify the drug. Forty days following the cessation of antimicrobial treatment, the 
components of the intestinal microbiota were very similar to the pre-antimicrobial state, indicating a 
recovery of the initial bacterial populations. Cefotaxime and ceftriaxone have been previously shown 
to induce simulated-CDI in the triple-stage in vitro human gut model (Freeman et al., 2003; Baines et 
al., 2013). 
 
4.1.3 Fluoroquinolones     
Fluoroquinolones are able to reach very high amounts in faeces given they are rapidly absorbed 
following oral administration (Sullivan et al., 2001). Enterobacteriaceae are susceptible to 
fluoroquinolones and consequently, they suffer a deleterious effect during exposure. Additionally some 
fluoroquinolones have been shown to reduce populations of Gram-positive cocci (Rafii et al., 2008). 
Dethlefsen and colleagues tracked disturbances to the distal gut bacterial populations of three healthy 
individuals prior to and after a five-day ciprofloxacin treatment (Dethlefsen et al., 2008; Dethlefsen & 
Relman 2011). Although the intestinal microbiota of each individual reacted in a unique manner to the 
antimicrobial, some common trends were observed. The impact of ciprofloxacin on the gut microbiota 
was swift and profound, bringing about a marked decrease in diversity, depleting up to 50% of the 
bacterial community, and causing major shifts in microbiota composition (with declines in 
Faecalibacterium and Ruminococcaceae) within 3 – 4 days of antimicrobial treatment initiation. Even 
though the microbiota composition was very similar to the pre-treatment state within 1 – 4 weeks 
following cessation of treatment, some bacterial taxa such as Bilophila and Clostridiales did not recover 
even after 6 months of ciprofloxacin treatment. The propensity of fluoroquinolones to induce CDI was 




4.1.4 Aminopenicillins  
A number of studies have investigated the effect of amoxicillin, alone or in combination with the β-
lactamase inhibitor clavulanate, on the human gut microbiota. Upon culture-based experiments, 
amoxicillin treatment with or without clavulanate was linked to resistant Enterobacterial species 
overgrowth (Rafii et al. 2008). Barc et al., (2004) employed a human faecal microbiota-associated 
mouse model to investigate the impact of a seven-day amoxicillin-clavulanate course on the intestinal 
microbiota. The dominant bacterial groups were quantified by flow cytometry with 16S rRNA 
oligonucleotide probes and fluorescence in situ hybridisation. The total anaerobic bacteria was stable 
all through the experiment, but there was a considerable decline in the amounts of Clostridium 
coccoides-Eubacterium rectale group coupled with an increase in the levels of Enterobacteriaceae and 
Bacteroides-Porphyromonas-Prevotella groups during antimicrobial treatment. Upon antimicrobial 
discontinuation, all bacterial groups returned to pre-treatment levels within one week. Young and 
Schmidt (2004) monitored transient changes in faecal microbiota diversity in a patient that developed 
antibiotic-associated diarrhoea during a 10-day course of amoxicillin-clavulanate. Faecal samples 
obtained on days 0, 4 and 24 were analysed using 16S rRNA gene clone libraries. Before antimicrobial 
exposure, the faecal microbiota was chiefly made up of Bifidobacterium, Bacteroides, and members of 
Clostridium cluster IV and XIVa (butyrate-producing bacteria). After four days of amoxicillin-
clavulanate exposure, a considerable increase in Enterobacteriaceae populations were observed, but no 
sequences matching Clostridium cluster XIVa and Bifidobacterium were detected. The majority of these 
changes resolved after two weeks of antimicrobial cessation, except Bifidobacterium spp. which did not 
recover. Co-amoxiclav, a combination of amoxicillin and clavulanate have been previously reported to 
induce growth and toxin production in C. difficile RT027 in a human gut model (Chilton et al., 2012).           
A significant number of studies have investigated potential CDI preventive strategies such as probiotics, 
vaccines, and monoclonal antibodies (Songer et al., 2007; Mizrahi et al., 2014; Arruda et al., 2016; 
Kociolek & Gerding, 2016). Among strategies that seek to prevent CDI, the administration of non-
toxigenic C. difficile (NTCD) is emerging as a promising approach to prevent intestinal colonisation of 
toxigenic C. difficile strains (Songer et al., 2007; Gerding et al., 2015). Recently a NTCD, Z31 isolated 
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from a healthy dog was investigated for its potential use as a probiotic to prevent CDI in swine. Z31 
has since been characterised by whole genome sequencing (WGS), which showed the presence of 
important genes associated with sporulation and colonisation (Pereira et al., 2016). Additionally, the 
capacity of Z31 to prevent CDI was shown in as hamster model (Oliveira Junior et al., 2016). NTCD 
strains do not have genes for toxin production and are often found in hospital environments and 
colonised patients, even though such patients are asymptomatic (Shim et al., 1998). NTCD strains have 
been shown to safely colonise volunteer patients aged over 60 years when administered at doses of 104 
– 108 spores per day for 2 weeks upon vancomycin dosing to deplete the normal microbiota and mimic 
CDI treatment (Villano et al., 2012). 
 
4.2 Aim   
To ascertain the capacity of NTCD (RT010) to prevent antimicrobial-induced simulated-CDI 
in a triple stage in vitro human gut model. 
 
4.2.1 Objectives 
 To instil NTCD into a triple-stage human gut model prior to instillation of virulent C. difficile 
(RT027) and subsequent antimicrobial disruption with a range of recognised CDI-inciting 
agents (fluoroquinolones, aminopenicillins, lincosamides, and cephalosporins) in separate 
experiments. 
 To evaluate the effects of a range of recognised CDI-inciting agents (fluoroquinolones, 
aminopenicillins, lincosamides, and cephalosporins) on spore germination, outgrowth and 






4.3 Materials and Methods 
Materials and Methods were earlier described in 2.0. Selective and non-selective agars used for 
enumeration of gut model bacterial populations, in addition to methods of preparation and supplements 
are highlighted in Table 2.2. The minimum inhibitory concentrations (MICs) and the concentrations of 
antimicrobials used in the selective agars are shown in table 4.2. 
 
4.3.1 C. difficile strains 
The C. difficile strains used in the gut model experiments are described in 2.1.1 
The NTCD used in the present studies contains the chromosomal erm(B) gene (Dr. César Rodríguez 
Sánchez - Personal Communication). 
 
4.3.2 Determination of cytotoxicity of C. difficile strains 
Brain Heart infusion (BHI) broth (LAB049, Lab M limited Lancashire UK) was prepared according to 
the manufacturer’s instruction and pre-reduced for 24 hours at 37oC in the anaerobic cabinet before 
inoculation with about 4 – 8 colony forming units of C. difficile strains (isolated from the gut models at 
the start and end of every experiment) grown on Brazier’s agar plate. The C. difficile-inoculated BHI 
broth was incubated for 72 hours at 37oC in the anaerobic cabinet. The bacterial liquid culture was 
centrifuged at 13300g for 15 minutes (4oC) and the supernatants used to test for cytotoxicity as 
described in section 2.4.1 
 
4.3.2 Antimicrobial susceptibility testing  





4.3.3 Experimental design.  
Experimental time periods are shown in Table 4.1. Following inoculation of the gut model with 10% 
faecal slurry, the gut model was allowed to equilibrate in terms of bacterial populations for 14 days 
(period A). Bacterial counts were monitored during this period. At steady state, the model was dosed 
with ~108 NTCD spores, following which ~108 NTCD spores and ~108   RT027 spores were dosed into 
the experimental model. Thereafter, NTCD + 027 spores were added again with  the appropriate dose 
of the experimental antimicrobial (clindamycin 33.9 mg/L, ciprofloxacin 139 mg/L, cefotaxime 
20mg/L, and ampicillin 8mg/L) to achieve reported faecal/biliary levels (Ayliffe & Davies, 1965; 
Brown et al., 1976; Novick, 1982; Lambert-Zechovsky et al., 1985; Brismar et al., 1990). Clindamycin 
was instilled every 6 h for 7 days, ciprofloxacin and cefotaxime were instilled every 12 h for 7 days, 
ampicillin was instilled every 8 h for 7 days. The models were then allowed to a rest period of 14 days.  
The duration of each experiment was 9 weeks, with each antibiotic and C. difficile strain growth 
behaviour in completion and alone (control) evaluated in separate experiments.  
 
Table 4.1. Time periods in gut model experiments with NTCD (RT010) vs RT027 using different 
antimicrobials 
Day (Time 
period)   
0-14  (A) 15-21  (B) 22-28  (C)  29-35  (D) 36-62  (E)  
027 Control Steady state No 
intervention 
027 spores  027 spores + 
antimicrobial 
Rest 
027 vs 010 
(experimental) 
Steady state ~108 010 
spores 
010 + 027 
spores 




010 Control Steady state No 
intervention 






























The NTCD used in the present study was not cytotoxic. 
The antimicrobial concentrations used in the selective agar are shown in table 4.2. The difference in 
MICs between strains were exploited to select for strains in the agar plates. The MICs of all 
antimicrobials used in the gut model experiments were determined to ascertain if the MIC of the 
antimicrobials conferred an advantage to one of the strains in the gut model. This is in addition to 
determining the concentration of antimicrobial that can be used in agar for selection.   
 
Table 4.2. Antimicrobial concentrations used in selective agar. 
 Tetracycline MIC (mg/L) Clindamycin MIC (mg/L) 
Drug concentration in agar 0.5 10 
 
Table 4.3. Antimicrobial MICs for C. difficile strains used in the gut model experiments 












2 128 4 ˃128 0.06 
RT027 8 64 4 2 16 
 
Given the high consistency between the effects of the antimicrobials on the microbiota in all the models, 





4.4.1 Gut bacterial populations in the clindamycin-dosed models  
The bacterial populations in different experimental periods in the clindamycin-dosed model are shown 
in figures 4.1a and 4.1b. Obligate anaerobes outnumbered facultative anaerobes during steady state. 
The instillation of NTCD spores showed no impact on the bacterial groups.  A re-administration of 
NTCD spores in addition to instillation of 027 spores coincided with a 2 log10 cfu/mL decline in total 
anaerobes viable count, but showed no effect on the other bacterial groups. Upon instillation of 
clindamycin, bifidobacteria, lactobacilli, total anaerobes, and Bacteroides fragilis group were the most 
depleted bacterial groups with a 1.5 - 3.5 log10 cfu/mL decline. In contrast, Lactose-fermenting 
Enterobacteriaceae, Enterococci, and total anaerobes counts increased by approx. 1 – 2.5 log10 cfu/mL. 
The bacterial populations generally recovered to or exceeded pre-antimicrobial levels within 7 days of 
administration of the final dose of clindamycin. Populations of Enterococci, facultative anaerobes, and 
lactose fermenting Enterobacteriaceae declined by approx. 0.5 – 1 log10 cfu/mL during the rest period. 
 



























Figure 4.1a. Mean (+/-SE) viable counts (log10cfu/mL) of total culturable total anaerobes, lactose 
fermenting Enterobacteriaceae, Enterococcus spp., and Bifidobacterium spp, in the clindamycin (DA) 
027 vs 010 competition gut model. Vertical lines indicate the final day of each experimental period. SS 






























Figure 4.1b. Mean (+/-SE) viable counts (log10cfu/mL) of Bacteroides fragilis group, Lactobacillus spp. 
and facultative anaerobes in the clindamycin (DA) competition gut model. Vertical lines indicate the 
final day of each experimental period. SS is steady state. 010 is C. difficile RT010, 027 is C. difficile 
RT027 
 
4.4.2 Gut bacterial populations in the cefotaxime-dosed models  
The bacterial populations in different experimental periods in the cefotaxime-dosed model are shown 
in figures 4.2a and 4.2b. Obligate anaerobes outnumbered facultative anaerobes during steady state. 
The instillation of NTCD spores showed no impact on the bacterial groups. Similarly, a re-
administration of NTCD spores in addition to instillation of 027 spores showed no effect on the bacterial 
groups but for a minor decline in the total anaerobes viable counts. Following cefotaxime instillation, 
an approximately 0.5 log10 cfu/mL decline was observed in the total anaerobe population.  Lactose 
fermenters, bifidobacteria, and Bacteroides spp. populations declined by approximately 1 – 2.5 log10 
cfu/mL. There was no observable effect on the counts of facultative anaerobes and Enterococci. In 
contrast, lactobacilli populations rose by 1 log10 cfu/mL upon cefotaxime instillation. Upon the cessation 
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of cefotaxime instillation, the total anaerobe, Bacteroides spp., bifidobacteria, and lactose fermenters 
recovered to at least steady state levels, whereas lactobacilli populations rose beyond the levels observed 
during cefotaxime instillation. No further change was observed during the rest period, but for a very 






























Figure 4.2a. Mean (+/-SE) viable counts (log10cfu/mL) of total anaerobes, Bacteroides fragilis group, 
Bifidobacterium spp. and Lactobacillus spp. in the cefotaxime (CFX) competition gut model. Vertical 
lines indicate the final day of each experimental period. SS is steady state. 010 is C. difficile RT010, 






























Figure 4.2b. Mean (+/-SE) viable counts (log10cfu/mL) of total culturable Enterococci, lactose 
fermenting Enterobacteriaceae, and facultative anaerobes in the cefotaxime (CFX) competition gut 
model. Vertical lines indicate the final day of each experimental period. SS is steady. 010 is C. difficile 
RT010, 027 is C. difficile RT027. 
 
 4.4.3 Gut bacterial populations in the ciprofloxacin-dosed models. 
The bacterial populations in different experimental periods in the ciprofloxacin-dosed model are shown 
in figures 4.3a and 4.3b. Bacterial populations showed minor fluctuations during steady state. Obligate 
anaerobes such as bifidobacteria outnumbered the facultative anaerobes during steady state. The 
instillation of NTCD showed no considerable effect on the bacterial populations. The instillation of 
NTCD spores together with 027 spores coincided with a slight increase and decrease of Bacteroides 
fragilis group and Enterococci respectively, but showed no impact on other bacterial groups.  Upon 
ciprofloxacin instillation, the counts of Bacteroides spp. decreased by approx. 1 log10 cfu/mL. Similarly, 
bifidobacteria, lactobacilli, and Enterococci counts decreased by 1 – 2 log10 cfu/mL. Additionally, 
lactose fermenters showed about 5 log10 cfu/mL decline below the limit of detection. However, the total 
anaerobe and facultative anaerobe populations were largely unaffected. Within 7 – 9 days of 
ciprofloxacin instillation cessation, the bacterial counts generally recovered to steady state levels, 
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except the lactose fermenters, which required 16 days to achieve steady state levels. No further change 
was observed during the rest period. 
 
 


























Figure 4.3a. Mean (+/-SE) viable counts (log10cfu/mL) of total culturable B. fragilis group, 
Bifidobacterium spp., Lactobacillus spp., and Enterococcus spp. in the ciprofloxacin (Cipro) 
competition gut model. Vertical lines indicate the final day of each experimental period. SS is steady 






























Figure 4.3b. Mean (+/-SE) viable counts (log10cfu/mL) of total culturable lactose fermenting 
Enterobacteriaceae, total anaerobes, and facultative anaerobes in the ciprofloxacin (Cipro) competition 
gut model. Vertical lines indicate the final day of each experimental period. SS is steady state. 010 is 
C. difficile RT010, 027 is C. difficile RT027. 
 
4.4.4 Gut bacterial populations in the ampicillin-dosed models. 
The bacterial populations in different experimental periods in the ampicillin-dosed model are shown in 
figures 4.4a and 4.4b. Obligate anaerobes such as bifidobacteria and Bacteroides fragilis group 
outnumbered the facultative anaerobes during steady state. The instillation of NTCD showed no 
considerable effect on the bacterial populations. Similarly, the instillation of NTCD spores together 
with 027 spores did not show any considerable effect on the bacterial populations. Following 
administration of ampicillin, populations of Bacteroides spp., and bifidobacteria declined by approx. 
1.5 – 2.5 log10 cfu/mL, whereas populations of facultative anaerobes, and lactose fermenters, and total 
anerobes increased by aprrox. 1.0 – 3.0 log10 cfu/mL. Bacterial populations recovered to steady state 
































Figure 4.4a. Mean (+/-SE) viable counts (log10cfu/mL) of total culturable Bacteroides fragilis group, 
Bifidobacterium spp., facultative anaerobes, and lactose fermenting Enterobacteriaceae in the ampicillin 
(Amp) competition gut model. Vertical lines indicate the final day of each experimental period. SS is 


































Figure 4.4b. Mean (+/-SE) viable counts (log10cfu/mL) of total culturable Enterococci, Lactobacilli, and 
total anaerobes in the ampicillin (Amp) competition gut model. Vertical lines indicate the final day of 
each experimental period. SS is steady state. 010 is C. difficile RT010, 027 is C. difficile RT027. 
 
4.4.5 C. difficile populations and cytotoxin production upon clindamycin administration 
Prior to clindamycin administration, C. difficile remained as spores in all three models (027 control, 
NTCD control, and 027 vs NTCD experimental model) and the spores were washed out of the models 
with no evidence of cytotoxin production. Four days into clindamycin administration the NTCD 
germinated in the NTCD control model. This was seen as a considerable divergence of the C. difficile 
total viable count and spore count. Ribotype 027 germinated 10 days after clindamycin instillation 
cessation in the RT027 control model followed by a high toxin production (4 RUs) on the next day. In 
the NTCD/RT027 competition model, NTCD germinated 4 days into clindamycin administration, 
whereas RT027 remained quiescent as spores, with no evidence of germination/outgrowth/proliferation 
or cytotoxin production throughout the experimental period. The total count of NTCD remained 
considerably above the spore count for the duration of the experiments, while in the control experiment 
with C. difficile PCR ribotype 027, the total count and cytotoxin titres began to decline, with the 
cytotoxin titre being 1 RU at the end of the experiment. C. difficile total viable counts, spore counts, 
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and cytotoxin titres in the NTCD vs 027 competition model, 027 control model, and the NTCD control 
model are shown in figures 4.5 a, b, and c respectively.  
 
 
   

















































                                                 
Figure 4.5a. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT010 vs RT027 clindamycin (DA) competition model. Vertical lines indicate 



















































Figure 4.5b. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT027 control clindamycin (DA) model. Vertical lines indicate the final day 
of each experimental period. LLOD is lower limit of detection. 
 














































Figure 4.5c. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT010 control clindamycin (DA) model. Vertical lines indicate the final day 




4.4.6 C. difficile populations and cytotoxin production upon cefotaxime administration 
C. difficile remained quiescent in all the models prior to cefotaxime administration, until the fifth day 
of cefotaxime administration when NTCD germination (an increase in TVC and a decrease in spores 
count) was observed in both the competition and NTCD control models. No toxin was detected in both 
models throughout the experimental period. There was no evidence of ribotype 027 
germination/outgrowth/proliferation or cytotoxin production in the competition model throughout the 
experiment.  In contrast, in the 027 control model, ribotype 027 germinated on the sixth day of 
cefotaxime administration with a toxin production of 3RUs. After 10 days of initial toxin detection, 
toxin production declined to 1RU until the end of the experiment. C. difficile total viable counts, spore 
counts, and cytotoxin titres in the NTCD vs 027 competition model, 027 control model, and the NTCD 
control model are shown in figures 4.6 a, b, and c respectively.  
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Figure 4.6a. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT010 vs RT027 competition cefotaxime (CFX) model. Vertical lines indicate 
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Figure 4.6b. C. difficile total viable counts, spore counts (log10cfu/mL ±SE)) and cytotoxin titres 
(relative log10 units, RU) in V3 of RT027 control cefotaxime (CFX) model. Vertical lines indicate the 
final day of each experimental period. LLOD is lower limit of detection. 
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Figure 4.6c. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT010 control cefotaxime (CFX) model. Vertical lines indicate the final day 
of each experimental period. LLOD is lower limit of detection. 
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4.4.7 C. difficile populations and cytotoxin production upon ciprofloxacin administration 
C. difficile remained as spores in all the models prior to ciprofloxacin administration. On the fourth and 
fifth day after ciprofloxacin administration, germination of NTCD occurred in the NTCD vs 027 
competition model and NTCD control model respectively. No toxins were detected in both models 
throughout the experimental period. There was no evidence of ribotype 027 
germination/outgrowth/proliferation or cytotoxin production in the competition model. However, in the 
027 control model, C. difficile PCR ribotype 027 germinated 7 days after ciprofloxacin administration, 
with an accompanying toxin production of 5 RUs 2 days after. C. difficile total viable counts began to 
decline towards the end of the experiment in all of the models and cytotoxin titres also declined towards 
the end of the experiment in the 027 control model, with the cytotoxin titre being 1 RU at the end of the 
experiment. C. difficile total viable counts, spore counts, and cytotoxin titres in the NTCD vs 027 
competition model, 027 control model, and the NTCD control model are shown in figures 4.7 a, b, and 
c respectively. 




















































Figure 4.7a. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT010 vs RT027 competition ciprofloxacin (Cipro) model. Vertical lines 
indicate the final day of each experimental period. LLOD is lower limit of detection. 
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Figure 4.7b. C. difficile total viable counts, spore counts (log10cfu/mL ±SE)) and cytotoxin titres 
(relative log10 units, RU) in V3 of RT027 control ciprofloxacin (Cipro) model. Vertical lines indicate 
the final day of each experimental period. LLOD is lower limit of detection. 















































Figure 4.7c. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT010 control ciprofloxacin (Cipro) model. Vertical lines indicate the final 
day of each experimental period. LLOD is lower limit of detection. 
126 
 
4.4.8 C. difficile populations and cytotoxin production upon ampicillin administration 
C. difficile remained as spores in all the models prior to ampicillin administration. On the third day of 
ampicillin administration NTCD germinated in the NTCD control experiment. This was followed by 
the germination of ribotype 027 in the 027 control model on the next day. NTCD germinated in the 
competition model on day 5 of ampicillin instillation. There was no evidence of ribotype 027 
germination/outgrowth/proliferation or cytotoxin production in the competition model throughout the 
experiment. Similarly, no toxins were detected in the   NTCD control model throughout the 
experimental period. However, a maximum cytotoxin titre of 3 RUs was observed in the 027 control 
model following germination and growth of ribotype 027. Cytotoxin titres declined to 2RUs in the 027 
control model towards the end of the experiment. C. difficile total viable counts, spore counts, and 
cytotoxin titres in the NTCD vs 027 competition model, 027 control model, and the NTCD control 
model are shown in figures 4.8 a, b, and c respectively. 
 



















































   
Figure 4.8a.  C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT010 vs RT027 experimental ampicillin (Amp) model. Vertical lines indicate 
the final day of each experimental period. 
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Figure 4.8b. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT010 control ampicillin (Amp) model. Vertical lines indicate the final day 
of each experimental period. 
















































Figure 4.8c. C. difficile total viable counts, spore counts (log10cfu/mL ±SE) and cytotoxin titres (relative 
log10 units, RU) in V3 of RT027 control ampicillin (Amp) model. Vertical lines indicate the final day 
of each experimental period. 
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4.5 Discussion    
C. difficile PCR ribotype 027 have been often revealed to be overrepresented in nosocomial outbreaks 
and have been associated with increased mortality and morbidity. Even though the mechanism through 
which it perpetrates   hyper-virulence continues to be foment controversy, the capacity of RT027 strains 
to spread across the world may be an indication of an acquisition of a heightened capacity to cause 
disease. In the present study, it was hypothesized that the differed physiology could confer a competitive 
advantage on a non-toxigenic C. difficile (NTCD) strain (RT010) over a virulent strain and contribute 
to the body of published evidence suggesting a benefit of NTCD in interrupting the cycle of CDI. The 
triple-stage in vitro human gut model was employed for these studies since this model system has been 
shown to accurately reflect in vivo observations with respect to CDI induction and treatment (Freeman 
et al., 2003; Baines et al., 2008; Chilton et al., 2012; Crowther et al., 2015; Moura et al., 2020). The 
gut model allows for the study of the capability of NTCD to interfere with a cycle of simulated CDI 
(RT027) following perturbation of the gut microbiota by a range of antimicrobial agents. This model is 
superior to studies of C. difficile in hamsters (Ebright et al., 1981; Larson & Welch 1993; Alcantara et 
al., 2001; Sambol et al., 2001; Razaq et al.,, 2007) and studies in faecal emulsions (Borriello & Barclay, 
1986; Wilson & Perini, 1988; Larson & Welch, 1993b) in that animals are not truly reflective of the 
human colon and faecal antibiotic concentrations and C. difficile exposure in studies using faecal 
emulsions are not well controlled. Even though antimicrobial concentrations within each vessel were 
not measured in the present studies, the instillation of antimicrobials at regular intervals was intended 
to mirror the fluctuation of antimicrobial concentrations in the colon. In this manner, the present study 
instilled antimicrobial agents to achieve published faecal concentrations of the antimicrobials and prior 
studies have demonstrated that the gut model dosing in this fashion achieves clinically relevant 
antimicrobial concentrations of fluoroquinolones, clindamycin, cephalosporins, and aminopenicillins 
(Freeman et al., 2003; Baines et al., 2008; Saxton et al., 2009; Chilton et al., 2012).  
Different antimicrobials (clindamycin, cefotaxime, ciprofloxacin, and ampicillin) were used in the 
present studies to ascertain if the type of antimicrobial impacted on the competition of the toxigenic and 
non-toxigenic strains in the models. Additionally the minimum inhibitory concentration (MIC) of the 
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inducing antimicrobial on the competition was also evaluated. This is because C. difficile outgrowth 
occurs when antimicrobial levels are below the MIC (Baines et al., 2008; 2013; Crowther et al., 2015).  
Both strains in the present studies appeared to respond to antimicrobial exposure; entering a cycle of 
spore germination, outgrowth, and proliferation when in monoculture in the gut model (control 
experiments).  
Studies on antimicrobial-enhancement of C. difficile toxin production have reported conflicting results 
(Nakamura et al., 1982; Barc et al., 1992; Drummond et al., 2003; Pultz & Donskey, 2005). The present 
studies showed C. difficile inactivity in the absence of antimicrobial disturbance in the gut models. 
Freeman et al., (2003) suggested that growth and toxin production by C. difficile occurs upon an effect 
of antimicrobials on members of the microbiota, instead of a direct effect on C. difficile. This they 
believe accounts for why CDI does not occur within a short time frame of of antimicrobial instillation, 
but days or even weeks later. However, Drummond et al., (2003) reported that the effect of 
antimicrobials on C. difficile growth and toxin production varied with strain and the type of 
antimicrobial, suggesting a more direct and complex relationship. They demonstrated that sub-
inhibitory concentrations of clindamycin potentiated higher levels of toxin production and in a shorter 
time when compared with antibiotic-free controls. Antibiotics are expected to cause stress in bacteria 
(including C. difficile). The bacteria under stress ‘’switch on’’ a number of genes, which the toxin 
promoters might be affected by (Drummond et al., 2003). Indeed, the physiological stress of increased 
temperature was shown to lead to higher toxin production in C. difficile (Onderdonk et al., 1979). The 
same authors showed an increased toxin production upon sub-inhibitory penicillin and vancomycin 
concentrations. Hennequin et al. (2001) demonstrated that C. difficile, when cultured with 
antimicrobials, produces higher amounts of GroEL, a 58 kDa surface adhesin that might assist C. 
difficile to colonise recently vacated binding sites left due to the depletion of the microbiota. Similarly, 
Deneve et al., (2008) demonstrated that both non-toxigenic and toxigenic C. difficile strains 
overexpressed the three adhesins Fbp68, Cwp66, and the S-layer protein P47 (although to different 
degrees) following exposure to sub-inhibitory antimicrobial concentrations in the growth medium. 
Ampicillin and clindamycin exposure led to higher levels of expression of the adhesins. Strikingly, 
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exposure to kanamycin led to a 1.3 – 2.3-fold increase in the adhesins for a toxigenic strain (79-685) 
and a 3.2 to 5-fold increase for a non-toxigenic strain (ATCC 43603). Upregulation of the genes 
encoding the adhesins was not associated with the resistance level of the strains (Deneve et al., 2008). 
Furthermore, Deneve et al., (2008) showed that the adherence of strain ATCC 43603 to Caco-2/TC7 
cells was increased 1.8-fold by clindamycin and 2.2-fold by ampicillin, consistent with the increased 
adhesin gene expression. Given the roles of S-layer protein, Fbp68, and Cwp66 in C. difficile adherence 
(Waligora et al., 2001; Calabi et al., 2002; Cerquetti et al., 2002), coupled with observations from the 
present studies where no strain of C. difficile germinated/grew/proliferated or produced cytotoxin prior 
to antimicrobial instillation, in addition to the likelihood that both C. difficile strains in the present 
studies proliferated when antimicrobial levels declined below their MICs for the strains in the control 
models, as well as the inability of ribotype 027 to germinate/outgrow/proliferate or produce cytotoxin 
in the presence of NTCD, it might be that the antimicrobials used in the present study (clindamycin, 
cefotaxime, ciprofloxacin, and ampicillin) increased colonisation factor gene expression in NTCD more 
than in RT027, leading a better adherence by NTCD and in turn a better utilisation of the new niche 
created by the depletion of bacterial groups by antimicrobials in the gut models. Such improved 
adherence might have conferred advantage on NTCD. Nonetheless, it is pertinent to state the inherent 
difficulties associated with comparing pure cultures and complex microbiota data.                            
Upon addition of C. difficile (toxigenic and non-toxigenic) spores to the gut models, and in the absence 
of antimicrobial perturbation in the present studies, no spore germination, growth, or toxin production 
were observed. This work demonstrates for the first time that ribotype NTCD (RT010) strains can 
directly outcompete ribotype 027 strains in a complex faecal microbiota. Given all the major 
antimicrobial groups were represented in the present studies, it is very unlikely that that the observed 
increased fitness of NTCD was due to a direct advantage by an antimicrobial. Similar amounts of both 
strains (108) were added to the gut models but only NTCD was able to germinate and grow, fuelling the 
suspicion that these particular strains cannot coexist. This is despite data from studies that showed two 
different C. difficile strains simultaneously proliferated in a complex in vitro model upon antimicrobial 
instillation, suggesting a possible in vivo coinfection by multiple virulent strains (Baines et al., 2013; 
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Crowther et al., 2015). Although the physiological differences present in ribotype 010 strains that 
enabled them to outcompete 027 is currently unknown, it is unlikely that the competitive advantage of 
RT010 over RT027 in the present studies was because of a simple advantage in growth rate since there 
was no evidence that RT027 spores germinated, unlike prior gut model studies where these 
antimicrobials have yielded growth and cytotoxin production for ribotype 027 (Freeman et al., 2003; 
Baines et al., 2008; Saxton et al., 2009; Chilton et al., 2012) . Robinson et al., (2014) showed using in 
vitro batch culture experiments in several different laboratory media that no significant distinctions 
exists between the growth rate of RT027 strains and other ribotypes. Even though it is plausible to 
suggest that RT010 strains are able to directly antagonise RT027 strains, it is more likely that RT010 
strains possess a heightened cellular fitness that enables them to compete better for limiting nutrients, 
hence indirectly leading to the elimination of RT027 strains from the gut model vessels. Nonetheless, 
it is plausible to suggest that RT010 might have produced substance(s) that may hinder the growth of 
RT027 in the present studies. Given RT010 and RT027 were not grown in a pure culture together, it 
can only be speculated that such a phenomenon happened with the strains used herein. Even though the 
present studies did not determine and characterise the presence of such inhibitory substances, it cannot 
be totally ruled out. The characterisation of a potential inhibitiory substance may be undertaken by 
treating the culture supernatants with catalase, pronase, or adjusting the culture supernatant to pH 6.5 
to ascertain if such inhibitory substance is hydrogen peroxide, bacteriocin, or an organic acid 
respectively. In theory, if RT010 produces substances that decrease the growth rate of RT027 even 
when RT027 is provided with a nutritionally rich medium. The effect will be a decrease in the maximum 
growth rate achievable by RT027. Such decrease in the maximum growth rate of RT027 would directly 
decrease its competitive capacity in a continuous culture environment such the triple-stage in vitro 
human gut model (Monod, 1950; Fredrickson, 1977). Some bacteria produce antibacterial compounds 
that can prevent/treat CDI. Bacteriocin molecules produced by Bacillus thuringiensis DPC 6431 (Mills 
et al., 2018) and reuterin produced by Lactobacillus reuteri have been reported to reduce the growth of 
C. difficile in vitro (Spinler et al., 2017).     
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Competition for nutrients may be another likely mechanism through which NTCD in the present studies 
prevented RT027 spores from germinating and growing. Chemostat theory holds that if different 
bacterial populations are growth-limited by a common substrate in a continuous culture, they will 
compete for that substrate. The population capable of depleting the common substrate to the lowest 
concentration while dividing at the dilution rate of the continuous culture will displace the other 
populations (Freter et al., 1983). Antimicrobials can impact on the availability of microbial resources 
in the colon in several ways. As an effect of decreasing bacterial biomass, antimicrobials reduce 
competition for nutrients and also establish previously unavailable ecological niches. Additionally, 
bacteria lysis due to antimicrobials give off carbon sources that may be utilised by the remaining 
members of the microbial community (Britton & Young, 2014).  
Over 30 years ago, Wilson and Perini demonstrated that components of mucin, N-acetylneuraminic acid 
(a sialic acid) and N-acetylglucosamine promoted in vitro growth of C. difficile. Moreover, the 
introduction of these monosaccharides to a culture of mouse caecal microbiota completely restored the 
capacity of the microbial community to prevent C. difficile proliferation upon a transfer to germ-free 
mice, an indication that these monosaccharides enhance the expansion of specific intestinal bacteria 
that can utilise them efficiently, thus outcompeting C. difficile (Wilson & Perini, 1988). More recently 
Ng et al., (2013) showed that under normal conditions, the indigenous intestinal microbiota competes 
for the utilisation of sialic acids which are given off from the colon’s mucus lining. Nevertheless, upon 
a disturbance of the resident microbiota by antimicrobial agents, sialic acids are left unutilised, thereby 
providing a window of opportunity for C. difficile to utilise these carbohydrates and proliferate. It is 
therefore plausible to suggest that in the present studies ribotype 010 have more affinity for these sialic 
acids or may have an improved utilisation profile in comparison to ribotype 027. This may explain why 
ribotype 027 did not proliferate in the gut models in the presence of ribotype 010 despite antimicrobial 
disturbance of the microbiota. This thinking is also reinforced by the inability of ribotype 010 to gain a 
foothold in the gut models prior to antimicrobial instillation, and the germination and growth of RT027 
in the absence of RT010. Future studies to investigate the substrate affinity and sialic acid utilisation 
profiles of toxigenic and NTCD may shed more light on this area. 
133 
 
An aspect of bacterial physiology that might likely affect competition outcome is differences in 
sporulation rates between strains. Despite reports that RT027 strains sporulate more efficiently than 
other ribotypes (Akerlund et al., 2008; Merrigan et al., 2010), bigger studies that compared many 
isolates of distinct ribotypes concluded that no significant association exists between ribotype and 
sporulation efficiency (Burns et al., 2011; Carlson et al., 2013). Given C. difficile was dosed into the 
gut models as spores in the present studies, the strains’ ability and speed to germinate will likely be 
more crucial for competitive advantage rather than their reduced sporulation efficiency. Besides, the 
present study does not have data to ascertain if the RT027 strains used in the present studies sporulate 
more efficiently than RT010 strains. C. difficile sporulation dynamics in the context of growing in a 
complex faecal microbiota should be an area of future research. Although it is crucial to consider the 
effect of sporulation dynamics on the outcome of bacterial competition, it is very unlikely that 
sporulation rates is responsible for ribotype 010 strains outcompeting ribotype 027 in the present 
studies.  
Differences in germination is an aspect of bacterial physiology that might have a role in competitive 
fitness in the simulated CDI model. Differential germination might have played a role in the competitive 
advantage of RT010 strains in the gut models given competition in the present studies was initiated by 
an administration of spores. Francis et al., (2013) reported that muricholic acids (murine bile acids) 
inhibit the germination of C. difficile spores, and that a strain variability exists in this inhibition. 
Additionally, there is evidence to suggest a significant difference in germination rates and substances 
that act as germinants (at least in vitro) among C. difficile strains of different ribotypes (Heeg et al., 
2012). Cholate and chenodeoxycholate are the primary bile acids produced by the liver in humans. They 
are often conjugated to glycine or taurine (for example taurocholate). The portion of produced bile acids 
(less than 5%) that is not reabsorbed in the small intestine (distal ileum) is passed into the colon, where 
they are subjected to bacterial metabolism (Gerard, 2014). A small fraction of intestinal bacteria can 
metabolise primary bile acids into secondary bile acids such as deoxycholate and lithocholate (Jones et 
al., 2008). In vitro research have demonstrated that deconjugated and conjugated forms of cholate act 
together with the amino acid glycine to induce C. difficile spore germination, whereas 
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chenodeoxycholate strongly inhibits germination of C. difficile spores (Sorg & Sonenshein, 2008; 
2009). Lithocholate (a secondary bile acid) inhibits spore germination, whereas deoxycholate enhances 
spore germination, but because of its toxicity to C. difficile vegetative cells, it prevents it growth (Sorg 
& Sonenshein, 2008; 2010). Under normal physiological functioning chenodeoxycholate competitively 
inhibits taurocholate-promoted spore germination in the colon, in addition to preventing C. difficile 
outgrowth similar to deoxycholate (Sorg & Sonenshein, 2008; 2009; 2010). 
Nevertheless, when the intestinal microbiota is disturbed by antimicrobials, primary bile acids are not 
metabolised into secondary bile acids, and this may ultimately enhance the germination and growth of 
C. difficile (Sorg & Sonenshein, 2009; 2010). In fact patients with severe CDI were shown to have very 
low or undetectable faecal secondary bile acid levels (Weingarden et al., 2014).  Buffie et al., (2015) 
recently reported that Clostridium scindens, a bile acid 7α-hydroxylating bacterium, showed inhibition 
against C. difficile in the microbiota of antimicrobial-treated humans and mice in a bile acid-dependent 
manner. The 7α-hydroxylation activity is thought to involve the metabolism of primary bile acids into 
secondary bile acids, and a limited number of intestinal bacterial species among the Eubacterium and 
Clostridium genera possess this activity (Gerard, 2013). C. difficile spores are necessary for infection 
transmission, but to cause disease spores must return to vegetative cell growth via germination. Indeed 
the germination response to bile salts differs among spores of different isolates (Heeg et al., 2012; 
Weingarden et al., 2016). This same group of researchers reported that despite its ability to inhibit spore 
germination, chenodeoxycholate did not show inhibition to germination or vegetative cell outgrowth in 
some isolates. Similarly, there was a considerable variation in the extent and rate of germination among 
different C. difficile isolates in response to taurocholate. Taken together, and given that ribotype 027 
strains did not germinate like ribotype 010 in the present studies, it can only be speculated that bile 
acids may have inhibited the germination of RT027 spores but not RT010 given the strain variability, 
or perhaps RT010 spores were able to utilise a nutrient or chemical (amino acid or bile salt) as a 
germinant while RT027 were unable to utilise same. It may also be that the germination or inhibition 
of C. difficile by bile acids may be in a concentration-dependent manner, such that RT010 may require 
very minimal amounts of bile acids for germination when compared to RT027. Ribotype 010 may also 
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require higher amounts of secondary bile acids to inhibit its germination. In fact Theriot et al., (2015) 
demonstrated that secondary bile acids that significantly interfered with taurocholate-mediated spore 
germination in C. difficile do so in a concentration-dependent manner. They demonstrated that C. 
difficile VPI 10463 spores germination was inhibited only at the appropriate concentration of secondary 
bile acids (ω-muricholate 0.004% and lithocholate 0.01%), in the presence of known germinants in 
murine caecum. Gut model studies may be designed with an instillation of different concentrations of 
bile acids to elucidate optimum bile acid concentrations that may enhance germination of NTCD or an 
inhibition of toxigenic C. difficile spores in the presence of a complex human intestinal microbiota. 
Exploiting the capacity of NTCD spores to germinate before its toxigenic counterparts is particularly 
promising in terms of preventing recurrent CDI (rCDI), which is a relapse of CDI symptoms within 2 
– 8 weeks of successful treatment of the initial episode (McDonald et al., 2018). This is because unlike 
commercially available standard probiotics such as L. casei Shirota and Saccharomyces boulardi, 
NTCD strains are able to sporulate. Therefore if the conditions in the colon permitted C. difficile spore 
germination after an initial successfully treated episode of CDI, it is the NTCD spores that may 
germinate and prevent toxigenic counterparts from germinating and growing, thus holding a huge 
potential to prevent rCDI. Colonisation with a NTCD in a randomised clinical trial was correlated with 
reduced rCDI (Gerding et al., 2015). The researchers reported a 31% recurrence of CDI in patients who 
were not colonised with NTCD as against 2% in patients who were colonised. These findings provide 
more impetus for research on targeted microbiome-based therapy to treat and prevent CDI. 
Owing to the reported inhibitory effect of chenodeoxycholate on C. difficile spore germination, it has 
been proposed as potential prophylactic to prevent CDI (Sorg & Sonenshein, 2010). However, Heeg et 
al., (2012) demonstrated that chenodeoxycholate does not inhibit the spore germination of every C. 
difficile strain. Accordingly, a chenodeoxycholate-based drug might be insufficient to tackle CDI, given 
its inhibitory effects on spore germination is not likely to apply to all C. difficile strains. To fully exploit 
the potential of germination-based interventions, more research on C. difficile spore germination 
mechanisms are required. Even though the presence of germinant receptors is supported by evidence 
(Sorg & Sonenshein, 2008), there is no evidence to suggest if germinants (for example taurocholate) 
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bind to a receptor or just move though the spore by diffusion and initiate the germination cascade. 
Therefore, it is difficult for the present study to speculate on what the molecular basis for the difference 
in germination characteristics of RT010 and RT027 in the present study. Investigating the germination 
differences between a potential probiotic candidate such as the NTCD RT010 strain and its toxigenic 
counterparts in more detail is a clear area for future research.  
The capacity to adapt effectively to environmental changes is a global trait in the bacterial world.  
Colonisation resistance by the host microbiota is crucial in preventing CDI and C. difficile must 
overcome it to proliferate in the colon (Wilson & Freter, 1986). Competition for nutrients is one way in 
which the indigenous microbiota mediate colonisation resistance. The production of TcdA and TcdB 
(large enterotoxins) thought to be the principal virulence factors (Lyras et al., 2009; Kuehne et al., 
2010), by C. difficile responds to the availability of specific nutrients (at least in vitro) (Yamakawa et 
al., 1996), an indication of the close link between virulence and metabolism. Colonisation of the colon 
by NTCD is frequently observed in hospitalised patients, possibly due to an ingestion of spores from 
the hands of clinicians or the environment (Shim et al., 1998). Studies in patients and hamster suggest 
a prevention of CDI by a colonisation with NTCD (Wilson & Sheagren, 1983; Borriello & Barclay 
1985; Seal et al., 1987). Subsequent studies in hamster showed long-term protection against toxigenic 
C. difficile (Sambol et al., 2002; Merrigan et al., 2003).     
Although the precise mechanism by which NTCD prevents CDI is unknown, the protection requires the 
presence of viable NTCD strains. No protection against toxigenic C. difficile was observed when study 
animals were given a heat-killed suspension of NTCD strains (Borriello et al., 1984). Similarly, in the 
same study, when the protective NTCD dose was decreased to undetectable amounts by vancomycin 
treatment prior to challenge with toxigenic C. difficile, no protection was observed. This is an indication 
that there was no memory for protection and that viable NTCD strains were necessary for such 
protection. This data suggests that a likely immune protective response is not the main factor involved 
in a protective role NTCD. Indeed, administration of NTCD to hasmters did not induce anti-toxin 
production in faecal pellets (Borriello et al., 1984). Given NTCD strains were unable to degrade C. 
difficile toxins (Borriello et al., 1984), in vivo degradation of the toxin as a mechanism of protection is 
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very unlikely. The protection by NTCD strains observed following the experiments of Borriello and co-
workers (1984) is very specific in that other clostridial species did not protect the animals against CDI. 
Similarly, a prior colonisation of the study animals with NTCD strains did not protect the animals form 
disease and death upon exposure to a distinct clostridial pathogen, C. spiroforme.  
The specific nature of protection coupled with the requirement for the presence of viable NTCD strains 
suggests that the means of protection against RT027 in the present studies might be competition for 
specific ecological niches (for example those at mucosal receptor sites) or limited nutrients. It is likely 
that RT010 occupies the same adherence or metabolic niche in the colon as does RT027, and once 
established, is capable of outcompeting newly ingested or resident RT027 strains. Mucosal association 
is a crucial pathogenic means for a number of bacteria. Studies have previously shown the intimate 
association of toxigenic C. difficile with the rectal mucosa of humans (Borriello, 1979), in addition to 
the mucosal lining of the caecum in hamsters (Borriello, 1984). Furthermore, Borriello et al., (1984) 
showed that a NTCD associated closely with the mucosal lining of the caecum, and that the colonisation 
was prolonged. Taken together, there is a likelihood that the non-proliferation of RT027 strains in the 
present studies might be due to the competition from RT010 for the binding niches within the biofilms 
in the gut models which are likely to be similar in their structure to in vivo biofilms which may be 
necessary for establishment of the toxigenic strain.    
The mechanisms through which C. difficile responds to Butyrl CoA is of huge potential interest. The 
role of butyrate in inducing toxin synthesis has been reported (Karlsson et al., 2000; Dubois et al., 
2016). Butyrl CoA is the precursor of both butanol and butyrate. Strikingly, butanol is an inhibitor of 
C. difficile toxin synthesis (Karlsson et al., 2000). Given NTCD strains’ lack the pathogenicity locus 
(PaLoc) and do not produce toxins, it is tempting to speculate that these strains convert more Butyrl 
CoA to butanol and less butyrate for biological efficiency, since they do not need to induce toxin 
synthesis. High amounts of butanol produced by the NTCD strains may then proceed to inhibit toxin 
synthesis in toxigenic strains, assuming ribotype 027 strains outgrew at low levels below the limits to 
detect it with microbial culture used in the present studies. In fact revealing how toxigenic C. difficile 
strains ’decide’ whether to convert butyrl CoA to butyrate or butanol and the ratios will discover a 
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crucial decision point for the bacterium and may potentially provide new approaches of decreasing 
virulence. Further work at the level of gene expression may provide more robust conclusions.        
The likelihood that NTCD strains could obtain toxin genes form toxigenic C. difficile in vivo remains a 
concern. An in vitro transfer for the pathogenicity locus (which contains toxins A and B) to NTCD has 
been successful in the laboratory (Brouwer et al., 2013). A toxigenic strain, 630Δerm, was used as a 
donor strain to transfer the pathogenicity locus to 3 NTCD strains at a frequency of about 
7.5 × 10−9 transconjugants per donor. Different large DNA fragments that contained the PaLoc were 
transferred, and toxin B production by one of the transconjugants was demonstrated (Brouwer et al., 
2013). Although these in vitro PaLoc transfer observations raise concern that transfers might happen in 
vivo, it is important to state that in vivo PaLoc transfer has not been demonstrated. Nevertheless, they, 
reemphasise the need to eliminate toxigenic C. difficile with treatment to reduce the likelihood of in 
vivo conjugation and PaLoc transfer. Although this is not presented as an evidence of the lack of PaLoc 
transfer in the present study, it is worth mentioning that the NTCD strain isolated from the gut models 
after the experiments using antimicrobial-embedded selective agar was grown in brain heart infusion 
broth (BHIB) and tested using Vero cell cytotoxicity assay. No toxin production by the NTCD was 
observed. Given the low PaLoc transfer frequency of about 7.5 × 10−9 reported by Brouwer et al., 
(2013), the few CFUs of NTCD (about 5 – 10) picked up in the present studies for the cytotoxicity assay 
are insufficient representatives of about 109 bacterial cells. Additionally, Brouwer et al., (2013) also 
reported that the transfer of PaLoc often happens with co-transfer of conjugative transposons that 
encode antibiotic resistance genes. They demonstrated this by the transfer of the PaLoc and a 
conjugative transposon that encodes tetracycline resistance Tn5397 on the same DNA fragment from 
630Δerm to CD37. While the present study acknowledges the low frequency of such transfer events, 
the NTCD strain (RT010) used in the present study retained its antimicrobial susceptibility profiles (at 
least MICs of tetracycline, clindamycin, ciprofloxacin, cefotaxime, and ampicillin) after the study, 
suggesting a non-receipt of antimicrobial resistance genes from toxigenic C. difficile or components of 
the faecal microbiota. Antimicrobial agar plates were quality controlled daily by inoculating both strains 
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on the two different selective agar plates. Studies in and out of the triple-stage in vitro human gut model 
are required with RT010 and RT027 to fully elucidate this phenomenon.          
New antimicrobial intervention upon a loss of NTCD colonisation could very likely place patients at 
CDI risk again if they ingest a toxigenic C. difficile. Injectable CDI antitoxin vaccines currently in 
clinical development would confer more prolonged protection, but need weeks to months to mount an 
antibody response, particularly in aged individuals (Foglia et al., 2012). An administration of NTCD to 
patients at high risk of CDI or rCDI might confer transient protection while waiting for a more durable 
vaccine to become effective. Additionally, given the NTCD  prevented proliferation and cytotoxin 
production of RT027 in the gut models in the present studies, it might decrease the risk of toxigenic C. 
difficile (for example RT027) transmission in high-risk settings such as nursing homes and hospitals, 
an effect that is not likely with current monoclonal antibodies and antitoxin vaccines which do not affect 
colonisation. Although the NTCD strains were detected in the gut models until the end of each 
experiment in the present studies, it is believed that the colonisation of the gastrointestinal tract by 
NTCD is not long-lived (Borriello & Barclay 1985; Villano et al., 2012; Gerding et al., 2015). This is 
not likely to be a problem as the loss of NTCD colonisation probably happens due to a restoration of 
the indigenous microbiota, which is capable of protection against subsequent CDI.  
Given the design of the experiments, the present studies are unable to provide evidence whether the 
NTCD strains can displace established toxigenic strains of C. difficile as a treatment for existing CDI. 
The extent to which this sort of prophylactic approach employed in the present studies may be 
therapeutically useful in managing already developed CDI remains to be known. Patients with a history 
of recurrent CDI may benefit from being colonised with NTCD strains against recolonization by a 
toxigenic strain. Borriello and Honour (1983) simultaneously isolated both non-toxigenic and toxigenic 
strains of C. difficile from the faeces of a patient with pseudomembranous colitis and cytotoxin detected. 
Whether their findings suggest an absence of antagonism by the NTCD strains is difficult to evaluate 
in the context of the results from the present studies, particularly as the sequence of colonisation of the 
patient was unknown. The lack of antagonism by the NTCD reported by Borriello and Honour (1983) 
may just be due to strain variability. 
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In the present studies, ribotype 027 germinated, grew, and produced toxins in all of the RT027 control 
experiments.  The timing of germination and toxin production showed no correlation with the extent of 
antimicrobial disturbance on the bacterial community (at least for the bacterial groups isolated in the 
present study). For example the cefotaxime and ampicillin-dosed models showed a comparatively 
reduced microbiota depletion when compared with the ciprofloxacin-dosed model. This is similar to the 
observations of Chilton et al., (2012) and Freeman et al., (2003), but the less disrupted models 
(cefotaxime- and ampicillin-dosed) recorded the earliest C. difficile germination and growth (Figures 
4.2a & 4.4a). It may be that cefotaxime and ampicillin disrupts the microbiota just enough for C. difficile 
proliferation or that these antimicrobials may promote C. difficile colonisation in a manner other than 
disruption of the intestinal microbiota as described earlier.   
Interestingly, in all of the control experiments in the present studies, RT027 seemed to produce toxin in 
V2 and V3 and not V1. This is despite an observation of C. difficile germination and growth in V1. 
Similar observations have been reported by Freeman et al., (2003) following a study using an in vitro 
gut model. The authors suggested that either the toxins produced were quickly degraded or toxin 
production was inhibited at low pH. Reduced levels of toxin production in C. difficile have been linked 
to low pH by prior studies (Onderdonk et al., 1979; Borriello & Barclay, 1986), similarly Qa’Dan, et 
al., (2000) reported a pH-induced conformational changes in C. difficile toxin B. Furthermore inhibition 
of spores at acidic pHs have been demonstrated in C. sporogenes (Valero et al., 2020) and C. botulinum 
(Blocher & Busta, 1985; Wong et al., 1988). Whereas the present study takes into consideration the 
effect of pH on C. difficile germination/growth, the absence of toxins in V1 in the present studies may 
be due to an abundance of metabolised carbon sources and nutrients such as glucose or amino acids for 
example cysteine that interfere with C. difficile   toxin synthesis (Dupuy & Sonenshein, 1998; Karlsson 
et al., 2000; 2008). It is very likely that following instillation of antimicrobials into V1, essential 
germinants or nutrients such as sialic acid which are left unused due to the depletion of the microbiota 
flow into V2 and V3 where they are utilised by C. difficile in its preferred more alkaline pH (May et 
al., 1994; Engevik et al., 2014; Wetzel & McBride, 2020) obtainable in V2 and V3. Events in vivo may 
be similar to these observations. 
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Unlike the NTCD-M3 strain that was shown to colonise the colon and significantly reduce CDI 
recurrence following a phase 2 randomised controlled trial (Gerding et al., 2015), the non-toxigenic C. 
difficile strain used in the present study is clindamycin resistant (MIC ˃128 mg/L). The MIC of 
clindamycin to NTCD-M3 is 0.5 mg/L (Merrigan et al., 2003). Although the effectiveness of NTCD in 
preventing CDI have been demonstrated in the present and prior studies (Borriello & Barclay 1985; 
Villano et al., 2012; Gerding et al., 2015), there are important factors in protection and timing of 
colonisation which are associated with  antimicrobial susceptibility of the strains (probiotic and 
challenge strain). Many toxigenic epidemic C. difficile strains are clindamycin resistant (Johnson et al., 
1999; Sambol et al., 2001). Consequently, they are more likely to infect and cause CDI during and after 
clindamycin treatment. This in turn elongates the period which patients are at risk of infection, as against 
clindamycin susceptible toxigenic C. difficile strains which are not likely to cause disease during 
clindamycin treatment. Sambol et al., (2002) demonstrated that colonisation by a clindamycin resistant 
NTCD during clindamycin treatment prevented CDI in hamsters when challenged with a toxigenic C. 
difficile. In contrast, the clindamycin susceptible NTCD-M3 failed to colonise during a multiple dose 
course of clindamycin, and prevented CDI in hamsters only if the hamsters were challenged ≥2 days 
after the last dose of clindamycin treatment (Sambol et al., 2002). This is an indication that the NTCD-
M3 strain is inadequate for effective prevention of CDI during antimicrobial administration. Therefore, 
resistance to an antimicrobial by NTCD such as RT010 used in the present studies may be useful in 
establishing colonisation and prevention of CDI during administration of such antimicrobial. Such 
potential benefit due to antimicrobial resistance was highlighted by the results of the control 
experiments in which the two strains responded differently to clindamycin, i.e. earlier germination of 
NTCD than ribotype 027. Furthermore, the NTCD used in the present studies contains the chromosomal 
erm(B) gene (Dr. César Rodríguez Sánchez - Personal Communication) that encodes a 23s rRNA 
methylase which confers resistance to macrolides, lincosamides, and streptogramines (MLS). 
Accordingly, an MLS mode of resistance to clindamycin is likely. Erm(B)-containing strains differ as 
to the presence of Tn5398 (mobilizable element) which was shown to transfer resistance (Farrow et al., 
2001; Spigaglia & Mastrantonio 2002), although erm(B) could still be transferred even in the absence 
of Tn5398 (Merrigan et al., 2003). Accordingly it is crucial to ascertain the transfer frequency of erm(B) 
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to toxigenic C. difficile and other bacteria resident in the colon.  Nonetheless, the most ideal probiotic 
C. difficile strain will be a NTCD strain that is both antimicrobial resistant and potent in preventing CDI 
but does not carry the risk of resistance transfer. Prior to consideration for human use, the clindamycin-
resistant NTCD strain employed in the present studies, should undergo rigorous genetic analysis and 
gene transfer experiments to ascertain the risk of resistance transfer. Such experiments may include but 
not limited to mating experiments used by Brouwer et al., (2013) to identify non-toxigenic C. difficile 
strains with the least likelihood of receiving the pathogenicity locus. Furthermore, the genome of non-
toxigenic C. difficile strains should be examined to ascertain the presence of mobile genetic elements 
that are in the form of conjugative transposons. These mobile elements are thought to be responsible 
for the acquisition of a wide range of genes involved in antimicrobial resistance, host interaction, and 
virulence (Sebaihia et al., 2006). 
In conclusion, the present studies provide evidence that NTCD RT010 has an ecological advantage over 
RT027 in a complex faecal microbiota. Similarly, the present studies favours the model in which RT010 
is able to outcompete RT027 in the triple stage in vitro human gut model due to its capacity to more 
efficiently exploit the limited resources in the bacterial community by demonstrating a fitness advantage 
despite the type of antimicrobial used to deplete the microbiota. These observations may mirror events 
in the human intestinal environment in vivo. NTCD behaves like its toxigenic counterpart in the absence 
of antimicrobials, i.e. it is unable to proliferate in an unperturbed microbiota. The present studies further 
expand on aspects of C. difficile physiology, which could be exploited by bacterial therapies to 
prevent/treat CDI, as well as demonstrating that the physiology of C. difficile is a crucial factor in its 
success or failure as a pathogen. A clear understanding of the conditions that favour PaLoc transfer to 
NTCD is crucial for its success as a probiotic, in addition to evaluating the propensity of mobile genetic 






4.6 General discussion and conclusions 
The role of antibiotics in shaping the landscape of modern medicine and the ability of humans to survive 
numerous bacterial diseases are significant. However, the effects of antimicrobials on the micro-ecology 
of the gut microbiome is becoming increasingly relevant. CDI is one of such negative consequences of 
antimicrobial use. FMT has been successfully used to treat rCDI, with resolution rates of about 90%. 
Notwithstanding, the composition and behaviour of the gut microbiota, especially in ill-defined 
microbiota replacement intervention such as FMT remains to be fully elucidated. 
The triple-stage in vitro human gut model was validated against the intestinal contents of sudden-death 
victims and is a reliable tool to depict or mirror bacterial activities and microbial content of the human 
colon (Macfarlane et al., 1998). This model has been previously employed to evaluate the tendency of 
various antimicrobials to stimulate CDI, as well as the potency of treatments (Baines et al., 2009; 2013; 
2015; Freeman et al., 2003; Chilton et al., 2012; 2014; Moura et al., 2019; 2020). Data obtained from 
the gut model have been reported to be consistent with phase III clinical trials (Freeman et al., 2003; 
Moura et al., 2019), an indication of the clinical importance of this tool.  
Bacteroides spp., Lactobacillus spp., Bifidobacterium spp. and Clostridium spp., constitute highly 
abundant bacterial genera in the human colon that are frequently depleted by antimicrobial intervention, 
as demonstrated by in vitro and ex vivo studies (Ben-Amor et al., 2005; Louie et al., 2012; Baines et 
al., 2013; Rajilic-Stojanovic & de Vos, 2014; Kelly et al., 2016). The depletion of bacterial populations 
brings about a potential new niche for C. difficile spore germination, cell growth, and toxin production, 
culminating in CDI (Freeman et al., 2003). Given the high degree of consistency and accuracy of gut 
model studies which show a depletion of bacterial populations upon antimicrobial intervention, it seems 
plausible to suggest that such bacterial populations provide an insight into a healthy microbiota (Rajilic-
Stojanovic & de Vos, 2014). 
Following the present studies, the administration of various antimicrobial groups such as lincosamides, 
aminopenicillins, fluoroquinolones, and third generation cephalosporins into the gut models culminated 
in simulated CDI, reflecting prior in vivo clinical observation (Freeman et al., 2003). Furthermore, L. 
casei Shirota dosage impacted positively on the gut microbial community confirming earlier studies, 
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however, long term colonization of the gut by LcS was absent. Similarly, a daily administration of a 
high dose of LcS failed to prevent C. difficile germination, outgrowth, and cytotoxin production in the 
gut model, although a decline in potentially pathogenic Enterobacteriaceae and Enterococci populations 
were observed. Although the gut model is limited by an absence of immunological responses, it is 
unlikely that immunomodulation may confer a more prolonged probiotic effect given studies involving 
human subjects (Saxelin et al., 1993; Alander et al. 1999) have also reported the short term colonisation 
and temporary probiotic benefits of Lactobacillus species. Nevertheless, the role of host immune system 
in preventing CDI is widely reported, especially in recurrent CDI and the inability of the gut model to 
mirror secretory and immunological events is acknowledged here.  
The failure of LcS to prevent C. difficile germination, outgrowth, and cytotoxin production in the gut 
model was initially thought to be due to the gut model growth media, as the production of substances 
such as acetic and butyric acid that are potentially inhibitory to C. difficile is largely dependent on 
constituents of the growth media in which they are cultivated (Tomás et al., 2002; Avonts et al., 2004; 
Zalán et al., 2005). However, using the gut model growth media, Macfarlane and colleagues 
demonstrated substantially high amounts of organic acid production in vessel 1 of the gut model, 
thereby fuelling speculations that such inhibitory effect of organic acids produced by lactobacilli may 
be concentration-dependent, such that the resultants concentrations of the organic acids in the vessels 2 
and 3 in the present study were below a concentration that may exert an antimicrobial effect on C. 
difficile. Large double-blind design studies are required to demonstrate the wider significance of these 
observations in terms of the capacity of LcS to prevent CDI. 
In the present series of experiments, C. difficile remained quiescent as spores prior to antimicrobial 
instillation. This internal control period of spore dormancy is an indication that the unperturbed gut 
microbiota may have a role in preventing C. difficile germination, growth, and toxin production. 
Although declines in the members of the microbiota due to antimicrobials did not correlate with the 
timing and extent of C. difficile germination and toxin production.  Cefotaxime and ampicillin exerted 
less deleterious effects than ciprofloxacin and clindamycin upon the gut microbiota enumerated, but 
induced C. difficile germination and toxin production in a shorter time. Similarly, ciprofloxacin and 
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clindamycin had very profound deleterious effects on the microbiota enumerated, but differed in the 
maximum cytotoxin titres produced by C. difficile following their administration. Furthermore, in the 
control experiments, the absence or presence of a particular bacterial group showed no relationship with 
C. difficile germination, growth, and toxin production. This reinforces suggestions that the relationship 
between C. difficile and the indigenous microbiota may be more complex than simple colonisation 
resistance, and that other factors may contribute. Although it could just be that the particular members 
of the indigenous microbiota responsible for colonisation resistance were not cultured and enumerated 
in the present studies.  
Antimicrobials were dosed into the gut models to mirror in vivo faecal/biliary levels, as well as the 
fluctuation of antimicrobial concentrations in the colon. An evaluation of C. difficile germination 
profiles of individual antimicrobial experiments in the present studies in conjunction with previous gut 
model data pertaining to antimicrobial induction of CDI (Freeman et al., 2003; Baines et al., 2008; 
2013; Chilton et al., 2014; Moura et al., 2019) indicated that C. difficile germination only occurred 
when antimicrobial levels declined to below the MIC for the C. difficile strain. This was particularly 
evident upon clindamycin administration, when germination of the NTCD with a MIC of ˃128 mg/L 
occurred on the fourth day of clindamycin instillation in the control model, whereas RT027 with a MIC 
of 2 mg/L required additional 13 days to germinate in the control model. Similar patterns were observed 
albeit less pronounced with the other antimicrobials. This might present further evidence to support the 
role of sub-MIC antimicrobial concentrations in promoting C. difficile spore germination and 
subsequent cytoxin production, in addition to the importance of C. difficile susceptibility or resistance 
to the antimicrobial, rather than the susceptibility of the microbiota. It may also explain why some 
antimicrobials carry more risk to induce CDI than others. This might be due to the MIC of the treatment 
antimicrobial to the infecting strain. If the concentration of antimicrobial does not decrease below the 
MIC before spores are eliminated (washed out), then symptomatic disease cannot occur. It was earlier 
suggested that the decline in antimicrobial concentrations may be a removal of an inhibitory barrier to 
germination rather than a direct stimulus for germination (Freeman et al., 2005). The present study 
favours the model in which sub-MIC antimicrobial concentrations induce stress in C. difficile, leading 
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to an improved adherence and utilisation of the new niche created by the depletion of bacterial groups 
by antimicrobials in the gut models. It is likely that NTCD produced higher amounts of such surface 
adhesins in response to the sub-MIC concentrations of antimicrobials used in the present studies leading 
to a competitive advantage.   
The present studies consistently instilled approximately 108 C. difficile spores into the gut models. This 
is likely higher than the number of spores patients are exposed to per time in the environment. The 
precise infective dose of C. difficile in humans remains to be ascertained. This is crucial as the inoculum 
size may influence the progression of colonisation to CDI. A smaller inoculum is more likely to be 
washed out of the gut by peristalsis before antimicrobial concentrations decrease to below inhibitory 
levels. Similarly, the antimicrobial concentrations achieved in the gut may also have a role in 
symptomatic disease. Antimicrobials present in lower gut concentrations might decrease to sub-
inhibitory levels before C. difficile spores are washed out of the gut by peristalsis. Further gut model 
studies using varying inoculum sizes are required.  
Given the concentrations of a particular antimicrobial in a population of individuals might differ 
substantially (Wilcox et al., 2001), and the results from the present studies reinforce evidence that 
antimicrobial levels are crucial in dictating C. difficile germination and cytotoxin production. It 
therefore appears that such individual factors may impact on the capacity of C. difficile to germinate 
and produce cytotoxin in vivo. This may in part explain why some individuals do not experience 
symptomatic CDI despite treatment with a high predisposing antimicrobial.                          
This work is limited because variations in microbial populations were investigated using bacterial 
culture. This limits the investigation to only culturable bacterial groups, as bacterial populations such 
as Clostridium leptum and Prevotella spp. that do not have a selective agar cannot be studied using 
bacterial culture despite their importance in a healthy microbiome (Ben-Amor et al., 2005; Hayashi et 
al., 2005; Louie et al., 2012). It is also a huge burden on personnel time as anaerobic bacterial culture 
plates require up to 48 h of incubation for colony growth, which may delay interventions. Molecular 
techniques such as real-time PCR can be employed to study gut microbiota variations quantitatively 
and in a lesser turnaround time (Bartosch et al., 2004; Louie et al., 2012; Thorpe et al., 2018). However 
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it is pertinent to state that toxin production and spore counts cannot be quantified by molecular methods 
such as qPCR. For example the presence of toxin gene(s) may be determined by PCR, but such a 
molecular method may not provide adequate information on the actual amounts of toxins produced per 
time. Similarly current understanding of gut microbiota depletion by antimicrobials can be improved 
by employing 16S sequencing (Hayashi et al., 2005; Kelly et al., 2016). However, given bacterial 
groups differ in the number of 16S gene copies encoded on their genomes, such variations determined 
by 16S sequencing are not quantitative but qualitative. Besides by detecting DNA, molecular methods 
such as qPCR cannot differentiate between non-viable and viable cells. In spite of the longer turnaround 
time associated with culture-based methods, it represents cell viability and thus provides information 
on the most abundant viable bacterial population at a given time in the gut model. This permits for a 
better understanding of active metabolic pathways and their likely relevance in disease. Besides, 
following a study that compared methods for the direct enumeration of bacterial species using the in 
vitro human gut model, Moura et al., (2020) observed a > 85% correlation between direct culture and 
qPCR for a majority of the bacterial populations investigated. Nonetheless, by employing bacterial 
culture, the present series of experiments were able to monitor the different phases of C. difficile life 
cycle by distinguishing vegetative cells and spores which cannot be achieved by molecular techniques 










4.7 Future work   
This study reinforced the gut model as a useful tool in which the interplay between the gut microbiota, 
antimicrobials, and C. difficile can be effectively studied. Even though minor differences in the impact 
of antimicrobials on C. difficile and the gut microbiota was observed between repeat experiments, the 
general reproducibility of events within the gut model was obvious. Given the gut model appeared 
reflective of in vivo observations with regards to the impact of antimicrobials on the gut microbiota and 
C. difficile, as well as the capability of NTCD to interfere with a cycle of CDI, it may be employed in 
future studies to examine the potency of novel interventions to prevent and/or treat CDI.  
Despite results from the present study as well as data from animal models and phase two clinical trials 
(Zhang et al., 2015; Gerding et al., 2015) indicating that NTCD is able to colonise the colon and 
significantly reduce CDI without adverse effects in the human trials, the likelihood that NTCD strains 
could obtain toxin genes from toxigenic C. difficile in vivo remains a concern given an in vitro transfer 
of the pathogenicity locus to NTCD has been successful in the laboratory (Brouwer et al., 2013). NTCD 
strain isolated from the gut models after the experiments using antimicrobial-embedded selective agar 
was grown in brain heart infusion broth (BHIB) and tested using Vero cell cytotoxicity assay. No toxin 
production by the NTCD was observed. Similarly, although the present study acknowledges the low 
frequency of PaLoc transfer events (Brouwer et al., 2013), the NTCD strain (RT010) used in the present 
study retained its antimicrobial susceptibility profiles after the study, suggesting a non-receipt of 
antimicrobial resistance genes from toxigenic C. difficile or components of the faecal microbiota. 
Nonetheless, Riedel et al (2017) reported that functional binary toxin-associated genes were encoded 
by a C. difficile bacteriophage genome. In a like manner, Ramirez-Vargas et al., (2018) demonstrated 
that C. difficle strains carried tcdB toxins on extrachromosomal elements, suggesting the transfer of 
toxin genes from toxigenic C. difficile to NTCD is more likely than previously thought. This raises 
questions about the distribution of C. difficle toxin loci and the pathogenicity mechanisms of this 
pathogen, in addition to reinforcing the notion that the epidemiology of this bacterium is not completely 
understood. Furthermore, a C. difficile isolate HMX-149 was associated with lower hamster mortality 
figures and a lower cell cytotoxicity than a NAP1 strain despite considerably producing more TcdB in 
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vitro (Ramirez-Vargas et al., 2018). This is in contrast to the widely propagated notion that 
hypervirulence is linked with tcdB overproduction (Warny et al., 2005), although in vivo toxin 
measurements are needed to confirm it. This controversy raises concerns that necessitate a continued 
surveillance on C. difficile using comprehensive genomic approaches 
 Nonetheless, gut model studies in addition to rigorous genetic analysis are required to investigate 
whether NTCD (RT010) can be converted into a toxigenic strain by receiving a C. difficile pathogenicity 
locus. This is in addition to studies to evaluate the capacity of NTCD to interfere with already 
established CDI. Furthermore, optimising NTCD spore dose to prevent development of CDI in the gut 
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